{ snpphena : { 1 : { 1 : " NN conj NN" 2 : 179 3 : { 1 : " *drug0* conj drug0" 2 : "drug0 conj *drug0*" 3 : "drug0 conj *drug0*" 4 : "drug0 conj *drug0*" 5 : "drug0 conj *drug0*" 6 : "drug0 conj *drug0*" 7 : "drug0 conj *drug0*" 8 : "drug0 conj *drug0*" 9 : "drug0 conj *drug0*" 10 : "drug0 conj *drug0*" } 4 : { 1 : "In 2001 , we published the first significant evidence of a genetic association between drug2 and a synonymous coding SNP drug1 in the androgen receptor gene , AR . " 2 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 3 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 4 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 5 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 6 : "Recently , TCF7L2 variants , including the microsatellite marker drug1 and the nearly perfectly linked SNP drug2 , were identified to associate with drug3 " 7 : "Multivariable logistic regression analysis of combined genotypes with adjustment for age , gender and drug3 mellitus revealed that drug1 and drug2 significantly and synergistically affected drug4 . " 8 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . " 9 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " 10 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " } } 2 : { 1 : "NN conj NN conj NN" 2 : 135 3 : { 1 : "drug0 conj *drug0* conj drug0" 2 : "drug0 conj *drug0* conj drug0" 3 : "drug0 conj *drug0* conj drug0" 4 : "drug0 conj *drug0* conj drug0" 5 : "drug0 conj drug0 conj *drug0*" 6 : "drug0 conj *drug0* conj drug0" 7 : "drug0 conj *drug0* conj drug0" 8 : "drug0 conj *drug0* conj drug0" 9 : "drug0 conj *drug0* conj drug0" 10 : "drug0 conj *drug0* conj drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " 2 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 3 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 4 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 5 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous glucose tolerance tests were performed , and found an association between drug1 and drug2 and drug3 ( P = 0.003 and P = 0.005 , respectively ) and drug4 ( P = 0.04 and P = 0.007 , respectively ) . " 6 : "We observed a strong association drug4 with all the polymorphisms , including drug1 ( odds ratio [ OR ] 1.50 [ 95 % CI = 1.24-1 .82 ] , p = 4.0 x 10 ( -5 ) ) , drug2 ( OR 1.48 [ 95 % CI = 1.24-1 .77 ] , p = 2.0 x 10 ( -5 ) ) and drug3 ( OR 1.46 [ 95 % CI = 1.22-1 .75 ] , p = 3.0 x 10 ( -5 ) ) . " 7 : "Our haplotype trend analysis identified a drug1 significantly associated with drug2 ( p = .0013 ) , drug3 ( p = .0024 ) , and drug4 ( p = .017 ) . " 8 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) . " 9 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 severity ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) " 10 : "In conditional logistic regression , there was no association between the number of alleles with drug1 > or = 21 ( or > or = 22 ) and risk of drug2 , drug3 or drug4 . " } } 3 : { 1 : "NN conj NN" 2 : 38 3 : { 1 : "drug0 conj *drug0*" 2 : "drug0 conj *drug0*" 3 : "drug0 conj *drug0*" 4 : "drug0 conj *drug0*" 5 : "drug0 conj *drug0*" 6 : "drug0 conj *drug0*" 7 : "drug0 conj *drug0*" 8 : "drug0 conj *drug0*" 9 : "drug0 conj *drug0*" 10 : "drug0 conj *drug0*" } 4 : { 1 : "CONCLUSIONS : drug1 , SFA intake , and drug2 were found to be associated with blood lipid levels in Lithuanian adult population . " 2 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . " 3 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . " 4 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " 5 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " 6 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 7 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 8 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 9 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [ OR ] 0.61 and OR 2.01 , respectively ) . " 10 : "CONCLUSIONS : We found no consistent association between drug1 and drug2 . " } } 4 : { 1 : "NN conj NN dep NN dep NN dep NN conj NN" 2 : 35 3 : { 1 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 6 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 7 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 8 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 9 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 10 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 5 : { 1 : " NN conj NN conj NN" 2 : 32 3 : { 1 : " *drug0* conj drug0 conj drug0" 2 : "drug0 conj *drug0* conj drug0" 3 : "drug0 conj *drug0* conj drug0" 4 : "drug0 conj *drug0* conj drug0" 5 : "drug0 conj *drug0* conj drug0" 6 : "drug0 conj *drug0* conj drug0" 7 : "drug0 conj *drug0* conj drug0" 8 : "drug0 conj *drug0* conj drug0" 9 : "drug0 conj *drug0* conj drug0" 10 : "drug0 conj *drug0* conj drug0" } 4 : { 1 : "CONCLUSIONS : We have confirmed associations between drug3 and drug1 and drug2 . " 2 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 3 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 4 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 5 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . " 6 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . " 7 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . " 8 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p < 0.004 ) . " 9 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p < 0.004 ) . " 10 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p < 0.004 ) . " } } 6 : { 1 : "NN dep NN conj NN conj NN dep NN" 2 : 28 3 : { 1 : "drug0 dep .0 conj *0p0* conj .0 dep drug0" 2 : "drug0 dep .0 conj *0p0* conj .0 dep drug0" 3 : "drug0 dep mthfd0l conj *0p0* conj .0 dep drug0" 4 : "drug0 dep apoe conj *0p0* conj .0 dep drug0" 5 : "drug0 dep znf0 conj *0p0* conj .0 dep drug0" 6 : "drug0 dep cxcl0 conj *0p0* conj .0 dep drug0" 7 : "drug0 dep lpl conj *0p0* conj .0 dep drug0" 8 : "drug0 dep .0 conj *0p0* conj .0 dep drug0" 9 : "drug0 dep mthfd0l conj *0p0* conj .0 dep drug0" 10 : "drug0 dep apoe conj *0p0* conj .0 dep drug0" } 4 : { 1 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 2 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 3 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 4 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 5 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 6 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 7 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 8 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 9 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 10 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " } } 7 : { 1 : "NN conj NN appos NN" 2 : 21 3 : { 1 : "drug0 conj *drug0* appos drug0" 2 : "drug0 conj *drug0* appos drug0" 3 : "drug0 appos ufd0l conj *drug0*" 4 : "drug0 appos drug0 conj *drug0*" 5 : "drug0 appos pro0his conj *drug0*" 6 : "drug0 conj *drug0* appos drug0" 7 : "drug0 appos *drug0* conj drug0" 8 : "drug0 appos *drug0* conj drug0" 9 : "drug0 appos *drug0* conj drug0" 10 : "drug0 appos *drug0* conj drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " 2 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " 3 : "The increased volumes in the genu , splenium and total CC in the drug3 group were associated with polymorphisms within the candidate genes : drug1 , drug2 and UFD1L ( drug4 ) . " 4 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 5 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 6 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 7 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 8 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 9 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 10 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " } } 8 : { 1 : "NN conj NN dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 21 3 : { 1 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 2 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 3 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 4 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 5 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 6 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 7 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 8 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 9 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 10 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 9 : { 1 : "NN appos NN" 2 : 17 3 : { 1 : "drug0 appos *drug0*" 2 : "drug0 appos *drug0*" 3 : "drug0 appos *drug0*" 4 : "drug0 appos *drug0*" 5 : "drug0 appos *drug0*" 6 : "drug0 appos *drug0*" 7 : "drug0 appos *drug0*" 8 : "drug0 appos *drug0*" 9 : "drug0 appos *drug0*" 10 : "drug0 appos *drug0*" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " 2 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 3 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 4 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 5 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " 6 : "Furthermore , studies of APOE drug1 , drug2 , ( defining e2/e3/e4 alleles ; 12 studies ) and APOB drug3 ( eight studies ) were included in meta-analyses , the observational hazard ratio ( HR ) for symptomatic drug4 for the fifth versus first quintile of LDL-C was 0.94 ( 95 % confidence interval : 0.76-1 .17 ) , despite a corresponding 134 % increase in LDL-C . " 7 : "Two polymorphisms ( drug1 , drug2 ) that define the epsilon2 , epsilon3 , and epsilon4 isoforms of apolipoprotein E were significantly associated with percent reduction in drug3 ( epsilon2 carriers 53.8 % , epsilon3/epsilon3 48.1 % , and epsilon4 carriers 46.4 % , respectively , P = 0.00039 ) and replicated in the drug4 ( epsilon2 carriers 22.1 % , epsilon3/epsilon3 21.8 % , and epsilon4 carriers 16.6 % , respectively , P = 0.00038 ) . " 8 : "OBJECTIVE : We aimed to replicate the association of the drug1 ( IVS3C/T ) and drug2 ( IVS3C/T ) polymorphisms of transcription factor 7-like 2 ( TCF7L2 ) and drug3 ( drug4 ) in Han Chinese people in Henan province , China . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 10 : { 1 : "NN nmod VBN nsubjpass NN" 2 : 16 3 : { 1 : "drug0 nmod *associated* nsubjpass drug0" 2 : "drug0 nmod *associated* nsubjpass drug0" 3 : "drug0 nmod *associated* nsubjpass drug0" 4 : "drug0 nsubjpass *associated* nmod drug0" 5 : "drug0 nmod *associated* nsubjpass drug0" 6 : "drug0 nmod *associated* nsubjpass drug0" 7 : "drug0 nmod *associated* nsubjpass drug0" 8 : "drug0 nmod *associated* nsubjpass drug0" 9 : "drug0 nmod *associated* nsubjpass drug0" 10 : "drug0 nmod *associated* nsubjpass drug0" } 4 : { 1 : "OBJECTIVE : drug1 has been associated with drug2 and athero-thrombosis however the association with drug3 ( AAA ) has not been previously examined . " 2 : "COMT genotype drug1 was associated with drug2 in the first 45 min in the PACU ( p = .04 ) . " 3 : "The nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of drug3 as well as drug4 . " 4 : "RESULTS : drug2 was significantly associated with SNP drug1 ( P ( allele ) = 3.6 x10 ( -3 ) ; OR = 1.56 ; 95 % c.i. : 1.12-2 .15 ) and HLA-DRB1 * 1501-DQB1 * 0602 haplotype ( P ( positivity ) = 9.2 x10 ( -11 ) ; OR = 3.97 ; 95 % c.i. : 2.55-6 .19 ) . " 5 : "drug1 , a SNP located between CPT1B and CHKB , was associated with drug3 in Japanese ( drug2 [ C ] , odds ratio ( OR ) = 1.79 , combined P = 4.4 x 10 ( -7 ) ) and other ancestry groups ( OR = 1.40 , P = 0.02 ) . " 6 : "drug1 , a SNP located between CPT1B and CHKB , was associated with drug3 in Japanese ( drug2 [ C ] , odds ratio ( OR ) = 1.79 , combined P = 4.4 x 10 ( -7 ) ) and other ancestry groups ( OR = 1.40 , P = 0.02 ) . " 7 : "We utilised statistical methods appropriate for the categorical nature of the phenotype and familial structure of the cohort , and determined that whilst SNP drug1 was strongly associated with drug2 ( P < 0.0001 ) , the GGN triplet repeat was not ( P = 0.13 ) . " 8 : "In the present study , we investigated whether drug1 was associated with drug2 in predominantly middle-aged persons . " 9 : "In the UK National Registry dataset , drug1 was significantly associated with drug2 in the male subgroup ; significant SNP-by-smoking interactions were observed . " 10 : "A candidate SNP drug1 in drug2 was significantly ( p = 0.015 ) associated with drug3 . " } } 11 : { 1 : "NN dep NN dep NN conj NN" 2 : 16 3 : { 1 : "drug0 dep drug0 dep b conj *drug0*" 2 : "drug0 dep tspan0 dep *drug0* conj drug0" 3 : "drug0 dep tspan0 dep *drug0* conj drug0" 4 : "drug0 dep tspan0 dep *drug0* conj drug0" 5 : "drug0 dep tspan0 dep *drug0* conj drug0" 6 : "drug0 dep tspan0 dep *drug0* conj drug0" 7 : "drug0 dep l0mbtl0 dep *drug0* conj drug0" 8 : "drug0 dep l0mbtl0 dep *drug0* conj drug0" 9 : "drug0 dep l0mbtl0 dep *drug0* conj drug0" 10 : "drug0 dep l0mbtl0 dep *drug0* conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 12 : { 1 : "NN conj NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 15 3 : { 1 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 6 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 7 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 8 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 9 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 10 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 13 : { 1 : "NN compound NNS conj NN" 2 : 15 3 : { 1 : "drug0 compound snps conj *drug0*" 2 : "drug0 compound symptoms conj *drug0*" 3 : "drug0 conj *genotypes* compound drug0" 4 : "drug0 conj *ratings* compound drug0" 5 : "drug0 conj *polymorphisms* compound drug0" 6 : "drug0 compound snps conj *drug0*" 7 : "drug0 compound polymorphisms conj *drug0*" 8 : "drug0 compound polymorphisms conj *drug0*" 9 : "drug0 compound snps conj *drug0*" 10 : "drug0 conj *variants* compound drug0" } 4 : { 1 : "BACKGROUND : Apolipoprotein E ( APOE ) functional haplotypes determined by drug1 and drug2 SNPs have been extensively studied and found to be one of the most consistent association in human drug3 studies . " 2 : "In contrast to previous findings , analysis by logistic regression failed to find any associations between drug1 and drug2 symptoms . " 3 : "There were no significant associations between drug1 genotypes and drug2 or drug3 . " 4 : "The OPRM1 drug1 genotype was associated with patients ' drug2 ratings at 15 min in the postanesthesia care unit ( PACU ) ( p = .01 ) and patients ' drug3 at 15 min in the PACU ( p = .02 ) . " 5 : "There were no associations between drug1 polymorphisms and drug2 , drug3 and drug4 " 6 : "Apolipoprotein E ( APOE ) functional haplotypes determined by drug1 and drug2 SNPs have been extensively studied and found to be one of the most consistent association in human drug3 studies . " 7 : "CONCLUSIONS : The study shows that drug1 , drug2 polymorphisms , APOE e2 variant , and several clinical/demographic variables are important determinants of drug3 dose requirements in Egyptian patients . " 8 : "In conclusion , this study indicated that the drug1 polymorphism of the TCF7L2 gene had a significant effect on drug4 risk in Chinese Han population , with drug2 and drug3 polymorphisms showing no significant effect . " 9 : "We evaluated the published evidence for association between drug1 ( k = 27 samples ) and drug2 ( k = 44 samples ) SNPs with drug3 using meta-analytic techniques . " 10 : "Meta-analysis indicated compelling evidence of an association between the drug1 variants and drug2 ( fixed effects : B = 0.91 , 95 % CI = 0.77 , 1.06 , p < .001 ; random effects : B = 1.01 , 95 % CI = 0.81 , 1.22 , p < .001 ) , equivalent to a per-allele effect of approximately 1 cigarette/day . " } } 14 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN conj NN" 2 : 15 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf conj drug0" 2 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf conj drug0" 3 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf conj drug0" 4 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf conj drug0" 5 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf conj drug0" 6 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf conj drug0" 7 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf conj drug0" 8 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod drug0 conj drug0" 9 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod drug0 conj drug0" 10 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod drug0 conj drug0" } 4 : { 1 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 2 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 3 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 4 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 5 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 6 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 7 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 8 : "The minor alleles of drug1 ( TCF7L2 ) , drug2 ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 9 : "The minor alleles of drug1 ( TCF7L2 ) , drug2 ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 10 : "The minor alleles of drug1 ( TCF7L2 ) , drug2 ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " } } 15 : { 1 : "NN nmod NN nmod NN" 2 : 15 3 : { 1 : "drug0 nmod *progression* nmod drug0" 2 : "drug0 nmod *effect* nmod drug0" 3 : "drug0 nmod *genotype* nmod drug0" 4 : "drug0 nmod *association* nmod drug0" 5 : "drug0 nmod *association* nmod drug0" 6 : "drug0 nmod *role* nmod drug0" 7 : "drug0 nmod *drug0* nmod drug0" 8 : "drug0 nmod *role* nmod drug0" 9 : "drug0 nmod allele nmod *drug0*" 10 : "drug0 nmod *progression* nmod drug0" } 4 : { 1 : "Over an average period of three years , participants with the risk-conferring TT genotype at drug1 were more likely to have progression from drug2 to drug3 than were CC homozygotes ( hazard ratio , 1.55 ; 95 percent confidence interval , 1.20 to 2.01 ; P < 0.001 ) . " 2 : "Although there was only moderate linkage disequilibrium between drug1 and the ApoE e4 defining SNP drug2 , we could not find an APOE-independent effect of drug3 on drug4 , either in cross-sectional or in longitudinal analyses . " 3 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [ OR ] 0.61 and OR 2.01 , respectively ) . " 4 : "CONCLUSIONS : The study extends on the observation of a strong multiethnic association of polymorphisms in the drug1 and drug2 with drug4 , but does not confirm the association of CPT1B/CHKB ( drug3 ) in the Chinese population . " 5 : "The T allele of drug1 showed an association with borderline significance ( OR = 1.19 , 95 % C.I. = 1.01-1 .42 , P = 0.04 ) , and the Cochran-Armitage test for trend revealed an allele dose-dependent association of drug2 with drug3 ( Ptrend = 0.04 ) . " 6 : "Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs , our analyses did not support a role of drug1 or drug2 on drug3 . " 7 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 8 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " 9 : "Among them , genetic variants in drug1 showed the strongest association with drug4 risk , with ORs ( 95 % CIs ) of 1.44 ( 1.29-1 .60 , P < 0.001 ) per T allele of drug2 and 1.46 ( 1.15-1 .84 , P = 0.002 ) per T allele of drug3 " 10 : "Over an average period of three years , participants with the risk-conferring TT genotype at drug1 were more likely to have progression from drug2 to drug3 than were CC homozygotes ( hazard ratio , 1.55 ; 95 percent confidence interval , 1.20 to 2.01 ; P < 0.001 ) . " } } 16 : { 1 : "NN conj NN amod JJ nmod:npmod NN" 2 : 14 3 : { 1 : "drug0 conj *tf* amod = nmod:npmod drug0" 2 : "drug0 conj *tf* amod = nmod:npmod drug0" 3 : "drug0 conj *tf* amod = nmod:npmod drug0" 4 : "drug0 conj *tf* amod = nmod:npmod drug0" 5 : "drug0 conj *tf* amod = nmod:npmod drug0" 6 : "drug0 conj *tf* amod = nmod:npmod drug0" 7 : "drug0 conj *tf* amod = nmod:npmod drug0" 8 : "drug0 conj *tf* amod = nmod:npmod drug0" 9 : "drug0 conj *tf* amod = nmod:npmod drug0" 10 : "drug0 conj *tf* amod = nmod:npmod drug0" } 4 : { 1 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 2 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 3 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 4 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 5 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 6 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 7 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 8 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 9 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 10 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " } } 17 : { 1 : "NN appos NN conj NN conj NN" 2 : 13 3 : { 1 : "drug0 appos ufd0l conj *drug0* conj drug0" 2 : "drug0 appos pro0his conj *drug0* conj drug0" 3 : "drug0 appos g0r conj *slc0a0* conj drug0" 4 : "drug0 appos g0r conj *slc0a0* conj drug0" 5 : "drug0 appos clstn0 conj *drug0* conj drug0" 6 : "drug0 appos clstn0 conj *drug0* conj drug0" 7 : "drug0 appos clstn0 conj *drug0* conj drug0" 8 : "drug0 appos hhex conj *drug0* conj drug0" 9 : "drug0 appos cdkn0a/b conj *drug0* conj drug0" 10 : "drug0 appos slc0a0 conj *drug0* conj drug0" } 4 : { 1 : "The increased volumes in the genu , splenium and total CC in the drug3 group were associated with polymorphisms within the candidate genes : drug1 , drug2 and UFD1L ( drug4 ) . " 2 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 3 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 4 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 5 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 6 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 7 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 8 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 9 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 10 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 18 : { 1 : " NN nmod NN conj NN" 2 : 12 3 : { 1 : " *drug0* nmod drug0 conj drug0" 2 : " *drug0* nmod drug0 conj drug0" 3 : " *drug0* nmod drug0 conj drug0" 4 : "drug0 conj *intake* nmod drug0" 5 : "drug0 conj drug0 nmod *drug0*" 6 : "drug0 conj drug0 nmod *drug0*" 7 : "drug0 conj drug0 nmod *drug0*" 8 : "drug0 conj *association* nmod drug0" 9 : "drug0 conj tcf0l0 nmod *drug0*" 10 : "drug0 conj slc0a0 nmod *drug0*" } 4 : { 1 : "CONCLUSIONS : Our results showed a significant independent additive effect on drug5 of the LPL polymorphisms drug1 , drug2 , drug3 and drug4 ; the S19W and -1131 T/C variants of APOA5 , and the epsilon4 allele of APOE in our study population . " 2 : "CONCLUSIONS : Our results showed a significant independent additive effect on drug5 of the LPL polymorphisms drug1 , drug2 , drug3 and drug4 ; the S19W and -1131 T/C variants of APOA5 , and the epsilon4 allele of APOE in our study population . " 3 : "CONCLUSIONS : Our results showed a significant independent additive effect on drug5 of the LPL polymorphisms drug1 , drug2 , drug3 and drug4 ; the S19W and -1131 T/C variants of APOA5 , and the epsilon4 allele of APOE in our study population . " 4 : "The aim of this study was to assess the effect of drug1 , the intake of drug2 , and drug3 in Lithuanian adult population . " 5 : "We investigated thecausal relationship between drug2 and symptoms of drug3 and drug4 in the Norwegian HUNT study using the drug1 single nucleotidepolymorphism ( SNP ) variant located in the nicotine acetylcholine receptor gene cluster on chromosome 15 as an instrumental variable for smokingphenotypes " 6 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " 7 : "CONCLUSIONS : The CC genotype and the recessive model of the variant drug1 ( IVS3C/T ) and CC haplotype of drug2 ( IVS3C/T ) and drug3 ( IVS3C/T ) in TCF7L2may be associated with drug4 in Han Chinese people in Henan province , China . . " 8 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . " 9 : "The consistent association between drug1 in TCF7L2 and drug2 in different ethnic groups , including the Japanese population , suggests that TCF7L2 is a common susceptibility gene for type 2 diabetes . " 10 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 19 : { 1 : "NN conj NN nmod NNS nmod NNS dep NN conj NN" 2 : 12 3 : { 1 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 2 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 3 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 4 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 5 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 6 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 7 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 8 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 9 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 10 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0 conj drug0" } 4 : { 1 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 2 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 3 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 4 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 5 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 6 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 7 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 8 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 9 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 10 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " } } 20 : { 1 : "NN conj NN dep NN dep NN dep NN" 2 : 12 3 : { 1 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0" 2 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0" 3 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0" 4 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0" 5 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0" 6 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0" 7 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0" 8 : "drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 9 : "drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 10 : "drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 21 : { 1 : "NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 12 3 : { 1 : "drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 6 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" 7 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" 8 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" 9 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" 10 : "drug0 conj drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 22 : { 1 : " NN nmod NN" 2 : 11 3 : { 1 : " *drug0* nmod drug0" 2 : "drug0 nmod *drug0*" 3 : "drug0 nmod *drug0*" 4 : "drug0 nmod *drug0*" 5 : "drug0 nmod *drug0*" 6 : "drug0 nmod *drug0*" 7 : "drug0 nmod *drug0*" 8 : "drug0 nmod *drug0*" 9 : "drug0 nmod *drug0*" 10 : "drug0 nmod *drug0*" } 4 : { 1 : "CONCLUSIONS : Our results showed a significant independent additive effect on drug5 of the LPL polymorphisms drug1 , drug2 , drug3 and drug4 ; the S19W and -1131 T/C variants of APOA5 , and the epsilon4 allele of APOE in our study population . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 3 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 4 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 5 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 6 : "We investigated thecausal relationship between drug2 and symptoms of drug3 and drug4 in the Norwegian HUNT study using the drug1 single nucleotidepolymorphism ( SNP ) variant located in the nicotine acetylcholine receptor gene cluster on chromosome 15 as an instrumental variable for smokingphenotypes " 7 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " 8 : "CONCLUSIONS : The CC genotype and the recessive model of the variant drug1 ( IVS3C/T ) and CC haplotype of drug2 ( IVS3C/T ) and drug3 ( IVS3C/T ) in TCF7L2may be associated with drug4 in Han Chinese people in Henan province , China . . " 9 : "A candidate SNP drug1 in drug2 was significantly ( p = 0.015 ) associated with drug3 . " 10 : "We conclude that drug1 GTCF7L2 variant is associated with peripheral drug2 in drug3 but this effect is not seen in control women . " } } 23 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN conj NN" 2 : 10 3 : { 1 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 2 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 3 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 4 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 5 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 6 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 7 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 8 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep *drug0* appos drug0" 9 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep *drug0* appos drug0" 10 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep *drug0* appos drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 24 : { 1 : "NN nmod VBN nsubjpass NN nmod NN" 2 : 10 3 : { 1 : "drug0 nmod *observed* nsubjpass ld nmod drug0" 2 : "drug0 nmod *associated* nsubjpass genotype nmod drug0" 3 : "drug0 nmod *associated* nsubjpass genotype nmod drug0" 4 : "drug0 nmod *associated* nsubjpass genotype nmod drug0" 5 : "drug0 nmod *associated* nsubjpass drug0 nmod drug0" 6 : "drug0 nmod *associated* nsubjpass allele nmod drug0" 7 : "drug0 nmod *associated* nsubjpass allele nmod drug0" 8 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0" 9 : "drug0 nmod *associated* nsubjpass allele nmod drug0" 10 : "drug0 nmod *associated* nsubjpass variant nmod drug0" } 4 : { 1 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . " 2 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [ OR ] 0.61 and OR 2.01 , respectively ) . " 3 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [ OR ] 0.61 and OR 2.01 , respectively ) . " 4 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " 5 : "A candidate SNP drug1 in drug2 was significantly ( p = 0.015 ) associated with drug3 . " 6 : "As expected , the T risk allele of drug1 was associated with higher drug2 ( p = 0.01 ) . " 7 : "We confirmed that the risk allele of drug1 is associated with drug2 and a drug3 . " 8 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 9 : "The T allele of drug1 was significantly associated with decreased drug2 ( Studies II , III ) . " 10 : "The variant of drug1 of TCF7L2 was associated with incident drug2 in the DPS and in a separate population-based cross-sectional study . " } } 25 : { 1 : "NN conj NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 10 3 : { 1 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" 2 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" 3 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" 4 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 5 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 6 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 7 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 8 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 9 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 10 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 26 : { 1 : "NN dep NN dep NN dep NN dep NN conj NN" 2 : 10 3 : { 1 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 2 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 3 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 4 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 5 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 6 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 7 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 8 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep *drug0*" 9 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep *drug0*" 10 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep *drug0*" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 27 : { 1 : "NN dep NN conj NN" 2 : 10 3 : { 1 : "drug0 dep b conj *drug0*" 2 : "drug0 conj *drug0* dep drug0" 3 : "drug0 conj *drug0* dep drug0" 4 : "drug0 dep igf0bp0 conj *drug0*" 5 : "drug0 dep *drug0* conj drug0" 6 : "drug0 conj *drug0* dep drug0" 7 : "drug0 conj *drug0* dep drug0" 8 : "drug0 conj *drug0* dep drug0" 9 : "drug0 conj *drug0* dep drug0" 10 : "drug0 conj *polymorphism* dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " 3 : "Three SNPs [ drug1 in APOE : odds ratio ( OR ) = 4.24 , 95 % confidence interval ( CI ) = 3.01-5 .96 , P = 1.23 * 10 ; drug2 in APOE : OR = 3.57 , 95 % CI = 2.51-5 .06 , P = 1.23 * 10 ; and drug3 in PICALM : OR = 0.63 , 95 % CI = 0.49-0 .81 , P = 0.00036 , log additive model ] were significantly associated with drug4 susceptibility after correction for multiple testing . " 4 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 5 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 6 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 7 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 8 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 9 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 10 : "We observed a significant association between the single-nucleotide polymorphism ( SNP ) drug1 and the microsatellite drug2 with drug3 in the Mexican sample " } } 28 : { 1 : "NN appos NN dep NN dep NN conj NN" 2 : 10 3 : { 1 : "drug0 appos drug0 dep l0mbtl0 dep *drug0* conj drug0" 2 : "drug0 appos drug0 dep l0mbtl0 dep *drug0* conj drug0" 3 : "drug0 appos drug0 dep l0mbtl0 dep *drug0* conj drug0" 4 : "drug0 appos drug0 dep l0mbtl0 dep *drug0* conj drug0" 5 : "drug0 appos drug0 dep l0mbtl0 dep *drug0* conj drug0" 6 : "drug0 appos drug0 dep l0mbtl0 dep *drug0* conj drug0" 7 : "drug0 appos drug0 dep l0mbtl0 dep *drug0* conj drug0" 8 : "drug0 conj drug0 dep runx0 dep *drug0* appos drug0" 9 : "drug0 conj drug0 dep runx0 dep *drug0* appos drug0" 10 : "drug0 conj drug0 dep runx0 dep *drug0* appos drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 9 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 10 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 29 : { 1 : "NN appos NN conj NNP conj NN appos NN" 2 : 10 3 : { 1 : "drug0 appos mdm0 conj *aurka* conj erbb0 appos drug0" 2 : "drug0 appos cdh0 conj *aurka* conj erbb0 appos drug0" 3 : "drug0 appos cdkn0a conj *aurka* conj erbb0 appos drug0" 4 : "drug0 appos tp0 conj *aurka* conj erbb0 appos drug0" 5 : "drug0 appos cdh0 conj *aurka* conj mdm0 appos drug0" 6 : "drug0 appos cdkn0a conj *aurka* conj mdm0 appos drug0" 7 : "drug0 appos tp0 conj *aurka* conj mdm0 appos drug0" 8 : "drug0 appos cdkn0a conj *aurka* conj cdh0 appos drug0" 9 : "drug0 appos tp0 conj *aurka* conj cdh0 appos drug0" 10 : "drug0 appos tp0 conj *aurka* conj cdkn0a appos drug0" } 4 : { 1 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 2 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 3 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 4 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 5 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 6 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 7 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 8 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 9 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 10 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " } } 30 : { 1 : "NN conj NN conj NN conj NN" 2 : 9 3 : { 1 : "drug0 conj drug0 conj *chrna0-chrnb0-chrna0* conj drug0" 2 : "drug0 conj drug0 conj *drug0* conj drug0" 3 : "drug0 conj drug0 conj *drug0* conj drug0" 4 : "drug0 conj *drug0* conj drug0 conj drug0" 5 : "drug0 conj *drug0* conj drug0 conj drug0" 6 : "drug0 conj *drug0* conj drug0 conj drug0" 7 : "drug0 conj *drug0* conj drug0 conj drug0" 8 : "drug0 conj *drug0* conj drug0 conj drug0" 9 : "drug0 conj *drug0* conj drug0 conj drug0" } 4 : { 1 : "We examined the associations between the nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 marking thegene cluster CHRNA3-CHRNB4-CHRNA5 , drug2 , and drug3 and drug4 in the general population . " 2 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 3 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 4 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 5 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 6 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 7 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 8 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 9 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " } } 31 : { 1 : "NN appos NN conj NN appos NN" 2 : 9 3 : { 1 : "drug0 appos apoe conj *apoa0* appos drug0" 2 : "drug0 appos drug0 conj *drug0* appos drug0" 3 : "drug0 appos pro0his conj *drug0* appos drug0" 4 : "drug0 appos g-0a conj *t-0c* appos drug0" 5 : "drug0 appos apoe conj *apoa0* appos drug0" 6 : "drug0 appos apoe conj *tomm0* appos drug0" 7 : "drug0 appos d0h conj *r0l* appos drug0" 8 : "drug0 appos r0c conj *r0l* appos drug0" 9 : "drug0 appos g-0c conj *c0t* appos drug0" } 4 : { 1 : "RESULTS : After correcting for multiple testing ( p < 0.05 ) and accounting for significant differences in the association effect sizes between subjects with and without drug4 ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with HDL-C and LDL-C responses in MetS subjects , while APOA4 drug3 was associated with TG response in non-MetS subjects . " 2 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 3 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 4 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " 5 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " 6 : "Inside this region of 26.9 kb , LD ( r2 > 0.50 ) between TOMM40 ( drug1 ) and APOE ( drug2 ) was observed in drug3 and in controls , but not in drug4 " 7 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " 8 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " 9 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 32 : { 1 : " NN conj NN compound NN" 2 : 9 3 : { 1 : " *drug0* conj allele compound drug0" 2 : "drug0 compound behavior conj *drug0*" 3 : "drug0 compound assessment conj *drug0*" 4 : " *drug0* conj genotype compound drug0" 5 : "drug0 compound allele conj *drug0*" 6 : "drug0 compound susceptibility conj *drug0*" 7 : "drug0 compound t-to-c conj *drug0*" 8 : "drug0 compound g-to-t conj *drug0*" 9 : "drug0 compound g-to-c conj *drug0*" } 4 : { 1 : "The association between drug2 and SIRT2 drug1 T allele was only present in APOE e4 noncarriers ( adjusted OR = 1.29 , 95 % CI : 1.03-1 .61 , P = .03 ) . " 2 : "CONCLUSIONS : Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 behavior was observed " 3 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " 4 : "The drug1 ( T ) allele genotype was significantly associated with drug3 ( P = 0.003 ) but drug2 ( T ) allele genotype was not associated with the clinico-pathologic characteristics . " 5 : "The non-synonymous drug1 polymorphism of the ADRB3 gene was associated with drug2 ( Trpallele , OR = 0.62 , p = 0.001 ) and drug3 ( Trp allele , OR = 0.74 , p = 0.018 ) . " 6 : "The association between drug1 and drug2 susceptibility has been widely studied . " 7 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " 8 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " 9 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " } } 33 : { 1 : "NN conj NN nmod NN" 2 : 9 3 : { 1 : "drug0 conj *association* nmod drug0" 2 : "drug0 nmod assessment conj *drug0*" 3 : "drug0 nmod risk conj *drug0*" 4 : "drug0 nmod *drug0* conj drug0" 5 : "drug0 nmod *drug0* conj drug0" 6 : "drug0 nmod *drug0* conj drug0" 7 : "drug0 nmod *drug0* conj drug0" 8 : "drug0 nmod *drug0* conj drug0" 9 : "drug0 nmod presence conj *drug0*" } 4 : { 1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous glucose tolerance tests were performed , and found an association between drug1 and drug2 and drug3 ( P = 0.003 and P = 0.005 , respectively ) and drug4 ( P = 0.04 and P = 0.007 , respectively ) . " 2 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " 3 : "In conditional logistic regression , there was no association between the number of alleles with drug1 > or = 21 ( or > or = 22 ) and risk of drug2 , drug3 or drug4 . " 4 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 5 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 6 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 7 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 8 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 9 : "We also found a strong correlation between the drug1 and the presence of drug2 ( P = 0.02 with a high OR = 8.28 ) . " } } 34 : { 1 : "NN compound NNS nmod VBN dep NN conj NN dep NN" 2 : 8 3 : { 1 : "drug0 compound events nmod *associated* dep 0p0 conj .0 dep drug0" 2 : "drug0 compound events nmod *associated* dep 0p0 conj .0 dep drug0" 3 : "drug0 compound events nmod *associated* dep 0p0 conj .0 dep drug0" 4 : "drug0 compound events nmod *associated* dep 0p0 conj mthfd0l dep drug0" 5 : "drug0 compound events nmod *associated* dep 0p0 conj apoe dep drug0" 6 : "drug0 compound events nmod *associated* dep 0p0 conj znf0 dep drug0" 7 : "drug0 compound events nmod *associated* dep 0p0 conj cxcl0 dep drug0" 8 : "drug0 compound events nmod *associated* dep 0p0 conj lpl dep drug0" } 4 : { 1 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 2 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 3 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 4 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 5 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 6 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 7 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 8 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " } } 35 : { 1 : "NN dep NN conj NN dep NN" 2 : 8 3 : { 1 : "drug0 dep .0 conj *0p0* dep drug0" 2 : "drug0 dep .0 conj *0p0* dep drug0" 3 : "drug0 dep .0 conj *0p0* dep drug0" 4 : "drug0 dep mthfd0l conj *0p0* dep drug0" 5 : "drug0 dep apoe conj *0p0* dep drug0" 6 : "drug0 dep znf0 conj *0p0* dep drug0" 7 : "drug0 dep cxcl0 conj *0p0* dep drug0" 8 : "drug0 dep lpl conj *0p0* dep drug0" } 4 : { 1 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 2 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 3 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 4 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 5 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 6 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 7 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " 8 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " } } 36 : { 1 : "NN conj NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 8 3 : { 1 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 2 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 3 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 4 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 6 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 7 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 8 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 8 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 37 : { 1 : "NN nmod NN nmod NN conj NN" 2 : 8 3 : { 1 : "drug0 nmod *association* nmod drug0 conj drug0" 2 : "drug0 conj totalcholesterol nmod *association* nmod drug0" 3 : "drug0 nmod *role* nmod drug0 conj drug0" 4 : "drug0 conj drug0 nmod *role* nmod drug0" 5 : "drug0 conj drug0 nmod *association* nmod drug0" 6 : "drug0 conj drug0 nmod *association* nmod drug0" 7 : "drug0 conj drug0 nmod *association* nmod drug0" 8 : "drug0 nmod *association* nmod drug0 conj drug0" } 4 : { 1 : "CONCLUSIONS : The study extends on the observation of a strong multiethnic association of polymorphisms in the drug1 and drug2 with drug4 , but does not confirm the association of CPT1B/CHKB ( drug3 ) in the Chinese population . " 2 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " 3 : "Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs , our analyses did not support a role of drug1 or drug2 on drug3 . " 4 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " 5 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . " 6 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . " 7 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . " 8 : "Comparison between allele and genotype frequencies of these SNPs in patients and controls showed marginal association for drug1 and drug2 with drug3 ( p = 0.063 , OR 1.982 , 95 % CI 1.128-3 .485 ; p = 0.071 , OR 1.237 , 95 % CI 0.983-1 .557 , respectively ) . " } } 38 : { 1 : "NN nmod VBN nsubjpass NNS dep NN conj NN" 2 : 7 3 : { 1 : "drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" 2 : "drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" 3 : "drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" 4 : "drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" 5 : "drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" 6 : "drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" 7 : "drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" } 4 : { 1 : "Two SNPs ( drug1 and drug2 ) in IREB2 were associated with drug3 ( P = 0.045 and 0.032 , respectively ) in non-smoker . " 2 : "Three SNPs ( drug1 in IREB2 , drug2 in LOC123688 , and drug3 in CHRNA3 ) were associated with drug4 of predicted in the AAT Genetic Modifiers Study . " 3 : "Three SNPs ( drug1 in IREB2 , drug2 in LOC123688 , and drug3 in CHRNA3 ) were associated with drug4 of predicted in the AAT Genetic Modifiers Study . " 4 : "Two SNPs ( drug1 and drug2 ) were associated with the drug3 of predicted and drug4 ; SNP-by-gender interactions were observed . " 5 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p < 0.004 ) . " 6 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p < 0.004 ) . " 7 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p < 0.004 ) . " } } 39 : { 1 : "NN nmod VBN nsubjpass NN compound NN" 2 : 7 3 : { 1 : "drug0 nmod *associated* nsubjpass allele compound drug0" 2 : "drug0 nmod *associated* nsubjpass polymorphism compound drug0" 3 : "drug0 nmod *associated* nsubjpass variant compound drug0" 4 : "drug0 nmod *associated* nsubjpass variant compound drug0" 5 : "drug0 nmod *associated* nsubjpass genotype compound drug0" 6 : "drug0 nmod *associated* nsubjpass polymorphism compound drug0" 7 : "drug0 nmod *associated* nsubjpass genotype compound drug0" } 4 : { 1 : "RESULTS : As previously reported in Spain , drug1 allele was strongly associated with drug2 in our series ( OR = 2.88 [ 95 % C.I. 2.16 - 3.84 ] , p = 7.38E-11 ) . " 2 : "Thus , the drug1 polymorphism is not associated with drug2 in the Caucasian population but acts as a modifier of the AAO in drug3 with a sexual dimorphism : the Val allele is associated with a younger AAO in men with idiopathic PD . " 3 : "The drug1 genetic variant within the CHRNA5-A3-B4 gene cluster is associated with drug2 and has recently been reported to be associated with likelihood of drug3 . " 4 : "We conclude that drug1 GTCF7L2 variant is associated with peripheral drug2 in drug3 but this effect is not seen in control women . " 5 : "The drug1 ( T ) allele genotype was significantly associated with drug3 ( P = 0.003 ) but drug2 ( T ) allele genotype was not associated with the clinico-pathologic characteristics . " 6 : "The non-synonymous drug1 polymorphism of the ADRB3 gene was associated with drug2 ( Trpallele , OR = 0.62 , p = 0.001 ) and drug3 ( Trp allele , OR = 0.74 , p = 0.018 ) . " 7 : "Whereas the NOD2 genotype and drug2 are positively associated with drug3 , the drug1 genotype is positively associated with drug4 ( L2 ) disease . " } } 40 : { 1 : "NN compound NN conj NN compound NN" 2 : 7 3 : { 1 : "drug0 compound *status* conj genotype compound drug0" 2 : "drug0 compound status conj *genotype* compound drug0" 3 : "drug0 compound g conj *g* compound drug0" 4 : "drug0 compound g conj *c* compound drug0" 5 : "drug0 compound t conj *c* compound drug0" 6 : "drug0 compound ct conj *c* compound drug0" 7 : "drug0 compound polymorphism conj *polymorphism* compound drug0" } 4 : { 1 : "RESULTS : We found no association between drug2 status and SNP drug1 genotype nor did we find a significant association to the degree of drug3 " 2 : "However , we found an association between drug1 genotype ( Val/Val ) and A drug2 carrier status and the risk of drug3 and drug4 . " 3 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 4 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 5 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 6 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 7 : "Furthermore , the risk alleles from TCF7L2 drug1 polymorphism either with drug2 polymorphism ( p = 0.0257 , OR = 1.398 ) or with drug3 polymorphism ( p = 0.0024 , OR = 1.514 ) were significantly associated with drug4 . " } } 41 : { 1 : "NN compound NN conj NN conj NN compound NN" 2 : 7 3 : { 1 : "drug0 compound or conj *ratio* conj t/c compound drug0" 2 : "drug0 compound t conj *c* conj g compound drug0" 3 : "drug0 compound ct conj *c* conj g compound drug0" 4 : "drug0 compound ct conj *c* conj t compound drug0" 5 : "drug0 compound g-to-t conj *drug0* conj t-to-c compound drug0" 6 : "drug0 compound g-to-c conj *drug0* conj t-to-c compound drug0" 7 : "drug0 compound g-to-c conj *drug0* conj g-to-t compound drug0" } 4 : { 1 : "RESULTS : Significant associations with drug4 were observed for genotypes drug1 A/T ( odds ratio [ OR ] , 2.1 ; 95 % confidence interval [ CI ] , 1.0-4 .5 ) , drug2 T/C ( OR , 4.4 ; 95 % CI , 1.9-10 .2 ) , and drug3 ( OR , 4.1 ; 95 % CI , 1.6-10 .9 ) " 2 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 3 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 4 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 5 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " 6 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " 7 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " } } 42 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 7 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 2 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 3 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 4 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 5 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 6 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 7 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 43 : { 1 : "NN conj NN nmod VBN nsubjpass NN nmod NN" 2 : 7 3 : { 1 : "drug0 conj drug0 nmod *observed* nsubjpass ld nmod drug0" 2 : "drug0 conj drug0 nmod *associated* nsubjpass genotype nmod drug0" 3 : "drug0 conj drug0 nmod *associated* nsubjpass genotype nmod drug0" 4 : "drug0 conj drug0 nmod *associated* nsubjpass genotype nmod drug0" 5 : "drug0 conj drug0 nmod *associated* nsubjpass allele nmod drug0" 6 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0 conj drug0" 7 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0 conj drug0" } 4 : { 1 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . " 2 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [ OR ] 0.61 and OR 2.01 , respectively ) . " 3 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [ OR ] 0.61 and OR 2.01 , respectively ) . " 4 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " 5 : "We confirmed that the risk allele of drug1 is associated with drug2 and a drug3 . " 6 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 7 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 44 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 7 3 : { 1 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 2 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 3 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 4 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 5 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 6 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" 7 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0* conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 6 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 7 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 45 : { 1 : "NN nmod NNS nmod NNS dep NN conj NN" 2 : 6 3 : { 1 : "drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 2 : "drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 3 : "drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 4 : "drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 5 : "drug0 nmod subjects nmod *snps* dep drug0 conj drug0" 6 : "drug0 nmod subjects nmod *snps* dep drug0 conj drug0" } 4 : { 1 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 2 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 3 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 4 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 5 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 6 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " } } 46 : { 1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN" 2 : 6 3 : { 1 : "drug0 nmod decline nmod *associated* nsubjpass aa nmod drug0" 2 : "drug0 nmod risk nmod *associated* nsubjpass carriage nmod drug0" 3 : "drug0 nmod risk nmod *associated* nsubjpass possession nmod drug0" 4 : "drug0 nmod risk nmod *associated* nsubjpass a-allele nmod drug0" 5 : "drug0 nmod or nmod *associated* nsubjpass allele nmod drug0" 6 : "drug0 nmod risk nmod *associated* nsubjpass genotype nmod drug0" } 4 : { 1 : "Patients homozygous AA for TLR1 polymorphism drug1 are more frequently associated with faster decline of drug2 compared to heterozygous genotype ( OR :7.33 ( 95 % CI :1.63 -33.11 ) " 2 : "We observed that carriage of two alleles with > or = 22 drug1 was associated with an increased risk of drug2 compared with carriage of two alleles with < 22 CAG repeats ( covariate-adjusted odds ratios , 1.31 ; 95 % confidence intervals , 1.01-1 .69 ) . " 3 : "Our results suggest that possession of two long AR alleles drug1 may be associated with increased risk of drug2 compared with women with two short AR alleles ( < 22 CAG repeats ) . " 4 : "A-allele of drug1 was associated with an increased risk of drug2 regardless of smoking exposure ( pooled OR = 1.26 , 95 % CI 1.18-1 .34 , p < 10 ⁻⁵ ) . " 5 : "The T ( minor ) allele of the variant drug1 was significantly associated with a greater OR for drug2 adjusted for age , sex and BMI in logistic regression analysis : " 6 : "In the DPS , the TT genotype of drug1 was significantly associated with an adjusted 2.85-fold risk ( 95 % CI 1.17-6 .95 , p = 0.021 ) of incident drug2 in the control group , but not in the intervention group . " } } 47 : { 1 : "NN appos NNP conj NN appos NN" 2 : 6 3 : { 1 : "drug0 appos iii conj *apoa0* appos drug0" 2 : "drug0 appos erbb0 conj *aurka* appos drug0" 3 : "drug0 appos mdm0 conj *aurka* appos drug0" 4 : "drug0 appos cdh0 conj *aurka* appos drug0" 5 : "drug0 appos cdkn0a conj *aurka* appos drug0" 6 : "drug0 appos tp0 conj *aurka* appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " 2 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 3 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 4 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 5 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 6 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " } } 48 : { 1 : "NN compound NN nmod NN nmod NN" 2 : 6 3 : { 1 : "drug0 compound combination nmod *association* nmod drug0" 2 : "drug0 compound treatment nmod *association* nmod drug0" 3 : "drug0 compound pathogenesis nmod *role* nmod drug0" 4 : "drug0 nmod *association* nmod genotype compound drug0" 5 : "drug0 compound susceptibility nmod *role* nmod drug0" 6 : "drug0 compound susceptibility nmod *association* nmod drug0" } 4 : { 1 : "The association of drug1 with the drug2 and drug3 combination could help to explain the contradictory results of previous studies . " 2 : "CONCLUSIONS : Our findings extend and add new information to the existing data regarding the association between drug1 and TG regulation during long-term atypical drug2 treatment . " 3 : "Our data are compatible with the hypothesis of a complex role of drug1 in the drug2 pathogenesis , with positive and negative effects occurring concomitantly according to its expression levels and its protein-protein interactions largely unclarified . " 4 : "There was evidence of association of drug1 genotype with drug2 in our open-label trial sample but not our placebo-controlled trial sample . " 5 : "RESULTS : Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs , our analyses did not support a role of drug1 or drug2 on drug3 susceptibility " 6 : "In addition to these polymorphisms , meta-analysis confirmed the association of drug4 susceptibility with KCNJ11 drug1 , TCF7L2 drug2 , and HHEX drug3 . " } } 49 : { 1 : "NN nmod NN nmod VBN nsubjpass NN" 2 : 6 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass drug0" 2 : "drug0 nmod risk nmod *associated* nsubjpass drug0" 3 : "drug0 nmod risk nmod *associated* nsubjpass drug0" 4 : "drug0 nmod risk nmod *associated* nsubjpass drug0" 5 : "drug0 nmod susceptibility nmod *associated* nsubjpass drug0" 6 : "drug0 nmod risk nmod *associated* nsubjpass drug0" } 4 : { 1 : "The nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of drug3 as well as drug4 . " 2 : "Based on 12 studies with 5,573 MetS cases and 8,290 controls from 5 East Asian studies , 5 European studies and 2 studies of other ethnic groups , the drug1 was associated with increased risk of drug2 with an OR ( 95 % CI ) = 1.33 ( 1.16 , 1.53 ) in the overall population , 1.43 ( 1.29 , 1.58 ) in East Asian and 1.30 ( 0.94 , 1.78 ) in European populations . " 3 : "Conclusions : The present study demonstrated that FTO drug1 and combined SNPs were significantly associated with risk of drug2 , which seems to be dependent on BMI . " 4 : "CONCLUSIONS : The present study demonstrated that FTO drug1 and combined SNPs were significantly associated with risk of drug2 , which seems to be dependent on BMI . " 5 : "In summary , by pooling all available qualified data from genetic studies on drug1 and drug3 , we have confirmed that drug2 is significantly associated with susceptibility to drug4 in the global population . " 6 : "These data suggest that drug1 are associated with increased risk for drug2 in Emirati subjects . " } } 50 : { 1 : "NN nmod NN nmod VBN nsubjpass NN compound NN" 2 : 6 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass snp compound drug0" 2 : "drug0 nmod risk nmod *associated* nsubjpass snp compound drug0" 3 : "drug0 nmod risk nmod *associated* nsubjpass polymorphism compound drug0" 4 : "drug0 nmod drug0 nmod *associated* nsubjpass variant compound drug0" 5 : "drug0 compound stage nsubjpass *associated* nmod frequency nmod drug0" 6 : "drug0 nmod risk nmod *associated* nsubjpass variation compound drug0" } 4 : { 1 : "In this study , we found that the COMT drug1 SNP was significantly associated with a reduced risk of drug2 , especially drug3 , which suggests that this SNP may have a protective effect . " 2 : "Moreover , the PLCH1 drug1 SNP was strongly associated with an increased risk of drug2 , " 3 : "CONCLUSIONS : Donor TCF7L2 drug1 polymorphism is associated with an increased risk of drug2 after LT and has a potential clinical value for the prediction of NODM . " 4 : "We conclude that drug1 GTCF7L2 variant is associated with peripheral drug2 in drug3 but this effect is not seen in control women . " 5 : "drug3 disease stage was marginally significantly associated with the frequency of the T variant at drug1 ( p = 0.057 ; adjusted p = 0.017 ) but not at drug2 ( p = 0.5 ; adjusted p = 0.2 ) . " 6 : "These data suggest that the TCF7L2 drug1 genetic variation is associated with an increased risk of drug2 . " } } 51 : { 1 : "NN conj NNS dep NN conj NN" 2 : 6 3 : { 1 : "drug0 conj *snps* dep drug0 conj drug0" 2 : "drug0 conj *snps* dep drug0 conj drug0" 3 : "drug0 conj *snps* dep drug0 conj drug0" 4 : "drug0 conj *snps* dep drug0 conj drug0" 5 : "drug0 conj *snps* dep drug0 conj drug0" 6 : "drug0 conj *polymorphisms* dep drug0 conj drug0" } 4 : { 1 : "Subgroups analyses show that significant associations are not found between the six SNPs ( drug1 , drug2 , drug3 , drug4 , drug5 , and drug6 ) and the drug7 in some ethnic populations . " 2 : "Subgroups analyses show that significant associations are not found between the six SNPs ( drug1 , drug2 , drug3 , drug4 , drug5 , and drug6 ) and the drug7 in some ethnic populations . " 3 : "Subgroups analyses show that significant associations are not found between the six SNPs ( drug1 , drug2 , drug3 , drug4 , drug5 , and drug6 ) and the drug7 in some ethnic populations . " 4 : "Subgroups analyses show that significant associations are not found between the six SNPs ( drug1 , drug2 , drug3 , drug4 , drug5 , and drug6 ) and the drug7 in some ethnic populations . " 5 : "Subgroups analyses show that significant associations are not found between the six SNPs ( drug1 , drug2 , drug3 , drug4 , drug5 , and drug6 ) and the drug7 in some ethnic populations . " 6 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 52 : { 1 : "NN appos NN dep NN dep NN" 2 : 5 3 : { 1 : "drug0 appos drug0 dep l0mbtl0 dep *drug0*" 2 : "drug0 appos drug0 dep celf0 dep *drug0*" 3 : "drug0 dep celf0 dep *drug0* appos drug0" 4 : "drug0 appos drug0 dep runx0 dep *drug0*" 5 : "drug0 dep runx0 dep *drug0* appos drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 53 : { 1 : "NN nmod NN nmod NN nmod NN compound NN" 2 : 5 3 : { 1 : "drug0 nmod risk nmod *interaction* nmod g/t compound drug0" 2 : "drug0 nmod inheritance nmod *role* nmod locus compound drug0" 3 : "drug0 nmod *risk* nmod copy nmod allele compound drug0" 4 : "drug0 nmod *risk* nmod copy nmod allele compound drug0" 5 : "drug0 nmod likelihood nmod *association* nmod glllenotype compound drug0" } 4 : { 1 : "Moreover , a significant positive interaction between drug1 G/T + T/T genotypes and fat intake > 25 % of total energy for the risk of drug2 was observed . " 2 : "We conducted additional genotyping to clarify the role of the drug1 locus in the inheritance of drug2 and other pigmentary traits associated with drug3 risk inwhite populations " 3 : "The increase in cotinine levels indicated an increased risk of drug3 with each additional copy of the drug1 - drug2 risk allele " 4 : "The increase in cotinine levels indicated an increased risk of drug3 with each additional copy of the drug1 - drug2 risk allele " 5 : "We investigated the potential association of drug1 gLLLenotype with reduced likelihood of drug2 in 2 cohorts of treatment-seeking smokers in primary care in the United Kingdom . " } } 54 : { 1 : "NN dep NN conj NN conj NN" 2 : 5 3 : { 1 : "drug0 dep b conj drug0 conj *drug0*" 2 : "drug0 dep igf0bp0 conj *drug0* conj drug0" 3 : "drug0 dep igf0bp0 conj *drug0* conj drug0" 4 : "drug0 conj drug0 conj *drug0* dep drug0" 5 : "drug0 conj drug0 conj *drug0* dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 3 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 4 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 5 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " } } 55 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NNS nmod NNS compound NNP conj NN appos NN" 2 : 5 3 : { 1 : "drug0 compound patients nmod cohort nmod *genotyped* nsubjpass polymorphisms nmod genes compound aurka conj erbb0 appos drug0" 2 : "drug0 compound patients nmod cohort nmod *genotyped* nsubjpass polymorphisms nmod genes compound aurka conj mdm0 appos drug0" 3 : "drug0 compound patients nmod cohort nmod *genotyped* nsubjpass polymorphisms nmod genes compound aurka conj cdh0 appos drug0" 4 : "drug0 compound patients nmod cohort nmod *genotyped* nsubjpass polymorphisms nmod genes compound aurka conj cdkn0a appos drug0" 5 : "drug0 compound patients nmod cohort nmod *genotyped* nsubjpass polymorphisms nmod genes compound aurka conj tp0 appos drug0" } 4 : { 1 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 2 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 3 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 4 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " 5 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " } } 56 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 5 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 57 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 5 3 : { 1 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 58 : { 1 : "NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 5 3 : { 1 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 59 : { 1 : "NN nsubjpass VBN nmod NN conj NN" 2 : 5 3 : { 1 : "drug0 nsubjpass *associated* nmod drug0 conj drug0" 2 : "drug0 nsubjpass *associated* nmod drug0 conj drug0" 3 : "drug0 nsubjpass *associated* nmod drug0 conj drug0" 4 : "drug0 nsubjpass *associated* nmod drug0 conj drug0" 5 : "drug0 nsubjpass *associated* nmod drug0 conj drug0" } 4 : { 1 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 2 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 3 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 4 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 5 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " } } 60 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 5 3 : { 1 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 61 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN conj NN" 2 : 5 3 : { 1 : "drug0 appos drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 2 : "drug0 appos drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 3 : "drug0 appos drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 4 : "drug0 appos drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" 5 : "drug0 appos drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 5 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 62 : { 1 : "NN appos NN conj NN conj NN appos NN" 2 : 5 3 : { 1 : "drug0 appos pro0his conj *drug0* conj drug0 appos drug0" 2 : "drug0 appos r0c conj *r0l* conj d0h appos drug0" 3 : "drug0 appos cdkn0a/b conj *drug0* conj hhex appos drug0" 4 : "drug0 appos slc0a0 conj *drug0* conj hhex appos drug0" 5 : "drug0 appos slc0a0 conj *drug0* conj cdkn0a/b appos drug0" } 4 : { 1 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 2 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " 3 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 4 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 5 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 63 : { 1 : "NN nmod NNS compound NN" 2 : 4 3 : { 1 : "drug0 nmod *associates* compound drug0" 2 : "drug0 compound subjects nmod *drug0*" 3 : "drug0 nmod *associates* compound drug0" 4 : "drug0 compound families nmod *drug0*" } 4 : { 1 : "The drug1 at-risk allele associates with decreased drug2 and earlier age at diagnosis in the drug3 subjects ( P = 8.0 x 10 ( -3 ) and P = 3.8 x 10 ( -4 ) , respectively ) , which is supported by quantitative family-based association tests . " 2 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " 3 : "The drug1 T at-risk allele associates with drug2 and earlier age at diagnosis in the drug3 subjects ( P = 8.0 x 10 ( -3 ) and P = 3.8 x 10 ( -4 ) , respectively ) , which is supportedby quantitative family-based association tests . " 4 : "These data show that drug1 and drug2 are significantly associated with high drug3 in drug4 families from two different populations . " } } 64 : { 1 : "NN conj NN nmod NN conj NN nmod NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod association conj *association* nmod drug0" 2 : "drug0 nmod association conj *association* nmod drug0 conj drug0" 3 : "drug0 conj drug0 nmod association conj *association* nmod drug0" 4 : "drug0 nmod association conj *association* nmod drug0 conj drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " 2 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " 3 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " 4 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 65 : { 1 : "NN appos NN conj NN conj NN dep NN" 2 : 4 3 : { 1 : "drug0 appos g-0c conj *c0t* conj g-0a dep drug0" 2 : "drug0 dep igf0bp0 conj *drug0* conj hhex appos drug0" 3 : "drug0 appos cdkn0a/b conj *drug0* conj igf0bp0 dep drug0" 4 : "drug0 appos slc0a0 conj *drug0* conj igf0bp0 dep drug0" } 4 : { 1 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " 2 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 3 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 4 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 66 : { 1 : "NN conj NN nmod NNS nmod NNS dep NN" 2 : 4 3 : { 1 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0" 2 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0" 3 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0" 4 : "drug0 conj drug0 nmod subjects nmod *snps* dep drug0" } 4 : { 1 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 2 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 3 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 4 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " } } 67 : { 1 : "NN compound NNS nmod VBD dobj NN conj NNS dep NN conj NN" 2 : 4 3 : { 1 : "drug0 compound cases nmod *genotyped* dobj microsatellite conj polymorphisms dep drug0 conj drug0" 2 : "drug0 compound cases nmod *genotyped* dobj microsatellite conj polymorphisms dep drug0 conj drug0" 3 : "drug0 compound cases nmod *genotyped* dobj microsatellite conj polymorphisms dep drug0 conj drug0" 4 : "drug0 compound cases nmod *genotyped* dobj microsatellite conj polymorphisms dep drug0 conj drug0" } 4 : { 1 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 2 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 3 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " 4 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " } } 68 : { 1 : "NN nmod NN dobj VB xcomp JJ nsubj NNS nmod NN nmod NN" 2 : 4 3 : { 1 : "drug0 nmod progression dobj have xcomp *likely* nsubj participants nmod genotype nmod drug0" 2 : "drug0 nmod progression dobj have xcomp *likely* nsubj participants nmod genotype nmod drug0" 3 : "drug0 nmod progression dobj have xcomp *likely* nsubj participants nmod genotype nmod drug0" 4 : "drug0 nmod progression dobj have xcomp *likely* nsubj participants nmod genotype nmod drug0" } 4 : { 1 : "Over an average period of three years , participants with the risk-conferring TT genotype at drug1 were more likely to have progression from drug2 to drug3 than were CC homozygotes ( hazard ratio , 1.55 ; 95 percent confidence interval , 1.20 to 2.01 ; P < 0.001 ) . " 2 : "Over an average period of three years , participants with the risk-conferring TT genotype at drug1 were more likely to have progression from drug2 to drug3 than were CC homozygotes ( hazard ratio , 1.55 ; 95 percent confidence interval , 1.20 to 2.01 ; P < 0.001 ) . " 3 : "Over an average period of three years , participants with the risk-conferring TT genotype at drug1 were more likely to have progression from drug2 to drug3 than were CC homozygotes ( hazard ratio , 1.55 ; 95 percent confidence interval , 1.20 to 2.01 ; P < 0.001 ) . " 4 : "Over an average period of three years , participants with the risk-conferring TT genotype at drug1 were more likely to have progression from drug2 to drug3 than were CC homozygotes ( hazard ratio , 1.55 ; 95 percent confidence interval , 1.20 to 2.01 ; P < 0.001 ) . " } } 69 : { 1 : "NN conj NN nmod NN conj NN" 2 : 4 3 : { 1 : "drug0 conj *association* nmod drug0 conj drug0" 2 : "drug0 conj drug0 nmod risk conj *drug0*" 3 : "drug0 conj drug0 nmod risk conj *drug0*" 4 : "drug0 conj *association* nmod drug0 conj drug0" } 4 : { 1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous glucose tolerance tests were performed , and found an association between drug1 and drug2 and drug3 ( P = 0.003 and P = 0.005 , respectively ) and drug4 ( P = 0.04 and P = 0.007 , respectively ) . " 2 : "In conditional logistic regression , there was no association between the number of alleles with drug1 > or = 21 ( or > or = 22 ) and risk of drug2 , drug3 or drug4 . " 3 : "In conditional logistic regression , there was no association between the number of alleles with drug1 > or = 21 ( or > or = 22 ) and risk of drug2 , drug3 or drug4 . " 4 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . " } } 70 : { 1 : "NN nmod VBN nsubjpass NN appos NN" 2 : 4 3 : { 1 : "drug0 nmod *associated* nsubjpass polymorphism appos drug0" 2 : "drug0 nmod *associated* nsubjpass apoa0 appos drug0" 3 : "drug0 nmod *associated* nsubjpass variant appos drug0" 4 : "drug0 nmod *associated* nsubjpass variant appos drug0" } 4 : { 1 : "The nicotinic acetylcholine receptor polymorphism ( drug1 ) on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of COPD as well as drug3 . " 2 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " 3 : "THADA variant ( drug1 ) was associated with drug2 ( OR 1.5 ; 95 % CI 1.04 , 2.22 ; p = 0.03 ) . " 4 : "One representative variant , drug1 , was nominally associated with drug2 in a general model ( additive P = 0.03 , dominant P = 0.005 ) but not in a within-family analysis ( additive P = 0.2 , dominant P = 0.07 ) . " } } 71 : { 1 : "NN dep NN dep NN" 2 : 4 3 : { 1 : "drug0 dep tspan0 dep *drug0*" 2 : "drug0 dep l0mbtl0 dep *drug0*" 3 : "drug0 dep celf0 dep *drug0*" 4 : "drug0 dep runx0 dep *drug0*" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 4 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 72 : { 1 : "NN nmod VBN nsubjpass NNS dep NN" 2 : 4 3 : { 1 : "drug0 nmod *associated* nsubjpass snps dep drug0" 2 : "drug0 nmod *associated* nsubjpass snps dep drug0" 3 : "drug0 nmod *associated* nsubjpass snps dep drug0" 4 : "drug0 nmod *associated* nsubjpass snps dep drug0" } 4 : { 1 : "Two SNPs ( drug1 and drug2 ) in IREB2 were associated with drug3 ( P = 0.045 and 0.032 , respectively ) in non-smoker . " 2 : "Three SNPs ( drug1 in IREB2 , drug2 in LOC123688 , and drug3 in CHRNA3 ) were associated with drug4 of predicted in the AAT Genetic Modifiers Study . " 3 : "Two SNPs ( drug1 and drug2 ) were associated with the drug3 of predicted and drug4 ; SNP-by-gender interactions were observed . " 4 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p < 0.004 ) . " } } 73 : { 1 : "NN dep NN" 2 : 4 3 : { 1 : "drug0 dep *drug0*" 2 : "drug0 dep *drug0*" 3 : "drug0 dep *drug0*" 4 : "drug0 dep *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " 3 : "Three SNPs [ drug1 in APOE : odds ratio ( OR ) = 4.24 , 95 % confidence interval ( CI ) = 3.01-5 .96 , P = 1.23 * 10 ; drug2 in APOE : OR = 3.57 , 95 % CI = 2.51-5 .06 , P = 1.23 * 10 ; and drug3 in PICALM : OR = 0.63 , 95 % CI = 0.49-0 .81 , P = 0.00036 , log additive model ] were significantly associated with drug4 susceptibility after correction for multiple testing . " 4 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " } } 74 : { 1 : "NN compound NN nmod NN conj VBN nmod NN conj NN" 2 : 4 3 : { 1 : "drug0 compound disease nmod *factor* conj described nmod drug0 conj drug0" 2 : "drug0 compound disease nmod *factor* conj described nmod drug0 conj drug0" 3 : "drug0 compound disease nmod *factor* conj described nmod drug0 conj drug0" 4 : "drug0 compound disease nmod *factor* conj described nmod drug0 conj drug0" } 4 : { 1 : "BACKGROUND : drug4 ( HTG ) is a well-established independent risk factor for drug5 disease and the influence of several geneti c variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " 2 : "BACKGROUND : drug4 ( HTG ) is a well-established independent risk factor for drug5 disease and the influence of several geneti c variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " 3 : "BACKGROUND : Hypertriglyceridemia ( HTG ) is a well-established independent risk factor for drug4 disease and the influence of several genetic variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " 4 : "BACKGROUND : Hypertriglyceridemia ( HTG ) is a well-established independent risk factor for drug4 disease and the influence of several genetic variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " } } 75 : { 1 : "NN conj NN conj NNS compound NN" 2 : 4 3 : { 1 : "drug0 conj drug0 conj *genotypes* compound drug0" 2 : "drug0 conj drug0 conj *polymorphisms* compound drug0" 3 : "drug0 conj drug0 conj *polymorphisms* compound drug0" 4 : "drug0 conj drug0 conj *levels* compound drug0" } 4 : { 1 : "There were no significant associations between drug1 genotypes and drug2 or drug3 . " 2 : "There were no associations between drug1 polymorphisms and drug2 , drug3 and drug4 " 3 : "There were no associations between drug1 polymorphisms and drug2 , drug3 and drug4 " 4 : "In drug1 , T2D patients carrying genotypes CT or TT had drug2 ( FPG ) levels ( p = 0.042 ) and drug3 ( p = 0.015 ) and drug4 ( p = 0.015 ) compared to the patients carrying CC genotype . " } } 76 : { 1 : "NN nmod NN nsubjpass VBN nmod NN conj NN appos NN" 2 : 3 3 : { 1 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0 conj hhex appos drug0" 2 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0 conj cdkn0a/b appos drug0" 3 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0 conj slc0a0 appos drug0" } 4 : { 1 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 2 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 3 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 77 : { 1 : "NN conj NN dep NN conj NN conj NN appos NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep igf0bp0 conj *drug0* conj hhex appos drug0" 2 : "drug0 appos cdkn0a/b conj *drug0* conj igf0bp0 dep drug0 conj drug0" 3 : "drug0 appos slc0a0 conj *drug0* conj igf0bp0 dep drug0 conj drug0" } 4 : { 1 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 2 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 3 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 78 : { 1 : "NN nmod VBZ nsubj NN compound NN" 2 : 3 3 : { 1 : "drug0 nmod *confers* nsubj allele compound drug0" 2 : "drug0 nmod *confers* nsubj allele compound drug0" 3 : "drug0 nmod *protects* nsubj polymorphism compound drug0" } 4 : { 1 : "The drug1 allele of the COMT gene confers a significantly increased risk for drug2 and drug3 in drug4 . " 2 : "CONCLUSIONS : While previous studies in adults demonstrated , that the drug1 -1131 C minor allele confers risk for drug2 , here we show , that the susceptibility nature of this SNP restricted to the APOA5 * 2 haplotype in pediatric obese subjects . " 3 : "CONCLUSIONS : TCF7L2 drug1 polymorphism protects Mexican children from drug2 . " } } 79 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NN" 2 : 3 3 : { 1 : "drug0 compound subjects nmod level nmod *associated* nsubjpass drug0" 2 : "drug0 compound subjects nmod dbp nmod *associated* nsubjpass drug0" 3 : "drug0 compound families nmod drug0 nmod *associated* nsubjpass drug0" } 4 : { 1 : "Polymorphism drug1 of CMA1 may be associated with serum IgE level in drug2 subjects , but not with chymase level in both groups . " 2 : "Only STK39 drug1 was significantly associated with higher DBP ( P = 0.02 ) in the drug2 subjects . " 3 : "These data show that drug1 and drug2 are significantly associated with high drug3 in drug4 families from two different populations . " } } 80 : { 1 : " NN dep NN conj NN compound NN" 2 : 3 3 : { 1 : " *drug0* dep c conj g compound drug0" 2 : " *drug0* dep c conj t compound drug0" 3 : " *drug0* dep c conj ct compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 2 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 3 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 81 : { 1 : "NN compound NN compound NN" 2 : 3 3 : { 1 : "drug0 compound *allele* compound drug0" 2 : "drug0 compound *allele* compound drug0" 3 : "drug0 compound *p* compound drug0" } 4 : { 1 : "In adiposity-matched , normal-weight humans , we showed that subjects homozygous for the FTO drug2 drug1 A allele have dysregulated circulating levels of the orexigenic hormone acyl-ghrelin and attenuated drug3 . " 2 : "The increase in cotinine levels indicated an increased risk of drug3 with each additional copy of the drug1 - drug2 risk allele " 3 : "However , GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in drug3 in carriers of the risk allele in two variants ( drug1 drug2 p < 0.02 ) , " } } 82 : { 1 : "NN compound NN nmod VBN nsubjpass NNS nmod NNS dep NN conj NN" 2 : 3 3 : { 1 : "drug0 compound predisposition nmod *involved* nsubjpass variants nmod genes dep drug0 conj drug0" 2 : "drug0 compound predisposition nmod *involved* nsubjpass variants nmod genes dep drug0 conj drug0" 3 : "drug0 compound auc nmod *associated* nsubjpass alleles nmod snps dep drug0 conj drug0" } 4 : { 1 : "In this study , we investigated whether variants in three key pigmentation genes - drug1 , drug2 , and drug3 -- were involved in drug4 predisposition " 2 : "In this study , we investigated whether variants in three key pigmentation genes - drug1 , drug2 , and drug3 -- were involved in drug4 predisposition " 3 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 83 : { 1 : "NN appos NN dep NN dep NN appos NN" 2 : 3 3 : { 1 : "drug0 appos apob dep *tc* dep hl/lipc appos drug0" 2 : "drug0 appos drug0 dep celf0 dep *drug0* appos drug0" 3 : "drug0 appos drug0 dep runx0 dep *drug0* appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 84 : { 1 : "NN conj NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" 2 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" 3 : "drug0 conj drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 85 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod important xcomp appear dep *runx0* dep drug0 conj drug0" 2 : "drug0 nmod important xcomp appear dep *runx0* dep drug0 conj drug0" 3 : "drug0 nmod important xcomp appear dep *runx0* dep drug0 conj drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 86 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN" 2 : 3 3 : { 1 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" 2 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep *drug0*" 3 : "drug0 dep runx0 dep drug0 dep celf0 dep *drug0* appos drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 3 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 87 : { 1 : "NN nmod NN dobj VBG acl NNS nmod NN dobj VBD advcl VBG dobj NN conj NN compound NN" 2 : 3 3 : { 1 : "drug0 nmod association dobj examining acl studies nmod meta-analysis dobj *performed* advcl containing dobj drug0 conj t-to-c compound drug0" 2 : "drug0 nmod association dobj examining acl studies nmod meta-analysis dobj *performed* advcl containing dobj drug0 conj g-to-t compound drug0" 3 : "drug0 nmod association dobj examining acl studies nmod meta-analysis dobj *performed* advcl containing dobj drug0 conj g-to-c compound drug0" } 4 : { 1 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " 2 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " 3 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " } } 88 : { 1 : "NN conj NN dep NN appos NN" 2 : 3 3 : { 1 : "drug0 conj drug0 dep gamma appos *drug0*" 2 : "drug0 conj drug0 dep gamma appos *drug0*" 3 : "drug0 conj drug0 dep *apob* appos drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 3 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 89 : { 1 : "NN appos NN conj NNS dep NN appos NN" 2 : 3 3 : { 1 : "drug0 appos snp conj *snps* dep drug0 appos drug0" 2 : "drug0 appos snp conj *snps* dep drug0 appos drug0" 3 : "drug0 appos g/a conj *polymorphisms* dep g/a appos drug0" } 4 : { 1 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " 2 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " 3 : "BACKGROUND : Evidence has suggested that tumour necrosis factor ( TNF ) - a may be involved in the aetiology of psoriasis , but the underlying association of the TNF-a polymorphisms -238 G/A ( drug1 ) and -308 G/A ( drug2 ) with the risk of drug3 is still unconfirmed . " } } 90 : { 1 : "NN compound NN conj NN dep NN nmod NNS nmod NNS acl VBG nmod NN dep NN conj NN compound NN" 2 : 3 3 : { 1 : "drug0 compound g conj c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g conj g compound drug0" 2 : "drug0 compound t conj c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g conj g compound drug0" 3 : "drug0 compound ct conj c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g conj g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 2 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 3 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 91 : { 1 : "NN compound NNS appos NN conj NN dep NN conj NN compound NN" 2 : 3 3 : { 1 : "drug0 compound gg appos hypothesis conj *drug0* dep c conj g compound drug0" 2 : "drug0 compound gg appos hypothesis conj *drug0* dep c conj t compound drug0" 3 : "drug0 compound gg appos hypothesis conj *drug0* dep c conj ct compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 2 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 3 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 92 : { 1 : "NN nmod NN dep NN appos NN dep NN" 2 : 3 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep *drug0*" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep *drug0*" 3 : "drug0 nmod *drug0* dep drug0 appos gamma dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 3 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 93 : { 1 : "NN compound NN conj NN dep NN nmod NNS nmod NNS acl VBG nmod NN dep NN compound NN" 2 : 3 3 : { 1 : "drug0 compound g conj c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g compound drug0" 2 : "drug0 compound t conj c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g compound drug0" 3 : "drug0 compound ct conj c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 2 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " 3 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 94 : { 1 : "NN nmod VBN acl:relcl NNS nmod VBN dep NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod associated acl:relcl polymorphisms nmod *performed* dep drug0 conj drug0" 2 : "drug0 nmod associated acl:relcl polymorphisms nmod *performed* dep drug0 conj drug0" 3 : "drug0 nmod associated acl:relcl polymorphisms nmod *performed* dep drug0 conj drug0" } 4 : { 1 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 2 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " 3 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " } } 95 : { 1 : "NN compound NN nmod NN nmod NN conj NN" 2 : 3 3 : { 1 : "drug0 compound susceptibility nmod *role* nmod drug0 conj drug0" 2 : "drug0 compound susceptibility nmod *association* nmod drug0 conj drug0" 3 : "drug0 compound susceptibility nmod *association* nmod drug0 conj drug0" } 4 : { 1 : "RESULTS : Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs , our analyses did not support a role of drug1 or drug2 on drug3 susceptibility " 2 : "In addition to these polymorphisms , meta-analysis confirmed the association of drug4 susceptibility with KCNJ11 drug1 , TCF7L2 drug2 , and HHEX drug3 . " 3 : "In addition to these polymorphisms , meta-analysis confirmed the association of drug4 susceptibility with KCNJ11 drug1 , TCF7L2 drug2 , and HHEX drug3 . " } } 96 : { 1 : "NN conj NNS nmod NN nmod NNS dep NN conj NN" 2 : 3 3 : { 1 : "drug0 conj blocks nmod *association* nmod snps dep drug0 conj drug0" 2 : "drug0 conj blocks nmod *association* nmod snps dep drug0 conj drug0" 3 : "drug0 conj blocks nmod *association* nmod snps dep drug0 conj drug0" } 4 : { 1 : "We observed nominal association between four SNPs ( drug1 , drug2 , drug3 , and drug4 ) in three haplotype blocks and drug5 , age at diagnosis , and 2-h glucose levels ( P = 0.001-0 .055 ) . " 2 : "We observed nominal association between four SNPs ( drug1 , drug2 , drug3 , and drug4 ) in three haplotype blocks and drug5 , age at diagnosis , and 2-h glucose levels ( P = 0.001-0 .055 ) . " 3 : "We observed nominal association between four SNPs ( drug1 , drug2 , drug3 , and drug4 ) in three haplotype blocks and drug5 , age at diagnosis , and 2-h glucose levels ( P = 0.001-0 .055 ) . " } } 97 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN compound NN" 2 : 3 3 : { 1 : "drug0 nmod *associated* nsubjpass polymorphisms nmod cluster compound drug0" 2 : "drug0 nmod *associated* nsubjpass alleles nmod polymorphism compound drug0" 3 : "drug0 nmod *associated* nsubjpass alleles nmod polymorphism compound drug0" } 4 : { 1 : "Singlenucleotide polymorphisms ( SNPs ) and haplotypes in the drug1 / C3/A4/A5 gene cluster are associated with drug2 in Caucasians and with elevatedtriglycerides ( TG ) in various ethnic groups . " 2 : "Furthermore , the risk alleles from TCF7L2 drug1 polymorphism either with drug2 polymorphism ( p = 0.0257 , OR = 1.398 ) or with drug3 polymorphism ( p = 0.0024 , OR = 1.514 ) were significantly associated with drug4 . " 3 : "Furthermore , the risk alleles from TCF7L2 drug1 polymorphism either with drug2 polymorphism ( p = 0.0257 , OR = 1.398 ) or with drug3 polymorphism ( p = 0.0024 , OR = 1.514 ) were significantly associated with drug4 . " } } 98 : { 1 : "NN compound NNS nmod NN nmod NNS compound NN" 2 : 3 3 : { 1 : "drug0 compound phenotypes nmod *effect* nmod polymorphisms compound drug0" 2 : "drug0 compound subjects nmod diagnosis nmod *associates* compound drug0" 3 : "drug0 compound subjects nmod diagnosis nmod *associates* compound drug0" } 4 : { 1 : "No combined effect of drug1 polymorphisms on drug2 phenotypes was observed . " 2 : "The drug1 at-risk allele associates with decreased drug2 and earlier age at diagnosis in the drug3 subjects ( P = 8.0 x 10 ( -3 ) and P = 3.8 x 10 ( -4 ) , respectively ) , which is supported by quantitative family-based association tests . " 3 : "The drug1 T at-risk allele associates with drug2 and earlier age at diagnosis in the drug3 subjects ( P = 8.0 x 10 ( -3 ) and P = 3.8 x 10 ( -4 ) , respectively ) , which is supportedby quantitative family-based association tests . " } } 99 : { 1 : "NN compound NNS nmod NN nmod NNS nmod NN" 2 : 3 3 : { 1 : "drug0 compound subjects nmod diagnosis nmod *associates* nmod drug0" 2 : "drug0 compound subjects nmod diagnosis nmod *associates* nmod drug0" 3 : "drug0 compound families nmod *tg* nmod alleles nmod drug0" } 4 : { 1 : "The drug1 at-risk allele associates with decreased drug2 and earlier age at diagnosis in the drug3 subjects ( P = 8.0 x 10 ( -3 ) and P = 3.8 x 10 ( -4 ) , respectively ) , which is supported by quantitative family-based association tests . " 2 : "The drug1 T at-risk allele associates with drug2 and earlier age at diagnosis in the drug3 subjects ( P = 8.0 x 10 ( -3 ) and P = 3.8 x 10 ( -4 ) , respectively ) , which is supportedby quantitative family-based association tests . " 3 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 100 : { 1 : "NN nmod NN conj NN nmod NN" 2 : 3 3 : { 1 : "drug0 nmod association conj *association* nmod drug0" 2 : "drug0 nmod t-allele conj *t-allele* nmod drug0" 3 : "drug0 nmod association conj *association* nmod drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " 2 : "Both the T-allele of drug1 and the T-allele of drug2 significantly increase drug3 risk with an allelic odds ratio ( OR ) of 1.69 ( 95 % CI 1.55-1 .83 ) ( P = 6.0 x 10 ( -35 ) ) and 1.60 ( 1.47-1 .74 ) ( P = 7.6 x 10 ( -28 ) ) , respectively . " 3 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 101 : { 1 : "NN appos NN nmod NN" 2 : 3 3 : { 1 : "drug0 appos *risk* nmod drug0" 2 : "drug0 nmod *intron0* appos drug0" 3 : "drug0 appos lrrk0 nmod *drug0*" } 4 : { 1 : "In this study , we found that the COMT drug1 SNP was significantly associated with a reduced risk of drug2 , especially drug3 , which suggests that this SNP may have a protective effect . " 2 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " 3 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 102 : { 1 : "NN nmod NN dobj VBZ nsubj NN nmod NN nmod NN conj NN" 2 : 3 3 : { 1 : "drug0 nmod risk dobj *has* nsubj cgtc nmod order nmod drug0 conj drug0" 2 : "drug0 nmod risk dobj *has* nsubj cgtc nmod order nmod drug0 conj drug0" 3 : "drug0 nmod risk dobj *has* nsubj cgtc nmod order nmod drug0 conj drug0" } 4 : { 1 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 2 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " 3 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " } } 103 : { 1 : "NN conj NN compound NN" 2 : 3 3 : { 1 : "drug0 conj *allele* compound drug0" 2 : "drug0 conj *genotype* compound drug0" 3 : "drug0 conj *disease* compound drug0" } 4 : { 1 : "RESULTS : In the discovery population , we observed an association between SIRT2 drug1 T allele and drug2 ( adjusted odds ratio [ OR ] = 1.23 , 95 % confidence interval [ CI ] : 1.02-1 .50 , P = .02 , after correction for sex , age , and APOE e4 genotype ) . " 2 : "However , no relationships were found between drug1 genotype and drug2 in 2 cohorts ( n = 1648 and n = 1039 ) of healthy middle-aged carriers of the APOE e3/e3 genotype . " 3 : "OBJECTIVE : We investigated if the FTO drug1 associates with food preferences in healthy adults with no drug2 , drug3 disease , or drug4 . " } } 104 : { 1 : "NN compound NNS nmod NN nmod NN" 2 : 3 3 : { 1 : "drug0 compound symptoms nmod *association* nmod drug0" 2 : "drug0 nmod risk nmod *polymorphisms* compound drug0" 3 : "drug0 compound families nmod replication nmod *drug0*" } 4 : { 1 : "RESULTS : With multivariate generalized linear models , the association of TEF drug1 with drug2 symptoms was confirmed . " 2 : "A significant association was observed between , drug1 ( OR = 1.95 , C.I. 1.13-3 .36 ) and drug2 ( OR = 2.39 , C.I. 1.24-4 .24 ) polymorphisms with the risk of drug3 . " 3 : "When testing drug1 and drug2 for replication in Finnish drug3 families , these single nucleotide polymorphisms were associated with drug4 ( p = 0.01 and p = 0.007 ) . " } } 105 : { 1 : "NN compound NN nmod NN conj VBN nmod NN" 2 : 2 3 : { 1 : "drug0 compound disease nmod *factor* conj described nmod drug0" 2 : "drug0 compound disease nmod *factor* conj described nmod drug0" } 4 : { 1 : "BACKGROUND : drug4 ( HTG ) is a well-established independent risk factor for drug5 disease and the influence of several geneti c variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " 2 : "BACKGROUND : Hypertriglyceridemia ( HTG ) is a well-established independent risk factor for drug4 disease and the influence of several genetic variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " } } 106 : { 1 : "NN compound NNS nmod NN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound components nmod number nmod *association* nmod drug0" 2 : "drug0 nmod marker nmod *application* nmod snps compound drug0" } 4 : { 1 : "The association of drug1 with the number of the drug2 components was significant regardless of age , sex , obesity and alcohol drinking , but almost disappeared after further adjusting for plasma triglycerides . " 2 : "If the application of TCF7L2 drug1 SNPs as a marker for drug2 is confirmed by further independent studies , replacing tacrolimus with other immunosuppressants could be warranted in patients at high risk of drug3 , as diagnosed by TCF7L2 genotyping . " } } 107 : { 1 : "NN compound NNS nsubj NNS compound NN conj NN" 2 : 2 3 : { 1 : "drug0 compound *factors* nsubj markers compound drug0 conj drug0" 2 : "drug0 compound *factors* nsubj markers compound drug0 conj drug0" } 4 : { 1 : "Thus , we have shown that the drug1 and drug2 markers are independent genetic drug3 risk factors in a Russian population . " 2 : "Thus , we have shown that the drug1 and drug2 markers are independent genetic drug3 risk factors in a Russian population . " } } 108 : { 1 : "NN compound NN conj NN nmod VBN nsubjpass NN compound NN" 2 : 2 3 : { 1 : "drug0 compound genotype conj drug0 nmod *associated* nsubjpass genotype compound drug0" 2 : "drug0 compound allele conj drug0 nmod *associated* nsubjpass polymorphism compound drug0" } 4 : { 1 : "The drug1 ( T ) allele genotype was significantly associated with drug3 ( P = 0.003 ) but drug2 ( T ) allele genotype was not associated with the clinico-pathologic characteristics . " 2 : "The non-synonymous drug1 polymorphism of the ADRB3 gene was associated with drug2 ( Trpallele , OR = 0.62 , p = 0.001 ) and drug3 ( Trp allele , OR = 0.74 , p = 0.018 ) . " } } 109 : { 1 : "NN compound NNS nsubj NNS compound NN" 2 : 2 3 : { 1 : "drug0 compound *factors* nsubj markers compound drug0" 2 : "drug0 compound *factors* nsubj markers compound drug0" } 4 : { 1 : "Thus , we have shown that the drug1 and drug2 markers are independent genetic drug3 risk factors in a Russian population . " 2 : "Thus , we have shown that the drug1 and drug2 markers are independent genetic drug3 risk factors in a Russian population . " } } 110 : { 1 : "NN nsubj NN conj VBN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nsubj *factor* conj described nmod drug0 conj drug0" 2 : "drug0 nsubj *factor* conj described nmod drug0 conj drug0" } 4 : { 1 : "BACKGROUND : drug4 ( HTG ) is a well-established independent risk factor for drug5 disease and the influence of several geneti c variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " 2 : "BACKGROUND : drug4 ( HTG ) is a well-established independent risk factor for drug5 disease and the influence of several geneti c variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " } } 111 : { 1 : "NN dep NN conj JJ dep VBN dep NN dep JJ dep CD" 2 : 2 3 : { 1 : "drug0 dep snp conj = dep associated dep *or* dep = dep drug0" 2 : "drug0 dep snp conj = dep associated dep *or* dep = dep drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " 2 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 112 : { 1 : "CD dep JJ dep VBN dep NN dep JJ dep CD" 2 : 2 3 : { 1 : "drug0 dep = dep associated dep *or* dep = dep drug0" 2 : "drug0 dep = dep associated dep *or* dep = dep drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " 2 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 113 : { 1 : "NN conj NN nmod NN nmod VB nsubj NN compound NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod risk nmod *contribute* nsubj polymorphism compound drug0" 2 : "drug0 conj drug0 nmod risk nmod *contribute* nsubj polymorphism compound drug0" } 4 : { 1 : "Stratified analysis by drug2 type revealed that the STK drug1 polymorphism may contribute to the risk of drug3 ( AA vs. TT : OR = 1.21 , 95 % CI = 1.01-1 .44 , Pheterogeneity = 0.002 ) , drug4 ( AA vs. UNASSIGNED : OR = 1.24 , 95 % CI = 1.05-1 .47 , Pheterogeneity = 0.124 ) , and drug5 ( AA vs. UNASSIGNED : OR = 1.19 , 95 % CI = 1.02-1 .39 , Pheterogeneity = 0.148 ) " 2 : "Stratified analysis by drug2 type revealed that the STK drug1 polymorphism may contribute to the risk of drug3 ( AA vs. TT : OR = 1.21 , 95 % CI = 1.01-1 .44 , Pheterogeneity = 0.002 ) , drug4 ( AA vs. UNASSIGNED : OR = 1.24 , 95 % CI = 1.05-1 .47 , Pheterogeneity = 0.124 ) , and drug5 ( AA vs. UNASSIGNED : OR = 1.19 , 95 % CI = 1.02-1 .39 , Pheterogeneity = 0.148 ) " } } 114 : { 1 : "NN nmod VBN nsubjpass NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod *associated* nsubjpass genotype conj drug0" 2 : "drug0 nmod *associated* nsubjpass drug0 conj drug0" } 4 : { 1 : "Whereas the NOD2 genotype and drug2 are positively associated with drug3 , the drug1 genotype is positively associated with drug4 ( L2 ) disease . " 2 : "These data show that drug1 and drug2 are significantly associated with high drug3 in drug4 families from two different populations . " } } 115 : { 1 : "NN conj NN nmod NNS nmod NN dobj VBP advcl VBZ nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod genetics nmod involvement dobj *suggest* advcl needs nsubj role nmod drug0" 2 : "drug0 conj drug0 nmod genetics nmod involvement dobj *suggest* advcl needs nsubj role nmod drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " 2 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 116 : { 1 : "NN compound NN nmod VBN dep NN dep JJ dep CD" 2 : 2 3 : { 1 : "drug0 compound susceptibility nmod associated dep *or* dep = dep drug0" 2 : "drug0 compound susceptibility nmod associated dep *or* dep = dep drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " 2 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 117 : { 1 : "NN nmod VBN acl:relcl NN conj NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod associated acl:relcl *r0l* conj d0h appos drug0" 2 : "drug0 nmod associated acl:relcl *r0l* conj r0c appos drug0" } 4 : { 1 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " 2 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " } } 118 : { 1 : "CD dep JJ dep NN dep NNS nmod NN appos NN" 2 : 2 3 : { 1 : "drug0 dep = dep or dep *data* nmod model appos drug0" 2 : "drug0 dep = dep or dep *data* nmod model appos drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " 2 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 119 : { 1 : "NN conj NN nmod NN nmod VB ccomp VBD nsubj NN nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod risk nmod contribute ccomp *revealed* nsubj analysis nmod type compound drug0" 2 : "drug0 conj drug0 nmod risk nmod contribute ccomp *revealed* nsubj analysis nmod type compound drug0" } 4 : { 1 : "Stratified analysis by drug2 type revealed that the STK drug1 polymorphism may contribute to the risk of drug3 ( AA vs. TT : OR = 1.21 , 95 % CI = 1.01-1 .44 , Pheterogeneity = 0.002 ) , drug4 ( AA vs. UNASSIGNED : OR = 1.24 , 95 % CI = 1.05-1 .47 , Pheterogeneity = 0.124 ) , and drug5 ( AA vs. UNASSIGNED : OR = 1.19 , 95 % CI = 1.02-1 .39 , Pheterogeneity = 0.148 ) " 2 : "Stratified analysis by drug2 type revealed that the STK drug1 polymorphism may contribute to the risk of drug3 ( AA vs. TT : OR = 1.21 , 95 % CI = 1.01-1 .44 , Pheterogeneity = 0.002 ) , drug4 ( AA vs. UNASSIGNED : OR = 1.24 , 95 % CI = 1.05-1 .47 , Pheterogeneity = 0.124 ) , and drug5 ( AA vs. UNASSIGNED : OR = 1.19 , 95 % CI = 1.02-1 .39 , Pheterogeneity = 0.148 ) " } } 120 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN" 2 : 2 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep *drug0*" 2 : "drug0 nmod important xcomp appear dep *runx0* dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 121 : { 1 : "NN nmod NN conj NN root , punct NN" 2 : 2 3 : { 1 : "drug0 nmod 0mo conj ratio root , punct *drug0*" 2 : "drug0 nmod abstinence conj ratio root , punct *drug0*" } 4 : { 1 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " 2 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " } } 122 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS dep NN" 2 : 2 3 : { 1 : "drug0 nmod reduction nmod *associated* nsubjpass polymorphisms dep drug0" 2 : "drug0 nmod association nmod *tested* nsubjpass polymorphisms dep drug0" } 4 : { 1 : "Two polymorphisms ( drug1 , drug2 ) that define the epsilon2 , epsilon3 , and epsilon4 isoforms of apolipoprotein E were significantly associated with percent reduction in drug3 ( epsilon2 carriers 53.8 % , epsilon3/epsilon3 48.1 % , and epsilon4 carriers 46.4 % , respectively , P = 0.00039 ) and replicated in the drug4 ( epsilon2 carriers 22.1 % , epsilon3/epsilon3 21.8 % , and epsilon4 carriers 16.6 % , respectively , P = 0.00038 ) . " 2 : "BACKGROUND : Single nucleotide polymorphisms ( SNPs ) drug1 ( e4 ) and drug2 ( e2 ) , both invoking changes in the amino-acid sequence of the apolipoprotein E ( APOE ) gene , have previously been tested for association with drug3 ( MS ) risk . " } } 123 : { 1 : "NN nmod VBN acl NNS nsubjpass VBN nmod NN punct -LRB- root NN punct , root NN conj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod associated acl alleles nsubjpass *associated* nmod abstinence punct [ root drug0 punct , root ratio conj 0mo nmod drug0" 2 : "drug0 nmod associated acl alleles nsubjpass *associated* nmod abstinence punct [ root drug0 punct , root ratio conj abstinence nmod drug0" } 4 : { 1 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " 2 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " } } 124 : { 1 : "NN nmod VBN nsubjpass NNS compound NN" 2 : 2 3 : { 1 : "drug0 nmod *associated* nsubjpass polymorphisms compound drug0" 2 : "drug0 nmod *associated* nsubjpass haplotypes compound drug0" } 4 : { 1 : "Though drug1 / C3/A4/A5 genetic polymorphisms are associated with drug2 , their effect on central drug3 is less known " 2 : "CONCLUSIONS : drug1 haplotypes are significantly associated with drug2 in our population . " } } 125 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN" 2 : 2 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass variants nmod drug0" 2 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod drug0" } 4 : { 1 : "Our results strengthen the evidence that one or more variants in drug1 are associated with increased risk of drug2 . " 2 : "The minor alleles of drug1 ( TCF7L2 ) , drug2 ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " } } 126 : { 1 : "NN nmod NN dobj VBD nsubj NN" 2 : 2 3 : { 1 : "drug0 nmod association dobj *showed* nsubj drug0" 2 : "drug0 nmod association dobj *showed* nsubj drug0" } 4 : { 1 : "For the combined sample set , in which we successfully genotyped 1,174 type 2 diabetes patients and 823 control subjects , drug1 showed a significant association with drug2 ( odds ratio = 1.69 [ 95 % CI 1.21-2 .36 ] , p = 0.002 ) with the same direction as the previous reports in samples from European and European-origin populations . " 2 : "while , drug1 showed a statistically significant association between drug2 and drug3 patients carrying the 26V allele ( OR = 1.69 , 95 % CI = 1.11-2 .56 , P = 0.013 ) . " } } 127 : { 1 : "NN nmod NNS dobj VB nsubj NN nmod NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod associations dobj *show* nsubj rest nmod snps dep drug0 conj drug0" 2 : "drug0 nmod associations dobj *show* nsubj rest nmod snps dep drug0 conj drug0" } 4 : { 1 : "The rest of the five SNPs ( drug1 , drug2 and drug3 ) did not show any significant associations with drug4 . " 2 : "The rest of the five SNPs ( drug1 , drug2 and drug3 ) did not show any significant associations with drug4 . " } } 128 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod *associated* nsubjpass variants nmod apoa0 appos drug0" 2 : "drug0 nmod *associated* nsubjpass variants nmod apoa0 appos drug0" } 4 : { 1 : "RESULTS : After correcting for multiple testing ( p < 0.05 ) and accounting for significant differences in the association effect sizes between subjects with and without drug4 ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with HDL-C and LDL-C responses in MetS subjects , while APOA4 drug3 was associated with TG response in non-MetS subjects . " 2 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 129 : { 1 : "NN nmod NN dobj VBD conj VBD nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod association dobj revealed conj *showed* nsubj allele nmod drug0" 2 : "drug0 nmod association dobj revealed conj *showed* nsubj allele nmod drug0" } 4 : { 1 : "The T allele of drug1 showed an association with borderline significance ( OR = 1.19 , 95 % C.I. = 1.01-1 .42 , P = 0.04 ) , and the Cochran-Armitage test for trend revealed an allele dose-dependent association of drug2 with drug3 ( Ptrend = 0.04 ) . " 2 : "The T allele of drug1 showed an association with borderline significance ( OR = 1.19 , 95 % C.I. = 1.01-1 .42 , P = 0.04 ) , and the Cochran-Armitage test for trend revealed an allele dose-dependent association of drug2 with drug3 ( Ptrend = 0.04 ) . " } } 130 : { 1 : "NN nmod NN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod risk nmod *influence* nmod drug0" 2 : "drug0 nmod effect nmod *association* nmod drug0" } 4 : { 1 : "Our results suggest a possible influence of TCF7L2 drug1 on the risk of drug2 . " 2 : "Multivariate analysis showed association between drug1 and drug3 , independently from the effect of drug2 . " } } 131 : { 1 : "NN nmod NN nmod NNS nmod NN nmod NNS dep NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod *reduction* nmod carriers nmod allele nmod variants dep p compound drug0" 2 : "drug0 nmod *reduction* nmod carriers nmod allele nmod variants dep p compound drug0" } 4 : { 1 : "However , GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in drug3 in carriers of the risk allele in two variants ( drug1 drug2 p < 0.02 ) , " 2 : "However , GLP-1-infusion combined with a hyperglycaemic clamp showed a significant reduction in drug3 in carriers of the risk allele in two variants ( drug1 drug2 p < 0.02 ) , " } } 132 : { 1 : "NN nmod NNS nmod NN dobj VBP advcl VBZ nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod genetics nmod involvement dobj *suggest* advcl needs nsubj role nmod drug0" 2 : "drug0 nmod genetics nmod involvement dobj *suggest* advcl needs nsubj role nmod drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " 2 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 133 : { 1 : "NN conj NN compound NNS nmod NNS nmod NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 conj lipid compound disorders nmod *roles* nmod polymorphisms nmod drug0 conj drug0" 2 : "drug0 conj lipid compound disorders nmod *roles* nmod polymorphisms nmod drug0 conj drug0" } 4 : { 1 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " 2 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " } } 134 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN amod JJ nmod:npmod NN" 2 : 2 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf amod = nmod:npmod drug0" 2 : "drug0 nmod risk nmod *associated* nsubjpass alleles nmod tf amod = nmod:npmod drug0" } 4 : { 1 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " 2 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " } } 135 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 136 : { 1 : "NN appos NN dep NN conj NN appos NN" 2 : 2 3 : { 1 : "drug0 appos leu0pro dep t0c conj *intron0* appos drug0" 2 : "drug0 appos drug0 dep g-0a conj *c0t* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " 2 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 137 : { 1 : "NN nmod NN nmod NN dobj VBD conj VBD dobj NNS nmod NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod prevention nmod importance dobj suggested conj *confirmed* dobj roles nmod polymorphisms nmod drug0 conj drug0" 2 : "drug0 nmod prevention nmod importance dobj suggested conj *confirmed* dobj roles nmod polymorphisms nmod drug0 conj drug0" } 4 : { 1 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " 2 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " } } 138 : { 1 : "NN compound NN nmod VBN advcl VBN ccomp VBD nsubj NN compound NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 compound risk nmod associated advcl associated ccomp *demonstrated* nsubj analysis compound 0-locus dep drug0 conj drug0" 2 : "drug0 compound risk nmod associated advcl associated ccomp *demonstrated* nsubj analysis compound 0-locus dep drug0 conj drug0" } 4 : { 1 : "The four tested TCF7L2 variants were in linkage disequilibrium , and 4-locus ( drug1 , drug2 , drug3 , drug4 ) haplotype analysis demonstrated that haplotype 1111 was negatively associated ( Pc < 0.001 ) , while haplotypes 2222 ( Pc = 0.008 ) and 2211 ( Pc = 0.020 ) were positively associated with drug5 risk , after controlling for a number of covariates . " 2 : "The four tested TCF7L2 variants were in linkage disequilibrium , and 4-locus ( drug1 , drug2 , drug3 , drug4 ) haplotype analysis demonstrated that haplotype 1111 was negatively associated ( Pc < 0.001 ) , while haplotypes 2222 ( Pc = 0.008 ) and 2211 ( Pc = 0.020 ) were positively associated with drug5 risk , after controlling for a number of covariates . " } } 139 : { 1 : "NN compound NN nmod VBN nsubjpass NNS nmod NNS dep NN" 2 : 2 3 : { 1 : "drug0 compound predisposition nmod *involved* nsubjpass variants nmod genes dep drug0" 2 : "drug0 compound auc nmod *associated* nsubjpass alleles nmod snps dep drug0" } 4 : { 1 : "In this study , we investigated whether variants in three key pigmentation genes - drug1 , drug2 , and drug3 -- were involved in drug4 predisposition " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 140 : { 1 : "NN conj NNS dep NN" 2 : 2 3 : { 1 : "drug0 conj *snps* dep drug0" 2 : "drug0 conj *polymorphisms* dep drug0" } 4 : { 1 : "Subgroups analyses show that significant associations are not found between the six SNPs ( drug1 , drug2 , drug3 , drug4 , drug5 , and drug6 ) and the drug7 in some ethnic populations . " 2 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 141 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN conj NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod *associated* nsubjpass variants nmod apoa0 conj apoe appos drug0" 2 : "drug0 nmod *associated* nsubjpass variants nmod apoa0 conj apoe appos drug0" } 4 : { 1 : "RESULTS : After correcting for multiple testing ( p < 0.05 ) and accounting for significant differences in the association effect sizes between subjects with and without drug4 ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with HDL-C and LDL-C responses in MetS subjects , while APOA4 drug3 was associated with TG response in non-MetS subjects . " 2 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 142 : { 1 : "NN compound NN nmod NN dobj VBP advcl VBZ nsubj NN nmod NN" 2 : 2 3 : { 1 : "drug0 compound locus nmod involvement dobj *suggest* advcl needs nsubj role nmod drug0" 2 : "drug0 nmod role nsubj needs advcl *suggest* dobj involvement nmod locus compound drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " 2 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 143 : { 1 : "NN nmod VBN xcomp VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 nmod associated xcomp *found* nsubjpass drug0" 2 : "drug0 nmod associated xcomp *considered* nsubjpass drug0" } 4 : { 1 : "drug1 , SFA intake , and drug2 were found to be associated with drug3 in Lithuanian adult population . " 2 : "CONCLUSIONS : The present results indicated PRCP drug1 can be considered as a marker for EH and Hap3 GAGCACTAACA ( PRCP ) and Hap16 TTTA ( CMA1 ) might be associated with drug2 in Chinese Han population . " } } 144 : { 1 : "NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" 2 : "drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 145 : { 1 : "NN appos NN dep NN dep VBD dep VBZ dep NN conj NN dep NN" 2 : 2 3 : { 1 : "drug0 appos hl/lipc dep tc dep *identified* dep designs dep .0 conj .0 dep drug0" 2 : "drug0 appos apob dep tc dep *identified* dep designs dep .0 conj .0 dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " 2 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 146 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj *drug0*" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 147 : { 1 : "NN compound NNS nmod VBN nsubjpass NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 compound patients nmod *studied* nsubjpass polymorphisms dep drug0 conj drug0" 2 : "drug0 compound patients nmod *studied* nsubjpass polymorphisms dep drug0 conj drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " 2 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 148 : { 1 : "NN conj NN dep NN appos NN dep NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep gamma appos drug0 dep *drug0*" 2 : "drug0 conj drug0 dep gamma appos drug0 dep *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 149 : { 1 : "NN conj NN dep NN appos NN dep NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj *drug0*" 2 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 150 : { 1 : "NN nmod NN nmod VBN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 nmod *associated* dep drug0 conj drug0" 2 : "drug0 nmod drug0 nmod *associated* dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 151 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0* conj drug0" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0* conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 152 : { 1 : "NN nmod VBN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod *associated* dep drug0 conj drug0" 2 : "drug0 nmod *associated* dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 153 : { 1 : "NN conj NN dep NN appos NN dep NN dep NN conj NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0* conj drug0" 2 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0* conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 154 : { 1 : "NN conj NN nmod NN appos NN conj NN compound NN" 2 : 2 3 : { 1 : "drug0 conj slc0a0 nmod drug0 appos *lrrk0* conj park0 compound drug0" 2 : "drug0 conj slc0a0 nmod drug0 appos *lrrk0* conj park0 compound drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 2 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 155 : { 1 : "NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 dep gamma appos *drug0*" 2 : "drug0 dep *apob* appos drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 156 : { 1 : "NN nmod NN nmod VBN dep NN conj NN conj NN dep NN dep NN appos NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0 appos gamma dep drug0 conj drug0" 2 : "drug0 nmod drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0 appos gamma dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 157 : { 1 : "NN nmod NN dep NN appos NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod *drug0* dep drug0 appos gamma dep drug0 conj drug0" 2 : "drug0 nmod *drug0* dep drug0 appos gamma dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 158 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 nmod drug0" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 nmod drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 159 : { 1 : "NN conj NN nmod NN appos NN nmod NN appos NNP nmod NN appos NN" 2 : 2 3 : { 1 : "drug0 conj slc0a0 nmod drug0 appos lrrk0 nmod drug0 appos snca nmod *e0k* appos drug0" 2 : "drug0 conj slc0a0 nmod drug0 appos lrrk0 nmod drug0 appos snca nmod *e0k* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 2 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 160 : { 1 : "NN nmod VBN dep NN conj NN conj NN dep NN dep NN appos NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0 appos gamma dep drug0 conj drug0" 2 : "drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0 appos gamma dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 161 : { 1 : "NN nmod NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos *drug0*" 2 : "drug0 nmod drug0 dep gamma appos *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 162 : { 1 : "NN nmod NN dep NN appos NN dep NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep *drug0* nmod drug0" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep *drug0* nmod drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 163 : { 1 : "NN nmod NN dep NN" 2 : 2 3 : { 1 : "drug0 nmod *drug0* dep drug0" 2 : "drug0 dep *snp* nmod drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "RESULTS : Genome-wide significance in fully adjusted models ( sex , age , APOE genotype , population stratification ) was observed for a SNP in drug1 ( drug2 , allele = G ; frequency , 0.09 cases and 0.06 controls ; odds ratio [ OR ] , 1.79 [ 95 % CI , 1.47-2 .12 ] ; P = 2.2 * 10 ( -9 ) ) , which is in linkage disequilibrium with SNPs previously associated with drug3 disease in Europeans ( 0.8 < D' < 0.9 ) . " } } 164 : { 1 : "NN nmod NNS nmod NNS dep NN" 2 : 2 3 : { 1 : "drug0 nmod subjects nmod *snps* dep drug0" 2 : "drug0 nmod subjects nmod *snps* dep drug0" } 4 : { 1 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " 2 : "We genotyped four of the SNPs ( drug1 , drug2 , drug3 , and drug4 ) in Amish subjects with drug5 ( n = 137 ) , drug6 ( IGT ; n = 139 ) , and drug7 ( NGT ; n = 342 ) . " } } 165 : { 1 : "NN appos NN dep NN dep VBD dep VBZ dep NN conj NN dep NN conj NN" 2 : 2 3 : { 1 : "drug0 appos hl/lipc dep tc dep *identified* dep designs dep .0 conj .0 dep drug0 conj drug0" 2 : "drug0 appos apob dep tc dep *identified* dep designs dep .0 conj .0 dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " 2 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 166 : { 1 : "NN appos NNS conj NN conj NN" 2 : 2 3 : { 1 : "drug0 appos 0fs conj *slc0a0* conj drug0" 2 : "drug0 appos 0fs conj *slc0a0* conj drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 2 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 167 : { 1 : "NN conj NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" 2 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 168 : { 1 : "NN conj JJ dep NN" 2 : 2 3 : { 1 : "drug0 conj = dep *drug0*" 2 : "drug0 dep *=* conj drug0" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " 2 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 169 : { 1 : "NN appos NNP conj NN dep VBD dep NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 appos iii conj apoa0 dep *identified* dep tc dep hl/lipc appos drug0" 2 : "drug0 appos iii conj apoa0 dep *identified* dep tc dep apob appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " 2 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 170 : { 1 : "NN compound NNS nsubj VBD dep NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 compound associations nsubj *identified* dep tc dep hl/lipc appos drug0" 2 : "drug0 compound associations nsubj *identified* dep tc dep apob appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " 2 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 171 : { 1 : "NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" 2 : "drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 172 : { 1 : "NN conj NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" 2 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 173 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 174 : { 1 : "NN nmod NN dobj VBD nsubj NNS dep NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod association dobj *showed* nsubj snps dep drug0 appos drug0" 2 : "drug0 nmod association dobj *showed* nsubj snps dep drug0 appos drug0" } 4 : { 1 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " 2 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " } } 175 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0*" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 176 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 177 : { 1 : "NN conj NN dep VBN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep *associated* nmod drug0 conj drug0" 2 : "drug0 conj drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 178 : { 1 : "NN compound NN appos NN nmod NNP appos NN nmod NN appos NN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 compound *disease* appos e0k nmod snca appos drug0 nmod lrrk0 appos drug0 nmod slc0a0 conj drug0" 2 : "drug0 compound *disease* appos e0k nmod snca appos drug0 nmod lrrk0 appos drug0 nmod slc0a0 conj drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 2 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 179 : { 1 : "NN appos NN conj NN nmod NNS conj NN conj NN" 2 : 2 3 : { 1 : "drug0 appos g0r conj nod0 nmod 0fs conj *slc0a0* conj drug0" 2 : "drug0 appos g0r conj nod0 nmod 0fs conj *slc0a0* conj drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 2 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 180 : { 1 : "NN appos NN dep VBD dep NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 appos apoa0 dep *identified* dep tc dep hl/lipc appos drug0" 2 : "drug0 appos apoa0 dep *identified* dep tc dep apob appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " 2 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 181 : { 1 : "NN conj NN dep NN appos NN dep NN dep NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0*" 2 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 182 : { 1 : "NN nmod NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" 2 : "drug0 nmod drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 183 : { 1 : " NN compound NN" 2 : 2 3 : { 1 : " *drug0* compound drug0" 2 : " *drug0* compound drug0" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " 2 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 184 : { 1 : "NN conj NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" 2 : "drug0 conj drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " 2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 185 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep *drug0* appos drug0" 2 : "drug0 nmod important xcomp appear dep *runx0* dep drug0 appos drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 186 : { 1 : "NN nmod NN nmod NN conj NNS compound NN" 2 : 2 3 : { 1 : "drug0 nmod *association* nmod drug0 conj snps compound drug0" 2 : "drug0 nmod *effect* nmod drug0 conj genotypes compound drug0" } 4 : { 1 : "We evaluated the published evidence for association between drug1 ( k = 27 samples ) and drug2 ( k = 44 samples ) SNPs with drug3 using meta-analytic techniques . " 2 : "We studied the effect of TCF7L2 drug1 and drug2 genotypes on drug3 " } } 187 : { 1 : "NN conj NN nmod NN appos NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj slc0a0 nmod drug0 appos lrrk0 nmod *drug0*" 2 : "drug0 conj slc0a0 nmod drug0 appos lrrk0 nmod *drug0*" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " 2 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 188 : { 1 : "NN nsubj VBD dep VBD nsubj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nsubj showed dep *showed* nsubj alleles nmod drug0 conj drug0" 2 : "drug0 nsubj showed dep *showed* nsubj alleles nmod drug0 conj drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " 2 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 189 : { 1 : "NN nmod NN conj NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod risk conj *genotype* compound drug0" 2 : "drug0 compound park0 conj lrrk0 nmod *drug0*" } 4 : { 1 : "However , we found an association between drug1 genotype ( Val/Val ) and A drug2 carrier status and the risk of drug3 and drug4 . " 2 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 190 : { 1 : "NN compound NNS nmod NN nmod CD xcomp VBN conj VBN nsubjpass NNS acl VBN nmod NN conj NNS compound NN" 2 : 2 3 : { 1 : "drug0 compound studies nmod association nmod one xcomp found conj *studied* nsubjpass haplotypes acl determined nmod drug0 conj snps compound drug0" 2 : "drug0 compound studies nmod association nmod one xcomp found conj *studied* nsubjpass haplotypes acl determined nmod drug0 conj snps compound drug0" } 4 : { 1 : "BACKGROUND : Apolipoprotein E ( APOE ) functional haplotypes determined by drug1 and drug2 SNPs have been extensively studied and found to be one of the most consistent association in human drug3 studies . " 2 : "Apolipoprotein E ( APOE ) functional haplotypes determined by drug1 and drug2 SNPs have been extensively studied and found to be one of the most consistent association in human drug3 studies . " } } 191 : { 1 : "NN nmod NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NNS conj NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod diagnosis nmod time nmod performed acl ogtt nmod *associated* nsubjpass alleles conj drug0 conj drug0" 2 : "drug0 nmod diagnosis nmod time nmod performed acl ogtt nmod *associated* nsubjpass alleles conj drug0 conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 192 : { 1 : "NN nmod NN nmod VB nsubj NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod marker nmod *operate* nsubj variant compound drug0" 2 : "drug0 nmod risk nmod *contribute* nsubj polymorphism compound drug0" } 4 : { 1 : "Moreover , the drug1 variant may not merely operate as a marker for drug2 . " 2 : "Stratified analysis by drug2 type revealed that the STK drug1 polymorphism may contribute to the risk of drug3 ( AA vs. TT : OR = 1.21 , 95 % CI = 1.01-1 .44 , Pheterogeneity = 0.002 ) , drug4 ( AA vs. UNASSIGNED : OR = 1.24 , 95 % CI = 1.05-1 .47 , Pheterogeneity = 0.124 ) , and drug5 ( AA vs. UNASSIGNED : OR = 1.19 , 95 % CI = 1.02-1 .39 , Pheterogeneity = 0.148 ) " } } 193 : { 1 : "NN nmod NN nmod NNS nmod NN" 2 : 2 3 : { 1 : "drug0 nmod development nmod *effects* nmod drug0" 2 : "drug0 nmod persons nmod *risk* nmod drug0" } 4 : { 1 : "There were also no significant effects of drug1 or E4 carriers on the development of drug2 , but multivariate logistic regression testing revealed that the duration of drug3 and triglyceride and hemoglobin A1c concentrations had independent effects on the development of drug4 . " 2 : "Common variants in drug1 seem to be associated with an increased risk of drug2 among persons with drug3 . " } } 194 : { 1 : "NN compound NN nmod VBN nsubjpass NNS conj NN conj NN" 2 : 2 3 : { 1 : "drug0 compound auc nmod *associated* nsubjpass alleles conj drug0 conj drug0" 2 : "drug0 compound auc nmod *associated* nsubjpass alleles conj drug0 conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 195 : { 1 : "NN nmod NNS nsubjpass VBN nmod NNS dep NN conj NN appos NN" 2 : 2 3 : { 1 : "drug0 nmod patients nsubjpass *genotyped* nmod variants dep drug0 conj drug0 appos drug0" 2 : "drug0 nmod patients nsubjpass *genotyped* nmod variants dep drug0 conj pro0his appos drug0" } 4 : { 1 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " 2 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " } } 196 : { 1 : "NN nmod NNS nmod NNS dobj VBD conj VBD dobj NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod subjects nmod frequencies dobj *compared* conj found dobj association nmod drug0" 2 : "drug0 nmod subjects nmod frequencies dobj *compared* conj found dobj association nmod drug0" } 4 : { 1 : "We compared genotype frequencies in subjects with drug2 with those with NGT and found marginal association for drug1 ( P = 0.05 ; odds ratio [ OR ] 1.51 ) ; " 2 : "We compared genotype frequencies in subjects with drug2 with those with NGT and found marginal association for drug1 ( P = 0.05 ; odds ratio [ OR ] 1.51 ) ; " } } 197 : { 1 : "NN dep NN dep NN dep NN dep NN" 2 : 2 3 : { 1 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" 2 : "drug0 dep runx0 dep drug0 dep celf0 dep *drug0*" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 198 : { 1 : "NN compound NNS nmod NN nmod CD xcomp VBN conj VBN nsubjpass NNS acl VBN nmod NN" 2 : 2 3 : { 1 : "drug0 compound studies nmod association nmod one xcomp found conj *studied* nsubjpass haplotypes acl determined nmod drug0" 2 : "drug0 compound studies nmod association nmod one xcomp found conj *studied* nsubjpass haplotypes acl determined nmod drug0" } 4 : { 1 : "BACKGROUND : Apolipoprotein E ( APOE ) functional haplotypes determined by drug1 and drug2 SNPs have been extensively studied and found to be one of the most consistent association in human drug3 studies . " 2 : "Apolipoprotein E ( APOE ) functional haplotypes determined by drug1 and drug2 SNPs have been extensively studied and found to be one of the most consistent association in human drug3 studies . " } } 199 : { 1 : "NN compound NN conj NN dobj VBP" 2 : 2 3 : { 1 : "drug0 compound t/c conj ratio dobj *drug0*" 2 : "drug0 compound or conj ratio dobj *drug0*" } 4 : { 1 : "RESULTS : Significant associations with drug4 were observed for genotypes drug1 A/T ( odds ratio [ OR ] , 2.1 ; 95 % confidence interval [ CI ] , 1.0-4 .5 ) , drug2 T/C ( OR , 4.4 ; 95 % CI , 1.9-10 .2 ) , and drug3 ( OR , 4.1 ; 95 % CI , 1.6-10 .9 ) " 2 : "RESULTS : Significant associations with drug4 were observed for genotypes drug1 A/T ( odds ratio [ OR ] , 2.1 ; 95 % confidence interval [ CI ] , 1.0-4 .5 ) , drug2 T/C ( OR , 4.4 ; 95 % CI , 1.9-10 .2 ) , and drug3 ( OR , 4.1 ; 95 % CI , 1.6-10 .9 ) " } } 200 : { 1 : "NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 2 3 : { 1 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 2 : "drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 201 : { 1 : "NN nmod NN dobj VB advcl VBD nmod NN" 2 : 2 3 : { 1 : "drug0 nmod effect dobj *find* advcl was nmod drug0" 2 : "drug0 nmod effect dobj *find* advcl was nmod drug0" } 4 : { 1 : "Although there was only moderate linkage disequilibrium between drug1 and the ApoE e4 defining SNP drug2 , we could not find an APOE-independent effect of drug3 on drug4 , either in cross-sectional or in longitudinal analyses . " 2 : "Although there was only moderate linkage disequilibrium between drug1 and the ApoE e4 defining SNP drug2 , we could not find an APOE-independent effect of drug3 on drug4 , either in cross-sectional or in longitudinal analyses . " } } 202 : { 1 : "NN dobj VBD conj VBN nsubj NNS amod JJ nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 dobj attenuated conj *dysregulated* nsubj subjects amod homozygous nmod allele compound drug0" 2 : "drug0 dobj attenuated conj *dysregulated* nsubj subjects amod homozygous nmod allele compound drug0" } 4 : { 1 : "In adiposity-matched , normal-weight humans , we showed that subjects homozygous for the FTO drug2 drug1 A allele have dysregulated circulating levels of the orexigenic hormone acyl-ghrelin and attenuated drug3 . " 2 : "In adiposity-matched , normal-weight humans , we showed that subjects homozygous for the FTO drug2 drug1 A allele have dysregulated circulating levels of the orexigenic hormone acyl-ghrelin and attenuated drug3 . " } } 203 : { 1 : "NN nmod NN dobj VBZ nsubj NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod risk dobj *confers* nsubj allele compound drug0" 2 : "drug0 nmod risk dobj *affects* nsubj allele compound drug0" } 4 : { 1 : "The drug1 allele of the COMT gene confers a significantly increased risk for drug2 and drug3 in drug4 . " 2 : "CONCLUSIONS : The drug1 allele , associated with higher fasting triglyceride levels , strongly affects the risk for early-onset drug2 , even after adjusting for triglycerides . " } } 204 : { 1 : "NN compound NN nmod NN dobj VBD nsubj NNS nmod NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 compound severity nmod association dobj *demonstrated* nsubj alleles nmod polymorphisms nmod drug0 conj drug0" 2 : "drug0 compound severity nmod association dobj *demonstrated* nsubj alleles nmod polymorphisms nmod drug0 conj drug0" } 4 : { 1 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 severity ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) " 2 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 severity ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) " } } 205 : { 1 : "NN conj NN nsubj VBD dep VBD nsubj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nsubj showed dep *showed* nsubj alleles nmod drug0 conj drug0" 2 : "drug0 conj drug0 nsubj showed dep *showed* nsubj alleles nmod drug0 conj drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " 2 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 206 : { 1 : "NN nmod NN dobj VBD nsubj NNS nmod NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod association dobj *demonstrated* nsubj alleles nmod polymorphisms nmod drug0 conj drug0" 2 : "drug0 nmod association dobj *demonstrated* nsubj alleles nmod polymorphisms nmod drug0 conj drug0" } 4 : { 1 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) . " 2 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) . " } } 207 : { 1 : "NN dep NN dep NN dep NN dep NN dep NN" 2 : 2 3 : { 1 : "drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 2 : "drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 208 : { 1 : "NN nmod NNS nsubjpass VBN nmod NNS acl VBP dobj NN conj NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod associations nsubjpass *observed* nmod genotypes acl drug0 dobj ratio conj t/c compound drug0" 2 : "drug0 nmod associations nsubjpass *observed* nmod genotypes acl drug0 dobj ratio conj or compound drug0" } 4 : { 1 : "RESULTS : Significant associations with drug4 were observed for genotypes drug1 A/T ( odds ratio [ OR ] , 2.1 ; 95 % confidence interval [ CI ] , 1.0-4 .5 ) , drug2 T/C ( OR , 4.4 ; 95 % CI , 1.9-10 .2 ) , and drug3 ( OR , 4.1 ; 95 % CI , 1.6-10 .9 ) " 2 : "RESULTS : Significant associations with drug4 were observed for genotypes drug1 A/T ( odds ratio [ OR ] , 2.1 ; 95 % confidence interval [ CI ] , 1.0-4 .5 ) , drug2 T/C ( OR , 4.4 ; 95 % CI , 1.9-10 .2 ) , and drug3 ( OR , 4.1 ; 95 % CI , 1.6-10 .9 ) " } } 209 : { 1 : "NN conj NN nmod NN conj NN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod association conj *association* nmod drug0 conj drug0" 2 : "drug0 conj drug0 nmod association conj *association* nmod drug0 conj drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " 2 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 210 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 2 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 211 : { 1 : "NN compound NNS nmod JJR nsubj NN nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 compound patients nmod *higher* nsubj frequency nmod drug0 conj drug0" 2 : "drug0 compound patients nmod *higher* nsubj frequency nmod drug0 conj drug0" } 4 : { 1 : "The minor allele frequency of drug1 , drug2 and drug3 was significantly higher in drug4 patients compared with that in non-diabetic individuals . " 2 : "The minor allele frequency of drug1 , drug2 and drug3 was significantly higher in drug4 patients compared with that in non-diabetic individuals . " } } 212 : { 1 : "NN conj NN dep NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 dep igf0bp0 conj *drug0* conj drug0" 2 : "drug0 conj drug0 dep igf0bp0 conj *drug0* conj drug0" } 4 : { 1 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " 2 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 213 : { 1 : "NN nmod NNS dobj VBD nsubj NNS nmod NN conj NN" 2 : 2 3 : { 1 : "drug0 nmod associations dobj *showed* nsubj alleles nmod drug0 conj drug0" 2 : "drug0 nmod associations dobj *showed* nsubj alleles nmod drug0 conj drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " 2 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 214 : { 1 : "NN nmod NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NNS conj NN" 2 : 2 3 : { 1 : "drug0 nmod diagnosis nmod time nmod performed acl ogtt nmod *associated* nsubjpass alleles conj drug0" 2 : "drug0 nmod diagnosis nmod time nmod performed acl ogtt nmod *associated* nsubjpass alleles conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 215 : { 1 : "NN appos NN nmod NN dobj VB conj VBZ nmod NN nmod NN nmod NN" 2 : 2 3 : { 1 : "drug0 appos cpt0b/chkb nmod association dobj confirm conj *extends* nmod observation nmod association nmod drug0" 2 : "drug0 nmod association nmod observation nmod *extends* conj confirm dobj association nmod cpt0b/chkb appos drug0" } 4 : { 1 : "CONCLUSIONS : The study extends on the observation of a strong multiethnic association of polymorphisms in the drug1 and drug2 with drug4 , but does not confirm the association of CPT1B/CHKB ( drug3 ) in the Chinese population . " 2 : "CONCLUSIONS : The study extends on the observation of a strong multiethnic association of polymorphisms in the drug1 and drug2 with drug4 , but does not confirm the association of CPT1B/CHKB ( drug3 ) in the Chinese population . " } } 216 : { 1 : "NN nsubjpass VBN nmod NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 nsubjpass *associated* nmod drug0 conj drug0 conj drug0" 2 : "drug0 nsubjpass *associated* nmod drug0 conj drug0 conj drug0" } 4 : { 1 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " 2 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " } } 217 : { 1 : "NN compound NN nmod VBN nsubjpass NNS conj NN" 2 : 2 3 : { 1 : "drug0 compound auc nmod *associated* nsubjpass alleles conj drug0" 2 : "drug0 compound auc nmod *associated* nsubjpass alleles conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 218 : { 1 : "NN conj NN conj NNS conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 conj *alleles* conj drug0" 2 : "drug0 conj drug0 conj *alleles* conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 219 : { 1 : "NN nmod JJ advcl VBN nsubjpass NN nmod NN" 2 : 2 3 : { 1 : "drug0 nmod relevant advcl *observed* nsubjpass association nmod drug0" 2 : "drug0 nmod relevant advcl *observed* nsubjpass association nmod drug0" } 4 : { 1 : "CONCLUSIONS : Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 behavior was observed " 2 : "Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 was observed . " } } 220 : { 1 : "NN conj NN conj NNS nmod NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 conj drug0 conj *alleles* nmod snps dep drug0 conj drug0" 2 : "drug0 conj drug0 conj *alleles* nmod snps dep drug0 conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 221 : { 1 : "NN conj NN nmod NN conj NN conj NN" 2 : 2 3 : { 1 : "drug0 conj *association* nmod drug0 conj drug0 conj drug0" 2 : "drug0 conj *association* nmod drug0 conj drug0 conj drug0" } 4 : { 1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous glucose tolerance tests were performed , and found an association between drug1 and drug2 and drug3 ( P = 0.003 and P = 0.005 , respectively ) and drug4 ( P = 0.04 and P = 0.007 , respectively ) . " 2 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . " } } 222 : { 1 : "NN conj NNS nmod NNS dep NN conj NN" 2 : 2 3 : { 1 : "drug0 conj *alleles* nmod snps dep drug0 conj drug0" 2 : "drug0 conj *alleles* nmod snps dep drug0 conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 223 : { 1 : "NN nmod JJ conj NN nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod *relevant* conj control nmod genotype compound drug0" 2 : "drug0 nmod *relevant* conj control nmod genotype compound drug0" } 4 : { 1 : "CONCLUSIONS : Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 behavior was observed " 2 : "Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 was observed . " } } 224 : { 1 : "NN conj NN dobj VBG acl NN nmod NNS nmod NN" 2 : 2 3 : { 1 : "drug0 conj chrna0-chrnb0-chrna0 dobj marking acl chromosome nmod *associations* nmod drug0" 2 : "drug0 conj chrna0-chrnb0-chrna0 dobj marking acl chromosome nmod *associations* nmod drug0" } 4 : { 1 : "We examined the associations between the nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 marking thegene cluster CHRNA3-CHRNB4-CHRNA5 , drug2 , and drug3 and drug4 in the general population . " 2 : "We examined the associations between the nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 marking thegene cluster CHRNA3-CHRNB4-CHRNA5 , drug2 , and drug3 and drug4 in the general population . " } } 225 : { 1 : "NN nmod NN dobj VB advcl VBD nmod NN conj NN acl VBG dobj NN" 2 : 2 3 : { 1 : "drug0 nmod effect dobj *find* advcl was nmod drug0 conj e0 acl defining dobj drug0" 2 : "drug0 nmod effect dobj *find* advcl was nmod drug0 conj e0 acl defining dobj drug0" } 4 : { 1 : "Although there was only moderate linkage disequilibrium between drug1 and the ApoE e4 defining SNP drug2 , we could not find an APOE-independent effect of drug3 on drug4 , either in cross-sectional or in longitudinal analyses . " 2 : "Although there was only moderate linkage disequilibrium between drug1 and the ApoE e4 defining SNP drug2 , we could not find an APOE-independent effect of drug3 on drug4 , either in cross-sectional or in longitudinal analyses . " } } 226 : { 1 : "NN nmod NN nsubjpass VBN advcl JJ conj NN nmod NN compound NN" 2 : 2 3 : { 1 : "drug0 nmod association nsubjpass *observed* advcl relevant conj control nmod genotype compound drug0" 2 : "drug0 nmod association nsubjpass *observed* advcl relevant conj control nmod genotype compound drug0" } 4 : { 1 : "CONCLUSIONS : Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 behavior was observed " 2 : "Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 was observed . " } } 227 : { 1 : "NN conj NN root , punct VBD xcomp VB dobj NN nmod NN" 2 : 2 3 : { 1 : "drug0 conj intake root , punct *was* xcomp assess dobj effect nmod drug0" 2 : "drug0 conj intake root , punct *was* xcomp assess dobj effect nmod drug0" } 4 : { 1 : "The aim of this study was to assess the effect of drug1 , the intake of saturated fatty acids ( SFA ) , and drug2 on serum lipid levels in Lithuanian adult population . " 2 : "The aim of this study was to assess the effect of drug1 , the intake of drug2 , and drug3 in Lithuanian adult population . " } } 228 : { 1 : "NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 2 3 : { 1 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 2 : "drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 229 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 2 3 : { 1 : "drug0 appos drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" 2 : "drug0 appos drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " 2 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 230 : { 1 : "NN conj NN nmod VBN acl NN" 2 : 2 3 : { 1 : "drug0 conj drug0 nmod associated acl *drug0*" 2 : "drug0 conj drug0 nmod associated acl *drug0*" } 4 : { 1 : "Our haplotype trend analysis identified a drug1 significantly associated with drug2 ( p = .0013 ) , drug3 ( p = .0024 ) , and drug4 ( p = .017 ) . " 2 : "Our haplotype trend analysis identified a drug1 significantly associated with drug2 ( p = .0013 ) , drug3 ( p = .0024 ) , and drug4 ( p = .017 ) . " } } 231 : { 1 : " NN nmod NNS nmod NN conj NN" 2 : 2 3 : { 1 : " *drug0* nmod polymorphisms nmod drug0 conj drug0" 2 : " *drug0* nmod polymorphisms nmod drug0 conj drug0" } 4 : { 1 : "We observed a strong association drug4 with all the polymorphisms , including drug1 ( odds ratio [ OR ] 1.50 [ 95 % CI = 1.24-1 .82 ] , p = 4.0 x 10 ( -5 ) ) , drug2 ( OR 1.48 [ 95 % CI = 1.24-1 .77 ] , p = 2.0 x 10 ( -5 ) ) and drug3 ( OR 1.46 [ 95 % CI = 1.22-1 .75 ] , p = 3.0 x 10 ( -5 ) ) . " 2 : "We observed a strong association drug4 with all the polymorphisms , including drug1 ( odds ratio [ OR ] 1.50 [ 95 % CI = 1.24-1 .82 ] , p = 4.0 x 10 ( -5 ) ) , drug2 ( OR 1.48 [ 95 % CI = 1.24-1 .77 ] , p = 2.0 x 10 ( -5 ) ) and drug3 ( OR 1.46 [ 95 % CI = 1.22-1 .75 ] , p = 3.0 x 10 ( -5 ) ) . " } } 232 : { 1 : "NN conj NN conj NNS nmod NNS dep NN" 2 : 2 3 : { 1 : "drug0 conj drug0 conj *alleles* nmod snps dep drug0" 2 : "drug0 conj drug0 conj *alleles* nmod snps dep drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 233 : { 1 : " NN nmod NNS nmod NN" 2 : 2 3 : { 1 : " *drug0* nmod polymorphisms nmod drug0" 2 : "drug0 nmod *effects* nmod drug0" } 4 : { 1 : "We observed a strong association drug4 with all the polymorphisms , including drug1 ( odds ratio [ OR ] 1.50 [ 95 % CI = 1.24-1 .82 ] , p = 4.0 x 10 ( -5 ) ) , drug2 ( OR 1.48 [ 95 % CI = 1.24-1 .77 ] , p = 2.0 x 10 ( -5 ) ) and drug3 ( OR 1.46 [ 95 % CI = 1.22-1 .75 ] , p = 3.0 x 10 ( -5 ) ) . " 2 : "Conclusion : This study highlights the gender-specific and weight-sensitive effects of APOA5 drug1 on central drug2 in Taiwanese individuals , and that these effects are dyslipidemia-independent and weight-loss responsive . " } } 234 : { 1 : "NN dobj VBD nsubj NNS compound NN" 2 : 2 3 : { 1 : "drug0 dobj *had* nsubj carriers compound drug0" 2 : "drug0 dobj *had* nsubj carriers compound drug0" } 4 : { 1 : "The results indicated that homozygous drug1 carriers aged 35 years or older had worse drug2 than heterozygous carriers and noncarriers . " 2 : "The results indicated that homozygous drug1 carriers aged 35 years or older had worse drug2 than heterozygous carriers and noncarriers . " } } 235 : { 1 : "NN compound NN appos JJ dep JJ amod NNS nmod NN nmod VBN nsubjpass NN" 2 : 2 3 : { 1 : "drug0 compound c appos japanese dep = amod groups nmod drug0 nmod *associated* nsubjpass drug0" 2 : "drug0 compound c appos japanese dep = amod groups nmod drug0 nmod *associated* nsubjpass drug0" } 4 : { 1 : "drug1 , a SNP located between CPT1B and CHKB , was associated with drug3 in Japanese ( drug2 [ C ] , odds ratio ( OR ) = 1.79 , combined P = 4.4 x 10 ( -7 ) ) and other ancestry groups ( OR = 1.40 , P = 0.02 ) . " 2 : "drug1 , a SNP located between CPT1B and CHKB , was associated with drug3 in Japanese ( drug2 [ C ] , odds ratio ( OR ) = 1.79 , combined P = 4.4 x 10 ( -7 ) ) and other ancestry groups ( OR = 1.40 , P = 0.02 ) . " } } 236 : { 1 : "NN conj NNS nmod NNS dep NN" 2 : 2 3 : { 1 : "drug0 conj *alleles* nmod snps dep drug0" 2 : "drug0 conj *alleles* nmod snps dep drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " 2 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 237 : { 1 : " NN nmod NNS amod JJ dep JJ appos NN compound NN" 2 : 2 3 : { 1 : " *drug0* nmod groups amod = dep japanese appos c compound drug0" 2 : " *drug0* nmod groups amod = dep japanese appos c compound drug0" } 4 : { 1 : "drug1 , a SNP located between CPT1B and CHKB , was associated with drug3 in Japanese ( drug2 [ C ] , odds ratio ( OR ) = 1.79 , combined P = 4.4 x 10 ( -7 ) ) and other ancestry groups ( OR = 1.40 , P = 0.02 ) . " 2 : "drug1 , a SNP located between CPT1B and CHKB , was associated with drug3 in Japanese ( drug2 [ C ] , odds ratio ( OR ) = 1.79 , combined P = 4.4 x 10 ( -7 ) ) and other ancestry groups ( OR = 1.40 , P = 0.02 ) . " } } 238 : { 1 : "NN compound NN nmod VB acl NN dobj VBD nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound gold nmod suffer acl risk dobj *had* nsubj aa-carriers compound drug0" } 4 : { 1 : "In the LEUVEN cohort , drug1 AA-carriers and rs8034191 GG-carriers had a two-fold increased risk to suffer from drug2 GOLD IV ( " } } 239 : { 1 : "NN nmod VBN xcomp VBN nsubjpass NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp *found* nsubjpass snps dep drug0 conj drug0" } 4 : { 1 : "Both TCF7L2 SNPs ( drug1 and drug2 ) were found to be significantly associated with drug3 when adjusting for insulin sensitivity , both in the whole cohort and when the diabetic subjects were excluded . " } } 240 : { 1 : "NN compound NNS nmod NN dobj VB nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound inpatients nmod risk dobj *confer* nsubj a0 nmod allele compound drug0" } 4 : { 1 : "These results strongly suggested that A1 + variants of the drug1 allele do confer an associated risk for drug2 inpatients who were treated with SGAs , and these variants may explain inconsistencies found across prior studies , when comparing FGAs and SGAs . " } } 241 : { 1 : "NN appos NN root LS dobj VBG acl NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos taq0a root 0 dobj containing acl repeat conj *i/d* dep g/a appos drug0" } 4 : { 1 : "We investigated the relationship between drug4 symptoms and dopamine receptor 2 DRD2 gene polymorphisms-141 C I/D ( drug1 ) exon 8 G/A ( drug2 ) and ANKK1 ( Ankyrin Repeat and Kinase Domain Containing 1 ) gene polymorphism Taq1A ( drug3 ) " } } 242 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod progression nmod *associated* nsubjpass polymorphism compound drug0" } 4 : { 1 : "CONCLUSIONS : Our results suggest that the CMA drug1 polymorphism is associated with the progression of drug2 inKorean patients . " } } 243 : { 1 : "NN compound NNS conj NN conj NN acl VBG dobj LS root NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *symptoms* conj i/d conj repeat acl containing dobj 0 root taq0a appos drug0" } 4 : { 1 : "We investigated the relationship between drug4 symptoms and dopamine receptor 2 DRD2 gene polymorphisms-141 C I/D ( drug1 ) exon 8 G/A ( drug2 ) and ANKK1 ( Ankyrin Repeat and Kinase Domain Containing 1 ) gene polymorphism Taq1A ( drug3 ) " } } 244 : { 1 : "NN compound NNS conj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *symptoms* conj i/d appos drug0" } 4 : { 1 : "We investigated the relationship between drug4 symptoms and dopamine receptor 2 DRD2 gene polymorphisms-141 C I/D ( drug1 ) exon 8 G/A ( drug2 ) and ANKK1 ( Ankyrin Repeat and Kinase Domain Containing 1 ) gene polymorphism Taq1A ( drug3 ) " } } 245 : { 1 : "NN dobj VBD nsubj NNS nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj *had* nsubj subjects nmod genotype nmod polymorphism compound drug0" } 4 : { 1 : "Normal glucose-tolerant subjects with the TT genotype of drug1 polymorphism had significantly higher drug2 ( mean + / - SD , 6.0 + / - 1.3 mmol/L ) than those with the CC genotype ( 5.6 + / - 1.0 mmol/L , P = .004 ) . " } } 246 : { 1 : "NN appos NN root LS dobj VBG acl NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos taq0a root 0 dobj containing acl repeat conj *i/d* appos drug0" } 4 : { 1 : "We investigated the relationship between drug4 symptoms and dopamine receptor 2 DRD2 gene polymorphisms-141 C I/D ( drug1 ) exon 8 G/A ( drug2 ) and ANKK1 ( Ankyrin Repeat and Kinase Domain Containing 1 ) gene polymorphism Taq1A ( drug3 ) " } } 247 : { 1 : "NN compound NNS conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *symptoms* conj i/d dep g/a appos drug0" } 4 : { 1 : "We investigated the relationship between drug4 symptoms and dopamine receptor 2 DRD2 gene polymorphisms-141 C I/D ( drug1 ) exon 8 G/A ( drug2 ) and ANKK1 ( Ankyrin Repeat and Kinase Domain Containing 1 ) gene polymorphism Taq1A ( drug3 ) " } } 248 : { 1 : "VB acl NN dobj VBP nsubj NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 acl susceptibility dobj *confer* nsubj allele nmod polymorphisms compound drug0" } 4 : { 1 : "In conclusion , the T allele of the drug1 and drug2 polymorphisms of TCF7L2 gene confer susceptibility to drug3 in Asian Indians . " } } 249 : { 1 : "NN nmod VBN nsubjpass NNS conj NNS conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *genotyped* nsubjpass polymorphisms conj snps conj polymorphism compound drug0" } 4 : { 1 : "Eleven tag single nucleotide polymorphisms ( SNPs ) in the PRCP gene and four tag SNPs and G-1903A drug1 polymorphism in the CMA1 gene were genotyped in the drug2 ( n = 1020 ) using a polymerase chain reaction-restriction fragment length polymorphism method " } } 250 : { 1 : "NN appos NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos g/a dep *i/d* appos drug0" } 4 : { 1 : "We investigated the relationship between drug4 symptoms and dopamine receptor 2 DRD2 gene polymorphisms-141 C I/D ( drug1 ) exon 8 G/A ( drug2 ) and ANKK1 ( Ankyrin Repeat and Kinase Domain Containing 1 ) gene polymorphism Taq1A ( drug3 ) " } } 251 : { 1 : "NN nmod NNS nmod NNS dobj VBG advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod levels dobj regulating advcl *involved* nsubjpass drug0" } 4 : { 1 : "Previous studies have indicated that CMA1 promoter polymorphism drug1 may be involved in regulating immunoglobulin E ( IgE ) levels in patients with drug2 , and it is associated with the progression of drug3 . " } } 252 : { 1 : "NN nmod NN nmod VBN conj VBN ccomp VBN advcl VBG dobj NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod progression nmod associated conj *indicated* ccomp involved advcl regulating dobj levels nmod patients nmod drug0" } 4 : { 1 : "Previous studies have indicated that CMA1 promoter polymorphism drug1 may be involved in regulating immunoglobulin E ( IgE ) levels in patients with drug2 , and it is associated with the progression of drug3 . " } } 253 : { 1 : "NN nmod NN nmod VBN conj VBN ccomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod progression nmod associated conj *indicated* ccomp involved nsubjpass drug0" } 4 : { 1 : "Previous studies have indicated that CMA1 promoter polymorphism drug1 may be involved in regulating immunoglobulin E ( IgE ) levels in patients with drug2 , and it is associated with the progression of drug3 . " } } 254 : { 1 : "NN nmod NNS dobj VB xcomp JJ conj VBD nmod NNS acl:relcl VBD nsubj DT nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod levels dobj report xcomp likely conj *found* nmod women acl:relcl smoked nsubj those nmod allele compound drug0" } 4 : { 1 : "We found among women who smoked pre-pregnancy , those with the drug1 T allele smoked more and were less likely to quit drug2 during pregnancy , but were also less likely to report high levels of drug3 at 18 weeks of pregnancy ( per allele OR = 0.84 , 95 % CI 0.72 to 0.99 , p = 0.034 ) . " } } 255 : { 1 : "NN nmod VBN parataxis JJ dep NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated parataxis = dep drug0 conj p conj *drug0*" } 4 : { 1 : "The most significant associations were observed with TCF7L2 intron 3 SNPs drug1 ( additive P = 4.10 x 10 ( -6 ) , odds ratio [ OR ] 1.51 ; admixture-adjusted P ( a ) = 3.77 x 10 ( -6 ) ) and drug2 ( P = 0.001 , OR 1.30 ; P ( a ) = 0.003 ) , The 2-SNP haplotype containing these SNPs was also associated with drug3 ( P = 3 x 10 ( -5 ) ) " } } 256 : { 1 : "NN nmod VBN conj JJ nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated conj *rare* nsubj drug0 conj drug0" } 4 : { 1 : "The previously reported SNPs drug1 and drug2 of the TCF7L2 gene were rare and were not associated with drug3 in a Chinese population , which may attribute to the low frequencies of these two SNPs . " } } 257 : { 1 : "NN nmod VBN conj JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod associated conj *rare* nsubj drug0" } 4 : { 1 : "The previously reported SNPs drug1 and drug2 of the TCF7L2 gene were rare and were not associated with drug3 in a Chinese population , which may attribute to the low frequencies of these two SNPs . " } } 258 : { 1 : "NN appos NN nmod NN appos NNP nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 appos lrrk0 nmod drug0 appos snca nmod *e0k* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 259 : { 1 : "NN compound NN nmod NN dobj VBD conj VBD dobj NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod role dobj analysed conj *genotyped* dobj participants nmod drug0 conj drug0" } 4 : { 1 : "We genotyped 6,516 participants for drug1 and drug2 and analysed the role in drug3 susceptibility using binary logistic regression . Age , sex and obesity status were examined as covariates " } } 260 : { 1 : "NN nmod VBN conj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* conj showed nsubj drug0" } 4 : { 1 : "RESULTS : All investigated polymorphisms were significantly associated with drug2 , and drug1 showed the strongest association ( T vs G , chi2 = 9.20 , p = 0.0024 , odds ratio = 1.70 , 95 % CI = 1.20-2 .41 ) , " } } 261 : { 1 : "NN compound NN conj NN nmod NN appos NNP nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound park0 conj lrrk0 nmod drug0 appos snca nmod *e0k* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 262 : { 1 : "NN compound NN dobj VBZ nmod NN" 2 : 1 3 : { 1 : "drug0 compound disease dobj *associates* nmod drug0" } 4 : { 1 : "OBJECTIVE : We investigated if the FTO drug1 associates with food preferences in healthy adults with no drug2 , drug3 disease , or drug4 . " } } 263 : { 1 : "NN conj NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 conj disease dobj *associates* nsubj drug0" } 4 : { 1 : "OBJECTIVE : We investigated if the FTO drug1 associates with food preferences in healthy adults with no drug2 , drug3 disease , or drug4 . " } } 264 : { 1 : "NN appos NNP nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 appos snca nmod *e0k* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 265 : { 1 : "NN dobj VBG advcl JJ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj determining advcl *critical* nsubj polymorphism compound drug0" } 4 : { 1 : "We conclude that HIF1A drug1 polymorphism by itself is not critical in determining drug2 . " } } 266 : { 1 : "NN appos NNP nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 appos deltainsulin nmod association dobj *showed* nsubj drug0" } 4 : { 1 : "However , drug1 showed association with 30 ' Deltainsulin ( drug2 ) in an interaction with percentage of body fat ( Bonferroni-corrected P = 0.027 ) . " } } 267 : { 1 : "NN appos NNS conj NN nmod NN appos NN nmod NN appos NNP nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 appos 0fs conj slc0a0 nmod drug0 appos lrrk0 nmod drug0 appos snca nmod *e0k* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 268 : { 1 : "NN compound NN dobj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 compound disease dobj *associates* nsubj drug0" } 4 : { 1 : "OBJECTIVE : We investigated if the FTO drug1 associates with food preferences in healthy adults with no drug2 , drug3 disease , or drug4 . " } } 269 : { 1 : "NN nmod VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod *associates* nsubj drug0" } 4 : { 1 : "OBJECTIVE : We investigated if the FTO drug1 associates with food preferences in healthy adults with no drug2 , drug3 disease , or drug4 . " } } 270 : { 1 : "NN appos NN conj NN nmod NN appos NN nmod NN appos NNP nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj slc0a0 nmod drug0 appos lrrk0 nmod drug0 appos snca nmod *e0k* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 271 : { 1 : "NN compound NN appos NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *disease* appos e0k appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 272 : { 1 : "NN appos NN conj NN nmod NNS conj NN nmod NN appos NN nmod NN appos NNP nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj nod0 nmod 0fs conj slc0a0 nmod drug0 appos lrrk0 nmod drug0 appos snca nmod *e0k* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 273 : { 1 : "NN nmod NN nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod compensation nmod association dobj *showed* nsubj drug0" } 4 : { 1 : "drug1 also showed an association with beta-cell compensation for drug2 based on 30 ' Deltainsulin in an interaction with percentage of body fat ( Bonferroni-corrected P = 0.014 ) . " } } 274 : { 1 : "NN nmod VBN parataxis JJ dep NN" 2 : 1 3 : { 1 : "drug0 nmod associated parataxis = dep *drug0*" } 4 : { 1 : "The most significant associations were observed with TCF7L2 intron 3 SNPs drug1 ( additive P = 4.10 x 10 ( -6 ) , odds ratio [ OR ] 1.51 ; admixture-adjusted P ( a ) = 3.77 x 10 ( -6 ) ) and drug2 ( P = 0.001 , OR 1.30 ; P ( a ) = 0.003 ) , The 2-SNP haplotype containing these SNPs was also associated with drug3 ( P = 3 x 10 ( -5 ) ) " } } 275 : { 1 : "NN nmod NN dobj VB acl:relcl NN nmod NN dobj VBZ nsubj NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod extent dobj influence acl:relcl actn0 nmod presence dobj *determines* nsubj polymorphism compound r0x appos drug0" } 4 : { 1 : "The ACTN3 R577X ( drug1 ) polymorphism determines the presence or absence of functional ACTN3 , which may influence the extent of exercise-induced drug2 . " } } 276 : { 1 : "NN compound NN nmod NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound cancer nmod risk dobj *increase* nsubj polymorphism compound drug0" } 4 : { 1 : "CONCLUSIONS : drug1 polymorphism of MTHFR gene may increase the risk of drug2 cancer in the complete over-dominant model . " } } 277 : { 1 : "NN nmod NN nsubj JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk nsubj *evident* nmod drug0" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 278 : { 1 : "NN nmod NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 conj *polymorphism* dep drug0" } 4 : { 1 : "We observed a significant association between the single-nucleotide polymorphism ( SNP ) drug1 and the microsatellite drug2 with drug3 in the Mexican sample " } } 279 : { 1 : "NN compound NN dep JJ conj NN" 2 : 1 3 : { 1 : "drug0 compound drug0 dep *=* conj drug0" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 280 : { 1 : "NN compound NNS nmod NN dobj VB nsubj NN appos NN compound NN" 2 : 1 3 : { 1 : "drug0 compound symptoms nmod presentation dobj *produce* nsubj variation appos polymorphism compound drug0" } 4 : { 1 : "Conclusions : Genetic variation of DRD2 , specifically the drug1 polymorphism , may produce an earlier clinical presentation of drug2 disease neuropsychiatric symptoms and signs that occur in the course of dopaminergic system impairment due to copper accumulation in the brain . " } } 281 : { 1 : "NN dep JJ dep NN" 2 : 1 3 : { 1 : "drug0 dep = dep *drug0*" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 282 : { 1 : "NN dobj VBD nsubj NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj *had* nsubj subjects nmod genotype nmod drug0" } 4 : { 1 : "Normal glucose-tolerant subjects with the TT genotype of drug1 had significantly higher drug2 ( mean + / - SD , 6.1 + / - 1.4 mmol/L ) than those with the GG genotype ( 5.6 + / - 1.0 mmol/L , P = .011 ) . " } } 283 : { 1 : "NN compound NN dep JJ dep NN" 2 : 1 3 : { 1 : "drug0 compound drug0 dep = dep *drug0*" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 284 : { 1 : "NN compound NN nmod NN dobj VBD conj VBD dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod role dobj analysed conj *genotyped* dobj participants nmod drug0" } 4 : { 1 : "We genotyped 6,516 participants for drug1 and drug2 and analysed the role in drug3 susceptibility using binary logistic regression . Age , sex and obesity status were examined as covariates " } } 285 : { 1 : "NN nmod NN nsubj JJ nmod NN dep JJ conj NN" 2 : 1 3 : { 1 : "drug0 nmod risk nsubj *evident* nmod drug0 dep = conj drug0" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 286 : { 1 : "NN dobj VB xcomp JJ conj VBD nsubj DT nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj quit xcomp likely conj *smoked* nsubj those nmod allele compound drug0" } 4 : { 1 : "We found among women who smoked pre-pregnancy , those with the drug1 T allele smoked more and were less likely to quit drug2 during pregnancy , but were also less likely to report high levels of drug3 at 18 weeks of pregnancy ( per allele OR = 0.84 , 95 % CI 0.72 to 0.99 , p = 0.034 ) . " } } 287 : { 1 : "NN nmod NN nsubj JJ nmod NN dep JJ dep NN" 2 : 1 3 : { 1 : "drug0 nmod risk nsubj *evident* nmod drug0 dep = dep drug0" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 288 : { 1 : "NN conj NN dobj VBZ nmod NN" 2 : 1 3 : { 1 : "drug0 conj disease dobj *associates* nmod drug0" } 4 : { 1 : "OBJECTIVE : We investigated if the FTO drug1 associates with food preferences in healthy adults with no drug2 , drug3 disease , or drug4 . " } } 289 : { 1 : "NN nmod NN nsubj JJ conj VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod association nsubj strong conj *shows* nsubj drug0" } 4 : { 1 : "The SNP drug1 shows similar trends , but its association with drug2 is not as strong ( OR = 1.39 , p = 0.152 ) . " } } 290 : { 1 : "NN nmod NN nsubj JJ nmod NN dep JJ dep NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod risk nsubj *evident* nmod drug0 dep = dep drug0 compound drug0" } 4 : { 1 : "The increased risk of brain drug5 was evident for CYP1A1 drug1 ( P = 0.0028 ; OR = 2.06 ; 95 % CI , 1.27-3 .34 ) and minor haplotypes drug2 - drug3 - drug4 in females ( global haplotypeassociation P value , 0.0011 ) . " } } 291 : { 1 : "NN dobj VB xcomp JJ ccomp VB advcl VBD dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj report xcomp likely ccomp determine advcl *investigated* dobj polymorphism compound drug0" } 4 : { 1 : "We investigated the drug1 single nucleotide polymorphism in the nicotine acetylcholine receptor gene cluster ( CHRNA5-CHRNA3-CHRNB4 ) , associated with smoking phenotypes , to determine whether women who continued to smoke were also more likely to report a drug2 during pregnancy . " } } 292 : { 1 : "NN compound NNS nsubj NN dep NN" 2 : 1 3 : { 1 : "drug0 compound patients nsubj *genotypedfor* dep drug0" } 4 : { 1 : "METHODS : All drug2 patients were genotypedfor the FTO single nucleotide polimorphysm ( SNP ) drug1 . " } } 293 : { 1 : "NN compound NN nmod RB conj NN acl:relcl VBZ nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod independently conj *r0q* acl:relcl acts nmod modifier nmod snp compound drug0" } 4 : { 1 : "We were also able to demonstrate the OCA2 R419Q , drug1 , coding SNP acts as a penetrance modifier of this new drug2 SNP for eye color , and somewhat independently , of drug3 risk . " } } 294 : { 1 : "NN nmod NN conj VB dobj NN ccomp NN nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *marker* conj add dobj evidence ccomp allele nsubj allele nmod drug0" } 4 : { 1 : "Our data suggest that the haplotype restricted to Europe is the strongest marker for drug2 globally and add further inferential evidence that the derived allele of drug1 is an East Asian drug3 allele . " } } 295 : { 1 : "NN compound NN nmod NN nmod VBZ acl:relcl NN conj NN" 2 : 1 3 : { 1 : "drug0 compound snp nmod modifier nmod acts acl:relcl *r0q* conj drug0" } 4 : { 1 : "We were also able to demonstrate the OCA2 R419Q , drug1 , coding SNP acts as a penetrance modifier of this new drug2 SNP for eye color , and somewhat independently , of drug3 risk . " } } 296 : { 1 : "NN nmod NN nmod VBN ccomp VBN advcl VBG nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod susceptibility nmod associated ccomp *confirmed* advcl pooling nmod studies nmod drug0 conj drug0" } 4 : { 1 : "In summary , by pooling all available qualified data from genetic studies on drug1 and drug3 , we have confirmed that drug2 is significantly associated with susceptibility to drug4 in the global population . " } } 297 : { 1 : " NN appos NNS nmod NN" 2 : 1 3 : { 1 : " *drug0* appos polymorphisms nmod drug0" } 4 : { 1 : "In recent years , it has been widely accepted that transcription factor 7-like 2 ( TCF7L2 ) is associated with type 2 diabetes mellitus drug3 in multiple ethnic groups , especially its single nucleotide polymorphisms of drug1 , drug2 and rs290487T/C . " } } 298 : { 1 : "NN nmod NN nmod NN nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod *factor* nsubj genotype compound drug0" } 4 : { 1 : "These results extend previous observations to other ethnic groups , and strongly confirm that drug1 genotype is a major risk factor for development of drug2 . " } } 299 : { 1 : "NN nmod JJ dep NN dep NN compound NNS appos NN nsubjpass VBN conj JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod = dep cyp0a0 dep polypeptide compound regions appos p0 nsubjpass observed conj *=* nmod drug0" } 4 : { 1 : "Nominally significant associations with candidateSNPs within cholinergic receptors , nicotinic , alpha 3/5 ( CHRNA3/CHRNA5 ; eg , p = 0.00011 for SNP drug1 ) and cytochrome P450 , family 2 , subfamily A , polypeptide 6 ( CYP2A6 ; eg , p = 2.78 * 10 ( -5 ) for a non-synonymous SNP drug2 ) regions were observed for drug3 , however only CYP2A6 showed evidence of significant association with drug4 . " } } 300 : { 1 : "NN conj NN nmod NNS nmod VBG advcl VBN ccomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod studies nmod pooling advcl *confirmed* ccomp associated nsubjpass drug0" } 4 : { 1 : "In summary , by pooling all available qualified data from genetic studies on drug1 and drug3 , we have confirmed that drug2 is significantly associated with susceptibility to drug4 in the global population . " } } 301 : { 1 : "NN nmod VBN conj JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod observed conj *=* nmod drug0" } 4 : { 1 : "Nominally significant associations with candidateSNPs within cholinergic receptors , nicotinic , alpha 3/5 ( CHRNA3/CHRNA5 ; eg , p = 0.00011 for SNP drug1 ) and cytochrome P450 , family 2 , subfamily A , polypeptide 6 ( CYP2A6 ; eg , p = 2.78 * 10 ( -5 ) for a non-synonymous SNP drug2 ) regions were observed for drug3 , however only CYP2A6 showed evidence of significant association with drug4 . " } } 302 : { 1 : "NN nmod NN nmod VBN ccomp VBN advcl VBG nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod susceptibility nmod associated ccomp *confirmed* advcl pooling nmod studies nmod drug0" } 4 : { 1 : "In summary , by pooling all available qualified data from genetic studies on drug1 and drug3 , we have confirmed that drug2 is significantly associated with susceptibility to drug4 in the global population . " } } 303 : { 1 : "NN nsubjpass VBN ccomp VBN advcl VBG nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass associated ccomp *confirmed* advcl pooling nmod studies nmod drug0" } 4 : { 1 : "In summary , by pooling all available qualified data from genetic studies on drug1 and drug3 , we have confirmed that drug2 is significantly associated with susceptibility to drug4 in the global population . " } } 304 : { 1 : "NN nmod NN nmod NN dobj VBD parataxis JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod evidence dobj showed parataxis *=* nmod drug0" } 4 : { 1 : "Nominally significant associations with candidateSNPs within cholinergic receptors , nicotinic , alpha 3/5 ( CHRNA3/CHRNA5 ; eg , p = 0.00011 for SNP drug1 ) and cytochrome P450 , family 2 , subfamily A , polypeptide 6 ( CYP2A6 ; eg , p = 2.78 * 10 ( -5 ) for a non-synonymous SNP drug2 ) regions were observed for drug3 , however only CYP2A6 showed evidence of significant association with drug4 . " } } 305 : { 1 : " NN appos NNS nmod NN conj NN" 2 : 1 3 : { 1 : " *drug0* appos polymorphisms nmod drug0 conj drug0" } 4 : { 1 : "In recent years , it has been widely accepted that transcription factor 7-like 2 ( TCF7L2 ) is associated with type 2 diabetes mellitus drug3 in multiple ethnic groups , especially its single nucleotide polymorphisms of drug1 , drug2 and rs290487T/C . " } } 306 : { 1 : "NN compound NNS conj NN nmod VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound polymorphisms conj drug0 nmod *had* nsubj polymorphism compound drug0" } 4 : { 1 : "In conclusion , this study indicated that the drug1 polymorphism of the TCF7L2 gene had a significant effect on drug4 risk in Chinese Han population , with drug2 and drug3 polymorphisms showing no significant effect . " } } 307 : { 1 : "NN nmod NN nmod VBN xcomp VBN conj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod likelihood nmod associated xcomp reported conj *associated* nmod drug0" } 4 : { 1 : "The drug1 genetic variant within the CHRNA5-A3-B4 gene cluster is associated with drug2 and has recently been reported to be associated with likelihood of drug3 . " } } 308 : { 1 : "VB acl NN dobj VBP nsubj NN nmod NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 acl susceptibility dobj *confer* nsubj allele nmod polymorphisms compound drug0 conj drug0" } 4 : { 1 : "In conclusion , the T allele of the drug1 and drug2 polymorphisms of TCF7L2 gene confer susceptibility to drug3 in Asian Indians . " } } 309 : { 1 : "NN nmod VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *had* nsubj polymorphism compound drug0" } 4 : { 1 : "In conclusion , this study indicated that the drug1 polymorphism of the TCF7L2 gene had a significant effect on drug4 risk in Chinese Han population , with drug2 and drug3 polymorphisms showing no significant effect . " } } 310 : { 1 : "NN compound NN nmod NN dobj VBD nmod NN conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod effect dobj *had* nmod drug0 conj polymorphisms compound drug0" } 4 : { 1 : "In conclusion , this study indicated that the drug1 polymorphism of the TCF7L2 gene had a significant effect on drug4 risk in Chinese Han population , with drug2 and drug3 polymorphisms showing no significant effect . " } } 311 : { 1 : "NN compound NN nmod NN dobj VBD nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod effect dobj *had* nmod drug0" } 4 : { 1 : "In conclusion , this study indicated that the drug1 polymorphism of the TCF7L2 gene had a significant effect on drug4 risk in Chinese Han population , with drug2 and drug3 polymorphisms showing no significant effect . " } } 312 : { 1 : "NN dobj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj *predicted* nsubj genotypes nmod drug0" } 4 : { 1 : "The CT/TT genotypes of SNP drug1 strongly predicted future drug2 in 2 independent cohorts ( Swedish and Finnish ) . " } } 313 : { 1 : "NN compound NN nmod NN dobj VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod effect dobj *had* nsubj polymorphism compound drug0" } 4 : { 1 : "In conclusion , this study indicated that the drug1 polymorphism of the TCF7L2 gene had a significant effect on drug4 risk in Chinese Han population , with drug2 and drug3 polymorphisms showing no significant effect . " } } 314 : { 1 : "NN compound NN nmod VBN advcl VBN ccomp VBD nsubj NN compound NN dep NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod associated advcl associated ccomp *demonstrated* nsubj analysis compound 0-locus dep drug0" } 4 : { 1 : "The four tested TCF7L2 variants were in linkage disequilibrium , and 4-locus ( drug1 , drug2 , drug3 , drug4 ) haplotype analysis demonstrated that haplotype 1111 was negatively associated ( Pc < 0.001 ) , while haplotypes 2222 ( Pc = 0.008 ) and 2211 ( Pc = 0.020 ) were positively associated with drug5 risk , after controlling for a number of covariates . " } } 315 : { 1 : "NN nmod NNS dobj VB nsubj NN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod associations dobj *show* nsubj rest nmod snps dep drug0" } 4 : { 1 : "The rest of the five SNPs ( drug1 , drug2 and drug3 ) did not show any significant associations with drug4 . " } } 316 : { 1 : "NN nmod NN nmod VBN xcomp VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod associated xcomp *seem* nsubj variants nmod drug0" } 4 : { 1 : "Common variants in drug1 seem to be associated with an increased risk of drug2 among persons with drug3 . " } } 317 : { 1 : "NN nmod NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod *variant* nsubj drug0" } 4 : { 1 : "Our findings suggest that drug1 in CHRNA is a susceptibility variant for drug2 , in terms of both airway obstruction and parenchyma destruction . " } } 318 : { 1 : "NN nmod NN dobj VBD acl:relcl NNS nmod VBN ccomp VBD nsubj NN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod association dobj showed acl:relcl individuals nmod identified ccomp *correlated* nsubj marker nmod intron dep drug0" } 4 : { 1 : "Recently , a microsatellite marker in intron 3 drug1 and five correlated single nucleotide polymorphisms ( SNPs ) were identified in Icelandic individuals that showed strong association with drug2 , which was replicated in Danish and European-American cohorts . " } } 319 : { 1 : "NN compound NN conj NNS nmod NN nsubj VBD dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound group conj subjects nmod comparison nsubj *showed* dobj association nmod drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 320 : { 1 : "NN nmod NN nmod NN dobj VBD parataxis JJ conj VBN nsubjpass NN appos NNS compound NN dep NN dep JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod evidence dobj showed parataxis *=* conj observed nsubjpass p0 appos regions compound polypeptide dep cyp0a0 dep = nmod drug0" } 4 : { 1 : "Nominally significant associations with candidateSNPs within cholinergic receptors , nicotinic , alpha 3/5 ( CHRNA3/CHRNA5 ; eg , p = 0.00011 for SNP drug1 ) and cytochrome P450 , family 2 , subfamily A , polypeptide 6 ( CYP2A6 ; eg , p = 2.78 * 10 ( -5 ) for a non-synonymous SNP drug2 ) regions were observed for drug3 , however only CYP2A6 showed evidence of significant association with drug4 . " } } 321 : { 1 : "NN conj NN conj NN dobj VBG acl NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 conj chrna0-chrnb0-chrna0 dobj marking acl chromosome nmod *associations* nmod drug0" } 4 : { 1 : "We examined the associations between the nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 marking thegene cluster CHRNA3-CHRNB4-CHRNA5 , drug2 , and drug3 and drug4 in the general population . " } } 322 : { 1 : "NN nmod NN nmod NN dobj VBD parataxis JJ conj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod evidence dobj showed parataxis *=* conj observed nmod drug0" } 4 : { 1 : "Nominally significant associations with candidateSNPs within cholinergic receptors , nicotinic , alpha 3/5 ( CHRNA3/CHRNA5 ; eg , p = 0.00011 for SNP drug1 ) and cytochrome P450 , family 2 , subfamily A , polypeptide 6 ( CYP2A6 ; eg , p = 2.78 * 10 ( -5 ) for a non-synonymous SNP drug2 ) regions were observed for drug3 , however only CYP2A6 showed evidence of significant association with drug4 . " } } 323 : { 1 : "NN nmod NN nmod VBN acl:relcl NN nmod VBD dobj NNS appos NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod associated acl:relcl factor nmod *analysed* dobj polymorphisms appos drug0" } 4 : { 1 : "we analysed two single nucleotide polymorphisms ( SNPs ) , drug1 and drug2 , in the transcription factor 7-like 2 gene ( TCF7L2 ) , which are associated with an increased risk of drug3 . " } } 324 : { 1 : "NN nmod NNS nmod NN nmod VBN xcomp VBP nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod persons nmod risk nmod associated xcomp *seem* nsubj variants nmod drug0" } 4 : { 1 : "Common variants in drug1 seem to be associated with an increased risk of drug2 among persons with drug3 . " } } 325 : { 1 : "NN compound NN conj NNS nmod NN nsubj VBD dobj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound group conj subjects nmod comparison nsubj *showed* dobj association nmod drug0 conj drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 326 : { 1 : "NN compound NN conj NNS nmod NN nsubj VBD dobj NN conj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound group conj subjects nmod comparison nsubj *showed* dobj association conj association nmod drug0 conj drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 327 : { 1 : "NN conj NN dobj VBD conj VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj association dobj found conj *performed* nsubjpass tests compound drug0" } 4 : { 1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . " } } 328 : { 1 : "NN compound NN nmod NN nmod NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod *association* nmod variant nmod gene appos drug0" } 4 : { 1 : "we examined the association of a common variant of the TCF7L2 gene ( drug1 ) with drug2 risk among Caucasians . " } } 329 : { 1 : "NN compound NN conj NNS nmod NN nsubj VBD dobj NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound group conj subjects nmod comparison nsubj *showed* dobj association conj association nmod drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 330 : { 1 : "NN nmod VBN nsubjpass NN appos NNS compound NN dep NN dep JJ nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *observed* nsubjpass p0 appos regions compound polypeptide dep cyp0a0 dep = nmod drug0" } 4 : { 1 : "Nominally significant associations with candidateSNPs within cholinergic receptors , nicotinic , alpha 3/5 ( CHRNA3/CHRNA5 ; eg , p = 0.00011 for SNP drug1 ) and cytochrome P450 , family 2 , subfamily A , polypeptide 6 ( CYP2A6 ; eg , p = 2.78 * 10 ( -5 ) for a non-synonymous SNP drug2 ) regions were observed for drug3 , however only CYP2A6 showed evidence of significant association with drug4 . " } } 331 : { 1 : "NN compound NNS nsubjpass VBN conj VBD dobj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound tests nsubjpass *performed* conj found dobj association nmod drug0 conj drug0" } 4 : { 1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . " } } 332 : { 1 : "NN conj NN conj NN nmod NN dobj VBD conj VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 conj drug0 nmod association dobj found conj *performed* nsubjpass tests compound drug0" } 4 : { 1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . " } } 333 : { 1 : "NN compound NNS nsubjpass VBN conj VBD dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound tests nsubjpass *performed* conj found dobj association nmod drug0" } 4 : { 1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . " } } 334 : { 1 : "NN compound NN nmod RB conj NN conj NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod independently conj *r0q* conj drug0" } 4 : { 1 : "We were also able to demonstrate the OCA2 R419Q , drug1 , coding SNP acts as a penetrance modifier of this new drug2 SNP for eye color , and somewhat independently , of drug3 risk . " } } 335 : { 1 : "NN compound NN nmod VBN advcl VBN ccomp VBD nsubj NN compound NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod associated advcl associated ccomp *demonstrated* nsubj analysis compound 0-locus dep drug0 appos drug0" } 4 : { 1 : "The four tested TCF7L2 variants were in linkage disequilibrium , and 4-locus ( drug1 , drug2 , drug3 , drug4 ) haplotype analysis demonstrated that haplotype 1111 was negatively associated ( Pc < 0.001 ) , while haplotypes 2222 ( Pc = 0.008 ) and 2211 ( Pc = 0.020 ) were positively associated with drug5 risk , after controlling for a number of covariates . " } } 336 : { 1 : "NN compound NN dobj VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk dobj *increased* nsubj genotype nmod drug0" } 4 : { 1 : "Among women with a history of drug2 , the TT genotype of drug1 increased drug3 risk ( OR , 2.46 ; 95 % CI 1.28-4 .73 ) " } } 337 : { 1 : "NN nmod NNS dobj VB xcomp JJ conj VBD nmod NNS acl:relcl VBD conj JJ xcomp VB dobj NN" 2 : 1 3 : { 1 : "drug0 nmod levels dobj report xcomp likely conj *found* nmod women acl:relcl smoked conj likely xcomp quit dobj drug0" } 4 : { 1 : "We found among women who smoked pre-pregnancy , those with the drug1 T allele smoked more and were less likely to quit drug2 during pregnancy , but were also less likely to report high levels of drug3 at 18 weeks of pregnancy ( per allele OR = 0.84 , 95 % CI 0.72 to 0.99 , p = 0.034 ) . " } } 338 : { 1 : "NN compound NN nmod NN dobj VB conj VB dobj NN nmod NN acl VBG nmod NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound protein nmod expression dobj *investigate* conj examine dobj difference nmod breast acl taking nmod genotype dep snp appos drug0" } 4 : { 1 : "To investigate the expression of drug2 protein in normal breast tissue , and examine the difference in ABCC11 mRNA and proteinexpression between normal breast and drug3 tissues taking into account ABCC11 genotype ( a functional SNP , drug1 ) and estrogen receptor ( ER ) status " } } 339 : { 1 : "NN compound NNS conj NN acl VBG nmod NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound tissues conj *breast* acl taking nmod genotype dep snp appos drug0" } 4 : { 1 : "To investigate the expression of drug2 protein in normal breast tissue , and examine the difference in ABCC11 mRNA and proteinexpression between normal breast and drug3 tissues taking into account ABCC11 genotype ( a functional SNP , drug1 ) and estrogen receptor ( ER ) status " } } 340 : { 1 : "NN compound NNS nmod JJ nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound subjects nmod *frequent* nsubj allele nmod drug0" } 4 : { 1 : "However , the risk allele at TCF7L2 drug1 was more frequent in drug2 subjects than in controls when we restricted the analysis to the subjects with lower weight-for-height than the median of the PA subjects ( " } } 341 : { 1 : "NN nmod NN nmod NNS nmod VBN nsubjpass NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod factors nmod *identified* nsubjpass polymiorphisms dep drug0 conj drug0" } 4 : { 1 : "BACKGROUND : Single nucleotide polymiorphisms ( SNPs ) drug1 and drug2 located within TCF7L2 gene have been identified as the strongest common genetic risk factors for development of drug3 ( T2D ) . " } } 342 : { 1 : "NN conj NN nmod NN nmod NN nsubjpass VBN advcl VBD nsubj NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj breast nmod association nmod evidence nsubjpass *observed* advcl warranted nsubj biology conj association nmod drug0" } 4 : { 1 : "CONCLUSIONS : Although the biology of the Wnt/beta-catenin signaling pathway and prior association between drug1 and numerous phenotypes warranted examination of this TCF7L2 SNP , no compelling evidence for association with breast or drug2 was observed . " } } 343 : { 1 : "NN nmod NN nmod NNS nmod VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod factors nmod *identified* nsubjpass polymiorphisms dep drug0" } 4 : { 1 : "BACKGROUND : Single nucleotide polymiorphisms ( SNPs ) drug1 and drug2 located within TCF7L2 gene have been identified as the strongest common genetic risk factors for development of drug3 ( T2D ) . " } } 344 : { 1 : "NN nmod VBN xcomp VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp *found* nsubjpass snps dep drug0" } 4 : { 1 : "Both TCF7L2 SNPs ( drug1 and drug2 ) were found to be significantly associated with drug3 when adjusting for insulin sensitivity , both in the whole cohort and when the diabetic subjects were excluded . " } } 345 : { 1 : "NN compound NNS conj NN nmod NN dobj VB conj VB dobj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound tissues conj breast nmod difference dobj examine conj *investigate* dobj expression nmod protein compound drug0" } 4 : { 1 : "To investigate the expression of drug2 protein in normal breast tissue , and examine the difference in ABCC11 mRNA and proteinexpression between normal breast and drug3 tissues taking into account ABCC11 genotype ( a functional SNP , drug1 ) and estrogen receptor ( ER ) status " } } 346 : { 1 : "NN nmod VBN ccomp VBN xcomp VBN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod associated ccomp *shown* xcomp associated nmod pigmentation conj snp appos drug0" } 4 : { 1 : "In Europeans , three haplotypes in the region have been shown to be associated with eye pigmentation and a missense SNP ( drug1 ) has been associated with drug2 " } } 347 : { 1 : "NN conj NN nmod VBN nsubjpass NN nmod NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *associated* nsubjpass genotype nmod receptor dep polymorphism compound drug0" } 4 : { 1 : "Moreover , the TT genotype of the nicotinic acetylcholine receptor ( nAChR ) a3-subunit ( CHRNA3 ) drug1 polymorphism has previously been associated with drug2 and drug3 . " } } 348 : { 1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass allele nmod r0q appos drug0" } 4 : { 1 : "We found that the variant allele of OCA2 R419Q ( drug1 ) was associated with increased risk of drug2 ( " } } 349 : { 1 : "NN nmod NN nmod VB ccomp VB parataxis VBD dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod marker nmod serve ccomp *determine* parataxis examined dobj genotypes nmod drug0" } 4 : { 1 : "In the present study , to determine whether the SNP can serve as a diagnostic marker for drug2 ( AO ) , we examined genotypes at drug1 in 79 Japanese AO individuals . " } } 350 : { 1 : "NN nmod VBN nsubjpass NN nmod NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass genotype nmod receptor dep polymorphism compound drug0" } 4 : { 1 : "Moreover , the TT genotype of the nicotinic acetylcholine receptor ( nAChR ) a3-subunit ( CHRNA3 ) drug1 polymorphism has previously been associated with drug2 and drug3 . " } } 351 : { 1 : "NN compound NN nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound *allele* nsubj allele nmod drug0" } 4 : { 1 : "Our data suggest that the haplotype restricted to Europe is the strongest marker for drug2 globally and add further inferential evidence that the derived allele of drug1 is an East Asian drug3 allele . " } } 352 : { 1 : "NN compound NN ccomp NN dobj VB conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound allele ccomp evidence dobj add conj *marker* nmod drug0" } 4 : { 1 : "Our data suggest that the haplotype restricted to Europe is the strongest marker for drug2 globally and add further inferential evidence that the derived allele of drug1 is an East Asian drug3 allele . " } } 353 : { 1 : "NN compound NN dobj VBP nsubj NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk dobj *increase* nsubj t-allele conj t-allele nmod drug0" } 4 : { 1 : "Both the T-allele of drug1 and the T-allele of drug2 significantly increase drug3 risk with an allelic odds ratio ( OR ) of 1.69 ( 95 % CI 1.55-1 .83 ) ( P = 6.0 x 10 ( -35 ) ) and 1.60 ( 1.47-1 .74 ) ( P = 7.6 x 10 ( -28 ) ) , respectively . " } } 354 : { 1 : "NN nmod NN nmod NNS nmod VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod history nmod women nmod *increased* nsubj genotype nmod drug0" } 4 : { 1 : "Among women with a history of drug2 , the TT genotype of drug1 increased drug3 risk ( OR , 2.46 ; 95 % CI 1.28-4 .73 ) " } } 355 : { 1 : "NN nmod NN nmod VBN xcomp VBN conj VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod likelihood nmod associated xcomp reported conj *associated* nsubjpass variant compound drug0" } 4 : { 1 : "The drug1 genetic variant within the CHRNA5-A3-B4 gene cluster is associated with drug2 and has recently been reported to be associated with likelihood of drug3 . " } } 356 : { 1 : "NN compound NN conj NN nmod VBN parataxis VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound quantity conj bmi nmod associated parataxis *associated* nmod status compound drug0" } 4 : { 1 : "The drug1 variant was not significantly associated with drug2 status or snus use ( P > 0.05 ) ; the T allele was associated with lower BMI in the overall cohort ( b = -0.10 kg/m ( 2 ) , SE = 0.05 ; P = 0.03 ) and with drug3 quantity in those in whom this was measured ( n = 5,304 ) ( b = 0.08 , SE = 0.01 ; P < 0.0001 ) " } } 357 : { 1 : "NN conj NN root -LRB- punct NN" 2 : 1 3 : { 1 : "drug0 conj or root ( punct *drug0*" } 4 : { 1 : "In addition , an association of two SNPs of the TCF7L2 gene with drug3 was observed in both cities : drug1 , ( for Guerrero OR = 1.98 CI95 % 1.02-3 .89 and for Mexico OR = 1.94 CI95 % 1.31-2 .88 ) and drug2 ( OR = 1.79 CI95 % 1.08-2 .97 , OR = 1.78 CI95 % 1.17-2 .71 respectively ) . " } } 358 : { 1 : "NN nmod NN nsubjpass VBN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod association nsubjpass *observed* nmod cities dep drug0" } 4 : { 1 : "In addition , an association of two SNPs of the TCF7L2 gene with drug3 was observed in both cities : drug1 , ( for Guerrero OR = 1.98 CI95 % 1.02-3 .89 and for Mexico OR = 1.94 CI95 % 1.31-2 .88 ) and drug2 ( OR = 1.79 CI95 % 1.08-2 .97 , OR = 1.78 CI95 % 1.17-2 .71 respectively ) . " } } 359 : { 1 : "NN nmod NN nsubjpass VBN nmod NNS dep NN punct -LRB- root NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod association nsubjpass *observed* nmod cities dep drug0 punct ( root or conj drug0" } 4 : { 1 : "In addition , an association of two SNPs of the TCF7L2 gene with drug3 was observed in both cities : drug1 , ( for Guerrero OR = 1.98 CI95 % 1.02-3 .89 and for Mexico OR = 1.94 CI95 % 1.31-2 .88 ) and drug2 ( OR = 1.79 CI95 % 1.08-2 .97 , OR = 1.78 CI95 % 1.17-2 .71 respectively ) . " } } 360 : { 1 : "NN nmod NN nmod NNS nmod VBN advcl VBN nsubjpass NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod patients nmod *warranted* advcl confirmed nsubjpass application nmod marker nmod drug0" } 4 : { 1 : "If the application of TCF7L2 drug1 SNPs as a marker for drug2 is confirmed by further independent studies , replacing tacrolimus with other immunosuppressants could be warranted in patients at high risk of drug3 , as diagnosed by TCF7L2 genotyping . " } } 361 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk dobj increase xcomp *found* nsubjpass allele nmod drug0" } 4 : { 1 : "The minor T allele of TCF7L2 drug1 was found to significantly increase the risk of drug2 , with an allelic odds ratio ( OR ) of 1.458 ( 95 % CI 1.108-1 .918 , p = 0.007 ) . " } } 362 : { 1 : "NN nmod NN nmod NNS nmod VBN advcl VBN nsubjpass NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod patients nmod *warranted* advcl confirmed nsubjpass application nmod snps compound drug0" } 4 : { 1 : "If the application of TCF7L2 drug1 SNPs as a marker for drug2 is confirmed by further independent studies , replacing tacrolimus with other immunosuppressants could be warranted in patients at high risk of drug3 , as diagnosed by TCF7L2 genotyping . " } } 363 : { 1 : "NN compound NN dobj VBD nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk dobj *increased* nmod women nmod history nmod drug0" } 4 : { 1 : "Among women with a history of drug2 , the TT genotype of drug1 increased drug3 risk ( OR , 2.46 ; 95 % CI 1.28-4 .73 ) " } } 364 : { 1 : "NN nmod NN nmod VBN acl:relcl NN nmod VBD dobj NNS appos NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod associated acl:relcl factor nmod *analysed* dobj polymorphisms appos drug0 conj drug0" } 4 : { 1 : "we analysed two single nucleotide polymorphisms ( SNPs ) , drug1 and drug2 , in the transcription factor 7-like 2 gene ( TCF7L2 ) , which are associated with an increased risk of drug3 . " } } 365 : { 1 : "NN nmod VBN xcomp VBN acl:relcl CD nmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp shown acl:relcl 0 nmod *observed* nmod drug0" } 4 : { 1 : "No interaction was observed between drug1 and HLA-DQB1 * 0602 , which was shown to be negatively associated with drug2 in mothers born in Sweden ( P = 0.010 ) . " } } 366 : { 1 : "NN nmod VB xcomp VBN nsubjpass NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod interact xcomp *shown* nsubjpass variant nmod region appos drug0" } 4 : { 1 : "A genetic variant within the CHRNA5-CHRNA3-CHRNB4 region ( drug1 ) , previously associated with drug2 quantity , was recently shown to interact with drug3 on drug4 predisposition . " } } 367 : { 1 : "NN compound NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound status nmod *associated* nsubjpass variant compound drug0" } 4 : { 1 : "The drug1 variant was not significantly associated with drug2 status or snus use ( P > 0.05 ) ; the T allele was associated with lower BMI in the overall cohort ( b = -0.10 kg/m ( 2 ) , SE = 0.05 ; P = 0.03 ) and with drug3 quantity in those in whom this was measured ( n = 5,304 ) ( b = 0.08 , SE = 0.01 ; P < 0.0001 ) " } } 368 : { 1 : "NN compound NN conj NN nmod VBN parataxis VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound quantity conj bmi nmod associated parataxis *associated* nsubjpass variant compound drug0" } 4 : { 1 : "The drug1 variant was not significantly associated with drug2 status or snus use ( P > 0.05 ) ; the T allele was associated with lower BMI in the overall cohort ( b = -0.10 kg/m ( 2 ) , SE = 0.05 ; P = 0.03 ) and with drug3 quantity in those in whom this was measured ( n = 5,304 ) ( b = 0.08 , SE = 0.01 ; P < 0.0001 ) " } } 369 : { 1 : "NN compound NN nmod VBN acl NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound quantity nmod associated acl *variant* nmod region appos drug0" } 4 : { 1 : "A genetic variant within the CHRNA5-CHRNA3-CHRNB4 region ( drug1 ) , previously associated with drug2 quantity , was recently shown to interact with drug3 on drug4 predisposition . " } } 370 : { 1 : "NN compound NN nmod VB nmod NN" 2 : 1 3 : { 1 : "drug0 compound predisposition nmod *interact* nmod drug0" } 4 : { 1 : "A genetic variant within the CHRNA5-CHRNA3-CHRNB4 region ( drug1 ) , previously associated with drug2 quantity , was recently shown to interact with drug3 on drug4 predisposition . " } } 371 : { 1 : "NN nmod VB xcomp VBN nsubjpass NN acl VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod interact xcomp *shown* nsubjpass variant acl associated nmod quantity compound drug0" } 4 : { 1 : "A genetic variant within the CHRNA5-CHRNA3-CHRNB4 region ( drug1 ) , previously associated with drug2 quantity , was recently shown to interact with drug3 on drug4 predisposition . " } } 372 : { 1 : "NN compound NN nmod VB xcomp VBN nsubjpass NN acl VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound predisposition nmod interact xcomp *shown* nsubjpass variant acl associated nmod quantity compound drug0" } 4 : { 1 : "A genetic variant within the CHRNA5-CHRNA3-CHRNB4 region ( drug1 ) , previously associated with drug2 quantity , was recently shown to interact with drug3 on drug4 predisposition . " } } 373 : { 1 : "NN compound NN nmod VB xcomp VBN nsubjpass NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound predisposition nmod interact xcomp *shown* nsubjpass variant nmod region appos drug0" } 4 : { 1 : "A genetic variant within the CHRNA5-CHRNA3-CHRNB4 region ( drug1 ) , previously associated with drug2 quantity , was recently shown to interact with drug3 on drug4 predisposition . " } } 374 : { 1 : "NN compound NN dobj VBP nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk dobj *increase* nsubj t-allele nmod drug0" } 4 : { 1 : "Both the T-allele of drug1 and the T-allele of drug2 significantly increase drug3 risk with an allelic odds ratio ( OR ) of 1.69 ( 95 % CI 1.55-1 .83 ) ( P = 6.0 x 10 ( -35 ) ) and 1.60 ( 1.47-1 .74 ) ( P = 7.6 x 10 ( -28 ) ) , respectively . " } } 375 : { 1 : "NN appos NN conj NN nmod NNS appos NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj nod0 nmod *0fs* appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 376 : { 1 : "NN appos NNS conj NN nmod NN appos NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos 0fs conj slc0a0 nmod drug0 appos lrrk0 nmod *drug0*" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 377 : { 1 : "NN nmod VBN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *polymorphisms* dep drug0 conj drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 378 : { 1 : "NN nmod VBN xcomp VBD acl NN appos NN dobj VBP acl:relcl NN conj NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp reported acl haplotype appos a dobj tag acl:relcl drug0 conj *polymorphisms* dep drug0 conj drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 379 : { 1 : "NN nmod VBN dep NNS conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *polymorphisms* conj drug0 compound drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 380 : { 1 : "NN nmod VBN xcomp VBD acl NN appos NN dobj VBP acl:relcl NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp reported acl haplotype appos a dobj tag acl:relcl *drug0* compound drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 381 : { 1 : "NN compound NN conj NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound drug0 conj *polymorphisms* dep drug0 conj drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 382 : { 1 : "NN nmod VBN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *polymorphisms* dep drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 383 : { 1 : "NN nmod VBN xcomp VBD acl NN appos NN dobj VBP acl:relcl NN conj NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp reported acl haplotype appos a dobj tag acl:relcl drug0 conj *polymorphisms* dep drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 384 : { 1 : " NN acl VBN nmod NN" 2 : 1 3 : { 1 : " *drug0* acl associated nmod drug0" } 4 : { 1 : "Carbohydrate quality and quantity modified risk of drug2 associated with drug1 , which suggests that changes in risk attributable to the TCF7L2 variant are magnified under conditions of increased insulin demand . " } } 385 : { 1 : "NN compound NN conj NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound drug0 conj *polymorphisms* dep drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 386 : { 1 : "NN nmod NN dobj VBG acl NNS nmod NN dobj VBD advcl VBG dobj NN" 2 : 1 3 : { 1 : "drug0 nmod association dobj examining acl studies nmod meta-analysis dobj *performed* advcl containing dobj drug0" } 4 : { 1 : "The authors then performed a large meta-analysis of 36 studies examining the association of drug5 with polymorphisms in the TCF7L2 gene in various ethnicities , containing drug1 C-to-T ( IVS3C > T ) , drug2 T-to-C ( IVS3T > C ) , a drug3 G-to-T ( IVS4G > T ) , and drug4 G-to-C ( IVS4G > C ) polymorphisms and toevaluate the size of gene effect and the possible genetic mode of action " } } 387 : { 1 : "NN nmod VBN dep NNS conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *polymorphisms* conj drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 388 : { 1 : "NN nmod VBN xcomp VBD acl NN appos NN dobj VBP acl:relcl NN conj NNS dep VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp reported acl haplotype appos a dobj tag acl:relcl drug0 conj *polymorphisms* dep associated nmod drug0" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 389 : { 1 : "NN nsubjpass VBN nmod NN nmod NNS nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubjpass *associated* nmod drug0 nmod carriers nmod allele nmod snp compound drug0" } 4 : { 1 : "In summary , drug2 ( > or = 6.62 % of energy intake ) were associated with drug3 in carriers of the minor T allele at the TCF7L2 drug1 SNP and may predispose them to MetS , diabetes , and cardiovascular disease . " } } 390 : { 1 : " NN nmod NNS nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : " *drug0* nmod carriers nmod allele nmod snp compound drug0" } 4 : { 1 : "In summary , drug2 ( > or = 6.62 % of energy intake ) were associated with drug3 in carriers of the minor T allele at the TCF7L2 drug1 SNP and may predispose them to MetS , diabetes , and cardiovascular disease . " } } 391 : { 1 : "NN compound NNS dobj VBD nmod NN" 2 : 1 3 : { 1 : "drug0 compound levels dobj *had* nmod drug0" } 4 : { 1 : "In drug1 , T2D patients carrying genotypes CT or TT had drug2 ( FPG ) levels ( p = 0.042 ) and drug3 ( p = 0.015 ) and drug4 ( p = 0.015 ) compared to the patients carrying CC genotype . " } } 392 : { 1 : "NN nmod VBN xcomp VBD acl NN appos NN dobj VBP acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp reported acl haplotype appos a dobj tag acl:relcl *drug0*" } 4 : { 1 : "We genotyped the TCF7L2 single nucleotide polymorphisms drug1 and drug2 ( previously associated with drug5 ) and drug3 nd drug4 ( which tag haplotype A [ HapA ] , a haplotype reported to be associated with drug6 ) in 2,512 FHS participants . " } } 393 : { 1 : "NN conj NN nmod NN nmod NNS appos NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *effect* nmod polymorphisms appos drug0 conj drug0" } 4 : { 1 : "We investigated the effect of single nucleotide polymorphisms ( SNP ) , drug1 and drug2 , within the TCF7L2 locus on drug3 and other drug4 and their modulation by dietary fat . " } } 394 : { 1 : "NN nmod NNS dobj VBD dep VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod associations dobj *showed* dep showed nsubj drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 395 : { 1 : "NN nmod NN nmod NNS appos NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *effect* nmod polymorphisms appos drug0 conj drug0" } 4 : { 1 : "We investigated the effect of single nucleotide polymorphisms ( SNP ) , drug1 and drug2 , within the TCF7L2 locus on drug3 and other drug4 and their modulation by dietary fat . " } } 396 : { 1 : "NN nmod NN nmod NNS appos NN" 2 : 1 3 : { 1 : "drug0 nmod *effect* nmod polymorphisms appos drug0" } 4 : { 1 : "We investigated the effect of single nucleotide polymorphisms ( SNP ) , drug1 and drug2 , within the TCF7L2 locus on drug3 and other drug4 and their modulation by dietary fat . " } } 397 : { 1 : "NN conj NN nmod NN nmod NNS appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *effect* nmod polymorphisms appos drug0" } 4 : { 1 : "We investigated the effect of single nucleotide polymorphisms ( SNP ) , drug1 and drug2 , within the TCF7L2 locus on drug3 and other drug4 and their modulation by dietary fat . " } } 398 : { 1 : "NN conj NNS dobj VBD nmod NN" 2 : 1 3 : { 1 : "drug0 conj levels dobj *had* nmod drug0" } 4 : { 1 : "In drug1 , T2D patients carrying genotypes CT or TT had drug2 ( FPG ) levels ( p = 0.042 ) and drug3 ( p = 0.015 ) and drug4 ( p = 0.015 ) compared to the patients carrying CC genotype . " } } 399 : { 1 : " NN conj NN appos NNS compound NN" 2 : 1 3 : { 1 : " *drug0* conj hypothesis appos gg compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 400 : { 1 : "NN nmod VBN ccomp VBN nmod NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod observed ccomp *observed* nmod tg nmod alleles nmod drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 401 : { 1 : "NN compound NN nmod VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod *associated* nsubjpass snps dep drug0" } 4 : { 1 : "Three SNPs [ drug1 in APOE : odds ratio ( OR ) = 4.24 , 95 % confidence interval ( CI ) = 3.01-5 .96 , P = 1.23 * 10 ; drug2 in APOE : OR = 3.57 , 95 % CI = 2.51-5 .06 , P = 1.23 * 10 ; and drug3 in PICALM : OR = 0.63 , 95 % CI = 0.49-0 .81 , P = 0.00036 , log additive model ] were significantly associated with drug4 susceptibility after correction for multiple testing . " } } 402 : { 1 : "NN compound NN nmod VBN nsubjpass NNS dep NN dep NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod *associated* nsubjpass snps dep drug0 dep drug0" } 4 : { 1 : "Three SNPs [ drug1 in APOE : odds ratio ( OR ) = 4.24 , 95 % confidence interval ( CI ) = 3.01-5 .96 , P = 1.23 * 10 ; drug2 in APOE : OR = 3.57 , 95 % CI = 2.51-5 .06 , P = 1.23 * 10 ; and drug3 in PICALM : OR = 0.63 , 95 % CI = 0.49-0 .81 , P = 0.00036 , log additive model ] were significantly associated with drug4 susceptibility after correction for multiple testing . " } } 403 : { 1 : "NN compound NN nmod VBN nsubjpass NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod *associated* nsubjpass snps dep drug0 conj drug0" } 4 : { 1 : "Three SNPs [ drug1 in APOE : odds ratio ( OR ) = 4.24 , 95 % confidence interval ( CI ) = 3.01-5 .96 , P = 1.23 * 10 ; drug2 in APOE : OR = 3.57 , 95 % CI = 2.51-5 .06 , P = 1.23 * 10 ; and drug3 in PICALM : OR = 0.63 , 95 % CI = 0.49-0 .81 , P = 0.00036 , log additive model ] were significantly associated with drug4 susceptibility after correction for multiple testing . " } } 404 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod *tested* nsubjpass polymorphisms dep drug0 conj drug0" } 4 : { 1 : "BACKGROUND : Single nucleotide polymorphisms ( SNPs ) drug1 ( e4 ) and drug2 ( e2 ) , both invoking changes in the amino-acid sequence of the apolipoprotein E ( APOE ) gene , have previously been tested for association with drug3 ( MS ) risk . " } } 405 : { 1 : "NN nmod VBN acl:relcl NNS nmod VBN dep NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl polymorphisms nmod *performed* dep drug0 conj clstn0 appos drug0" } 4 : { 1 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " } } 406 : { 1 : "NN nmod VBN acl:relcl NNS nmod VBN dep NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl polymorphisms nmod *performed* dep drug0" } 4 : { 1 : "Genotyping was performed for five single-nucleotide polymorphisms that have been associated with drug6 : drug1 , drug2 , drug3 , drug4 , and CLSTN2 ( drug5 ) . " } } 407 : { 1 : "NN compound NNS nmod NN nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound families nmod *tg* nmod alleles nmod drug0 conj drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 408 : { 1 : "NN compound NN nmod VBN acl NNS nmod NN acl:relcl NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound disease nmod associated acl snps nmod disequilibrium acl:relcl *snp* nmod drug0" } 4 : { 1 : "RESULTS : Genome-wide significance in fully adjusted models ( sex , age , APOE genotype , population stratification ) was observed for a SNP in drug1 ( drug2 , allele = G ; frequency , 0.09 cases and 0.06 controls ; odds ratio [ OR ] , 1.79 [ 95 % CI , 1.47-2 .12 ] ; P = 2.2 * 10 ( -9 ) ) , which is in linkage disequilibrium with SNPs previously associated with drug3 disease in Europeans ( 0.8 < D' < 0.9 ) . " } } 409 : { 1 : "NN compound NN nmod VBN acl NNS nmod NN acl:relcl NN dep NN" 2 : 1 3 : { 1 : "drug0 compound disease nmod associated acl snps nmod disequilibrium acl:relcl *snp* dep drug0" } 4 : { 1 : "RESULTS : Genome-wide significance in fully adjusted models ( sex , age , APOE genotype , population stratification ) was observed for a SNP in drug1 ( drug2 , allele = G ; frequency , 0.09 cases and 0.06 controls ; odds ratio [ OR ] , 1.79 [ 95 % CI , 1.47-2 .12 ] ; P = 2.2 * 10 ( -9 ) ) , which is in linkage disequilibrium with SNPs previously associated with drug3 disease in Europeans ( 0.8 < D' < 0.9 ) . " } } 410 : { 1 : "NN nmod NNS dobj VBD dep VBD nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associations dobj *showed* dep showed nsubj drug0 conj drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 411 : { 1 : "NN appos NN nmod VBN ccomp VBN nmod NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod observed ccomp *observed* nmod tg nmod alleles nmod drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 412 : { 1 : "NN conj NN nmod VBN ccomp VBN nmod NN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod observed ccomp *observed* nmod tg nmod alleles nmod drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 413 : { 1 : "NN nmod NNS nmod NNS acl VBG nmod NN dep NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g conj g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 414 : { 1 : "NN compound NNS appos NN conj NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 compound gg appos hypothesis conj *drug0* dep c compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 415 : { 1 : " NN dep NN compound NN" 2 : 1 3 : { 1 : " *drug0* dep c compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 416 : { 1 : "NN compound NN dep NN nmod NNS nmod NNS acl VBG nmod NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 compound c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 417 : { 1 : "NN compound NNS appos NN conj NN nmod NNS nmod NNS acl VBG nmod NN dep NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound gg appos hypothesis conj drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g conj g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 418 : { 1 : "NN nmod NNS nmod NNS acl VBG nmod NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 419 : { 1 : "NN compound NN dep NN nmod NNS nmod NNS acl VBG nmod NN dep NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound c dep drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g conj g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 420 : { 1 : "NN compound NNS appos NN conj NN nmod NNS nmod NNS acl VBG nmod NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 compound gg appos hypothesis conj drug0 nmod *distributions* nmod snps acl relating nmod hypothesis dep g compound drug0" } 4 : { 1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . " } } 421 : { 1 : "NN nsubj VBD dobj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubj *demonstrated* dobj increase nmod allele compound drug0" } 4 : { 1 : "RESULTS : drug2 compared to healthy individuals demonstrated a statistically significant increase in drug1 allele ( p = 0.037 , OR = 2.12 , 95 % CI 1.29-3 .4 ) . " } } 422 : { 1 : "NN conj NN conj NNS dobj VBD nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 conj levels dobj *had* nmod drug0" } 4 : { 1 : "In drug1 , T2D patients carrying genotypes CT or TT had drug2 ( FPG ) levels ( p = 0.042 ) and drug3 ( p = 0.015 ) and drug4 ( p = 0.015 ) compared to the patients carrying CC genotype . " } } 423 : { 1 : "NN compound NN conj NN nmod NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound polymorphism conj polymorphism nmod *alleles* nmod polymorphism compound drug0" } 4 : { 1 : "Furthermore , the risk alleles from TCF7L2 drug1 polymorphism either with drug2 polymorphism ( p = 0.0257 , OR = 1.398 ) or with drug3 polymorphism ( p = 0.0024 , OR = 1.514 ) were significantly associated with drug4 . " } } 424 : { 1 : "NN nmod NN nmod VBN acl:relcl NN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod associated acl:relcl pathway nmod *association* nmod polymorphism nmod drug0" } 4 : { 1 : "We evaluated the association of a polymorphism in TCF7L2 drug1 in the WNT signaling pathway , which previously has been strongly associated with risk of drug2 , with drug3 and drug4 in the prospective Nurses ' Health Study ( NHS ) and Health ProfessionalsFollow-up Study ( HPFS ) cohorts . " } } 425 : { 1 : "NN nmod NN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod pathway nmod *association* nmod polymorphism nmod drug0" } 4 : { 1 : "We evaluated the association of a polymorphism in TCF7L2 drug1 in the WNT signaling pathway , which previously has been strongly associated with risk of drug2 , with drug3 and drug4 in the prospective Nurses ' Health Study ( NHS ) and Health ProfessionalsFollow-up Study ( HPFS ) cohorts . " } } 426 : { 1 : "NN conj NN nmod NN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod pathway nmod *association* nmod polymorphism nmod drug0" } 4 : { 1 : "We evaluated the association of a polymorphism in TCF7L2 drug1 in the WNT signaling pathway , which previously has been strongly associated with risk of drug2 , with drug3 and drug4 in the prospective Nurses ' Health Study ( NHS ) and Health ProfessionalsFollow-up Study ( HPFS ) cohorts . " } } 427 : { 1 : "NN nmod NN acl:relcl VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *pathway* acl:relcl associated nmod risk nmod drug0" } 4 : { 1 : "We evaluated the association of a polymorphism in TCF7L2 drug1 in the WNT signaling pathway , which previously has been strongly associated with risk of drug2 , with drug3 and drug4 in the prospective Nurses ' Health Study ( NHS ) and Health ProfessionalsFollow-up Study ( HPFS ) cohorts . " } } 428 : { 1 : "NN conj DT dep JJR amod NN dobj VBP acl NN appos NN" 2 : 1 3 : { 1 : "drug0 conj a dep > amod c dobj c. acl *drug0* appos drug0" } 4 : { 1 : "No association was found for drug1 , drug2 , c. 1,637 C > A and drug3 ( p = 0.278-1 .000 ) . " } } 429 : { 1 : "NN compound NN nmod VBN nsubjpass NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod *associated* nsubjpass variants compound drug0 conj drug0" } 4 : { 1 : "The drug1 and drug2 variants of TCF7L2 have been strongly associated with drug3 risk in most populations studied to date . " } } 430 : { 1 : "NN conj DT dep JJR amod NN dobj VBP acl NN" 2 : 1 3 : { 1 : "drug0 conj a dep > amod c dobj c. acl *drug0*" } 4 : { 1 : "No association was found for drug1 , drug2 , c. 1,637 C > A and drug3 ( p = 0.278-1 .000 ) . " } } 431 : { 1 : "NN compound NNS conj NN nmod NN dobj VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 compound patients conj drug0 nmod association dobj *showed* nsubj drug0" } 4 : { 1 : "while , drug1 showed a statistically significant association between drug2 and drug3 patients carrying the 26V allele ( OR = 1.69 , 95 % CI = 1.11-2 .56 , P = 0.013 ) . " } } 432 : { 1 : "NN compound NN nmod VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod *associated* nsubjpass variants compound drug0" } 4 : { 1 : "The drug1 and drug2 variants of TCF7L2 have been strongly associated with drug3 risk in most populations studied to date . " } } 433 : { 1 : "NN conj NN conj NNS nmod NN conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj *drug0* conj carriers nmod drug0 conj mutations compound drug0" } 4 : { 1 : "No statistically significant association of the SNPs was observed with drug3 or drug4 or between carriers and non-carriers of drug1 and drug2 mutations . " } } 434 : { 1 : "NN conj NN nmod NN acl:relcl VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *pathway* acl:relcl associated nmod risk nmod drug0" } 4 : { 1 : "We evaluated the association of a polymorphism in TCF7L2 drug1 in the WNT signaling pathway , which previously has been strongly associated with risk of drug2 , with drug3 and drug4 in the prospective Nurses ' Health Study ( NHS ) and Health ProfessionalsFollow-up Study ( HPFS ) cohorts . " } } 435 : { 1 : "NN nmod JJ nsubj NN acl VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *specific* nsubj drug0 acl associated nmod genotype compound drug0" } 4 : { 1 : "This result suggests that the increased drug2 associated with drug1 genotype is specific to drug3 . " } } 436 : { 1 : "NN compound NN nsubjpass VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound stage nsubjpass *associated* nmod frequency conj drug0" } 4 : { 1 : "drug3 disease stage was marginally significantly associated with the frequency of the T variant at drug1 ( p = 0.057 ; adjusted p = 0.017 ) but not at drug2 ( p = 0.5 ; adjusted p = 0.2 ) . " } } 437 : { 1 : "NN nmod NNS nmod NN nsubj VBD dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod subjects nmod comparison nsubj *showed* dobj association nmod drug0" } 4 : { 1 : "Comparison between subjects with drug3 and the combined drug4 showed a significant association with drug1 ( OR 1.47 , CI 1.04-2 .08 ; p = 0.03 ) but not with drug2 ( OR 1.16 , CI 0.81-1 .64 ; p = 0.4 ) . " } } 438 : { 1 : "NN conj NN nmod NNS nmod NN nsubj VBD dobj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod subjects nmod comparison nsubj *showed* dobj association nmod drug0 conj drug0" } 4 : { 1 : "Comparison between subjects with drug3 and the combined drug4 showed a significant association with drug1 ( OR 1.47 , CI 1.04-2 .08 ; p = 0.03 ) but not with drug2 ( OR 1.16 , CI 0.81-1 .64 ; p = 0.4 ) . " } } 439 : { 1 : " NN acl VBN nmod NN compound NN" 2 : 1 3 : { 1 : " *drug0* acl associated nmod genotype compound drug0" } 4 : { 1 : "This result suggests that the increased drug2 associated with drug1 genotype is specific to drug3 . " } } 440 : { 1 : "NN nmod VBN parataxis VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* parataxis conferred nmod drug0" } 4 : { 1 : "The minor allele of each variant was significantly associated with drug2 ; the greatest risk of developing the disease was conferred by drug1 , with an allelic odds ratio ( OR ) of 1.31 ( 95 % CI : 1.11 - 1.56 , p = 1.96 x 10 ( -3 ) ) . " } } 441 : { 1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass allele nmod polymorphism dep drug0" } 4 : { 1 : "Specifically , the same risk allele of single nucleotide polymorphism ( SNP ) drug1 that is associated with drug2 ( T allele ) has recently been associated with an increased risk of drug3 . " } } 442 : { 1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN acl:relcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *associated* nsubjpass allele nmod polymorphism acl:relcl associated nmod drug0" } 4 : { 1 : "Specifically , the same risk allele of single nucleotide polymorphism ( SNP ) drug1 that is associated with drug2 ( T allele ) has recently been associated with an increased risk of drug3 . " } } 443 : { 1 : "NN nmod JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod *specific* nsubj drug0" } 4 : { 1 : "This result suggests that the increased drug2 associated with drug1 genotype is specific to drug3 . " } } 444 : { 1 : "NN nmod VBN acl:relcl NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl *polymorphism* dep drug0" } 4 : { 1 : "Specifically , the same risk allele of single nucleotide polymorphism ( SNP ) drug1 that is associated with drug2 ( T allele ) has recently been associated with an increased risk of drug3 . " } } 445 : { 1 : "NN compound NN nmod NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound polymorphism nmod *alleles* nmod polymorphism compound drug0" } 4 : { 1 : "Furthermore , the risk alleles from TCF7L2 drug1 polymorphism either with drug2 polymorphism ( p = 0.0257 , OR = 1.398 ) or with drug3 polymorphism ( p = 0.0024 , OR = 1.514 ) were significantly associated with drug4 . " } } 446 : { 1 : " NN conj NNS nmod NN conj NNS compound NN" 2 : 1 3 : { 1 : " *drug0* conj carriers nmod drug0 conj mutations compound drug0" } 4 : { 1 : "No statistically significant association of the SNPs was observed with drug3 or drug4 or between carriers and non-carriers of drug1 and drug2 mutations . " } } 447 : { 1 : " NN conj NNS nmod NN" 2 : 1 3 : { 1 : " *drug0* conj carriers nmod drug0" } 4 : { 1 : "No statistically significant association of the SNPs was observed with drug3 or drug4 or between carriers and non-carriers of drug1 and drug2 mutations . " } } 448 : { 1 : "NN nmod NN nsubjpass VBN nmod NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0 conj igf0bp0 dep drug0 conj drug0" } 4 : { 1 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 449 : { 1 : "NN nmod NN dobj VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod ratio dobj *showed* nsubj polymorphism compound drug0" } 4 : { 1 : "The TCF7L2 drug1 polymorphism showed the highest odds ratio ( OR ) for drug2 ( OR 1.714 [ 1.298-2 .263 ] ) . " } } 450 : { 1 : "NN compound NNS nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *associated* nsubjpass allele nmod drug0" } 4 : { 1 : "Odds ratio of other polymorphisms ranged from 1.13 to 1.41 . The risk allele of CDKAL1 drug1 was significantly associated with drug2 patients after adjustment for other confounding factors . " } } 451 : { 1 : "NN nmod NNS dobj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod associations dobj *showed* nsubj alleles nmod drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 452 : { 1 : "NN nmod NN nsubjpass VBN nmod NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod susceptibility nsubjpass *replicated* nmod drug0 conj igf0bp0 dep drug0" } 4 : { 1 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 453 : { 1 : "NN nmod NN nmod VBN ccomp VBD nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod associated ccomp *showed* nsubj allele nmod drug0 conj drug0" } 4 : { 1 : "The allele and genotype frequencies of two SNP drug1 and drug2 showed that these are associated ( odds ratio up to 4 ) with the development of drug3 in the autoantibody-negative diabetic cohort , but not in the autoantibody-positive diabetic cohort . " } } 454 : { 1 : "NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep igf0bp0 conj *drug0*" } 4 : { 1 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . " } } 455 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass alleles nmod polymorphism conj polymorphism compound drug0" } 4 : { 1 : "Furthermore , the risk alleles from TCF7L2 drug1 polymorphism either with drug2 polymorphism ( p = 0.0257 , OR = 1.398 ) or with drug3 polymorphism ( p = 0.0024 , OR = 1.514 ) were significantly associated with drug4 . " } } 456 : { 1 : "NN nmod NN nmod VBN ccomp VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod associated ccomp *showed* nsubj allele nmod drug0" } 4 : { 1 : "The allele and genotype frequencies of two SNP drug1 and drug2 showed that these are associated ( odds ratio up to 4 ) with the development of drug3 in the autoantibody-negative diabetic cohort , but not in the autoantibody-positive diabetic cohort . " } } 457 : { 1 : "NN conj NN conj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj *drug0* conj carriers nmod drug0" } 4 : { 1 : "No statistically significant association of the SNPs was observed with drug3 or drug4 or between carriers and non-carriers of drug1 and drug2 mutations . " } } 458 : { 1 : "NN nsubjpass VBN nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nsubjpass *associated* nmod drug0 dep drug0" } 4 : { 1 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1 .79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1 .72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1 .49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1 .38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1 .43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2 .43 , p = 0.038 ) in TCF7L2 . " } } 459 : { 1 : "NN nmod NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NNS nmod NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod diagnosis nmod time nmod performed acl ogtt nmod *associated* nsubjpass alleles nmod snps dep drug0 conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 460 : { 1 : "NN conj NN nsubj VBD dep VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nsubj showed dep *showed* nsubj alleles nmod drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 461 : { 1 : "NN compound NNS nmod JJR nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *higher* nsubj frequency nmod drug0" } 4 : { 1 : "The minor allele frequency of drug1 , drug2 and drug3 was significantly higher in drug4 patients compared with that in non-diabetic individuals . " } } 462 : { 1 : "NN nsubj VBD dep VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj showed dep *showed* nsubj alleles nmod drug0" } 4 : { 1 : "The minor alleles of drug1 , drug2 , and drug3 showed significant associations with drug6 ( OR = 1.48 , P = 2.7 x 10 ( -4 ) ; OR = 1.39 , P = 4.6 x 10 ( -4 ) ; OR = 1.70 , P = 9.8 x 10 ( -5 ) , respectively ) in the combined sample sets , However , neither drug4 nor drug5 showed a significant association . " } } 463 : { 1 : "NN nmod NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NNS nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod diagnosis nmod time nmod performed acl ogtt nmod *associated* nsubjpass alleles nmod snps dep drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 464 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass alleles nmod gene dep drug0 conj drug0" } 4 : { 1 : "The risk alleles of the TCF7L2 gene ( drug1 and drug2 ) were strongly associated with drug3 , even after controlling for traditional risk factors in both a cross-sectional and prospective setting . " } } 465 : { 1 : "NN nmod NN nmod NN nmod VBN acl NN nmod VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod diagnosis nmod time nmod performed acl ogtt nmod *associated* nmod auc compound drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 466 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass alleles nmod gene dep drug0" } 4 : { 1 : "The risk alleles of the TCF7L2 gene ( drug1 and drug2 ) were strongly associated with drug3 , even after controlling for traditional risk factors in both a cross-sectional and prospective setting . " } } 467 : { 1 : "NN conj NNS conj NN" 2 : 1 3 : { 1 : "drug0 conj *alleles* conj drug0" } 4 : { 1 : "The risk alleles of the SNPs drug1 and drug2 in CDKAL1 ; drug3 in the CDKN2A-CDKN2B region ; and drug4 , drug5 and drug6 in HHEX were associated with drug7 AUC during a 100 g OGTT performed at the time of diagnosis of drug8 . " } } 468 : { 1 : "NN appos NN conj NN nmod NN appos NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj slc0a0 nmod drug0 appos lrrk0 nmod *drug0*" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 469 : { 1 : "NN compound NNS nmod NN dobj VB xcomp JJ conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod survival dobj predict xcomp likely conj *found* nsubjpass drug0" } 4 : { 1 : "CONCLUSIONS : The drug1 was found to be predictive of clinical response and was more likely to predict long-term survival in Japanese drug2 patients receiving definitive 5-FU/CDDP-based CRT . " } } 470 : { 1 : "NN compound NNS nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod *c0t* conj g-0c appos drug0" } 4 : { 1 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 471 : { 1 : "NN conj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj *alleles* nmod drug0" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 472 : { 1 : "NN nsubjpass VBN nmod NNS nmod NN conj NN dep NN conj VBN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass *associated* nmod alleles nmod drug0 conj drug0 dep or conj associated nmod alleles nmod drug0" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 473 : { 1 : "NN nsubjpass VBN nmod NNS nmod NN conj NN dep NN conj VBN nmod NNS conj NN" 2 : 1 3 : { 1 : "drug0 nsubjpass *associated* nmod alleles nmod drug0 conj drug0 dep or conj associated nmod alleles conj drug0" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 474 : { 1 : "NN appos NN conj NNS dep NN" 2 : 1 3 : { 1 : "drug0 appos snp conj *snps* dep drug0" } 4 : { 1 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " } } 475 : { 1 : "NN nsubjpass VBN nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nsubjpass *associated* nmod alleles nmod drug0 conj drug0" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 476 : { 1 : "NN nmod NNS nmod VBN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod alleles nmod associated conj or dep *drug0*" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 477 : { 1 : "NN conj NNS nmod VBN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 conj alleles nmod associated conj or dep *drug0*" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 478 : { 1 : "NN conj NNS nmod VBN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 conj alleles nmod associated conj or dep drug0 conj *drug0*" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 479 : { 1 : "NN nsubjpass VBN nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nsubjpass *associated* nmod alleles nmod drug0" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 480 : { 1 : "NN nmod NNS nmod VBN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod alleles nmod associated conj or dep drug0 conj *drug0*" } 4 : { 1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [ 1.13-4 .51 ] ) and 6q21 drug2 ( OR = 1.60 [ 1.10-2 .34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [ 0.11-0 .74 ] ) and DEFB1 drug4 ( OR = 0.50 [ 0.30-0 .80 ] ) . " } } 481 : { 1 : "NN nmod NN dobj VBD nsubj NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod association dobj *showed* nsubj snps dep drug0" } 4 : { 1 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " } } 482 : { 1 : "NN nmod VBN acl:relcl NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl *drug0* conj drug0" } 4 : { 1 : "When testing drug1 and drug2 for replication in Finnish drug3 families , these single nucleotide polymorphisms were associated with drug4 ( p = 0.01 and p = 0.007 ) . " } } 483 : { 1 : "NN nmod VBN nsubjpass NNS conj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass variants conj drug0" } 4 : { 1 : "Three NOD2/CARD15 variants , namely two missense polymorphisms drug1 and drug2 , and a frame shift polymorphism drug3 , were associated with drug4 in Caucasian populations . " } } 484 : { 1 : "NN compound NN nmod NN nmod NNS nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound development nmod cluster nmod *effects* nmod variants dep drug0" } 4 : { 1 : "Our analysis revealed that effects of two linked variants ( drug1 and drug2 ) in the AGPHD1/CHRNA3 cluster on drug3 development are significantly , yet not entirely , mediated by the smoking-related phenotypes " } } 485 : { 1 : "NN compound NN nmod NN nmod NNS nmod NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound development nmod cluster nmod *effects* nmod variants dep drug0 conj drug0" } 4 : { 1 : "Our analysis revealed that effects of two linked variants ( drug1 and drug2 ) in the AGPHD1/CHRNA3 cluster on drug3 development are significantly , yet not entirely , mediated by the smoking-related phenotypes " } } 486 : { 1 : "NN appos NN appos NN" 2 : 1 3 : { 1 : "drug0 appos *drug0* appos drug0" } 4 : { 1 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " } } 487 : { 1 : "NN nmod VBN nsubjpass NNS appos NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass variants appos drug0 conj drug0" } 4 : { 1 : "Three NOD2/CARD15 variants , namely two missense polymorphisms drug1 and drug2 , and a frame shift polymorphism drug3 , were associated with drug4 in Caucasian populations . " } } 488 : { 1 : "NN nmod VBN nsubjpass NNS appos NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass variants appos drug0" } 4 : { 1 : "Three NOD2/CARD15 variants , namely two missense polymorphisms drug1 and drug2 , and a frame shift polymorphism drug3 , were associated with drug4 in Caucasian populations . " } } 489 : { 1 : "NN conj NNS appos NN conj NN" 2 : 1 3 : { 1 : "drug0 conj *variants* appos drug0 conj drug0" } 4 : { 1 : "Three NOD2/CARD15 variants , namely two missense polymorphisms drug1 and drug2 , and a frame shift polymorphism drug3 , were associated with drug4 in Caucasian populations . " } } 490 : { 1 : "NN nmod NN dobj VBD nsubj NNS conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod association dobj *showed* nsubj snps conj snp appos drug0" } 4 : { 1 : "In genotype-association SNP analysis , all NOD2 SNPs ( drug1 , drug2 , drug3 ) and the IL23r SNP ( drug4 ) showed a significant association to drug5 ( p < 0.03 ) . " } } 491 : { 1 : "NN conj NNS appos NN" 2 : 1 3 : { 1 : "drug0 conj *variants* appos drug0" } 4 : { 1 : "Three NOD2/CARD15 variants , namely two missense polymorphisms drug1 and drug2 , and a frame shift polymorphism drug3 , were associated with drug4 in Caucasian populations . " } } 492 : { 1 : "NN compound NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound polymorphisms conj *association* nmod drug0" } 4 : { 1 : "In association analysis , we found statistically significant association of drug1 ( p = 0.001 , OR = 3.011 , CI95 % = 1.494-6 .071 ) and drug2 ( p = 2.62 * 10 ^ { -4 } , OR = 14.117 , CI95 % = 1.884-105 .799 ) polymorphisms with drug3 patients . " } } 493 : { 1 : "NN compound NN appos NN nmod NNP appos NN nmod NN appos NN nmod NN conj NNS nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *disease* appos e0k nmod snca appos drug0 nmod lrrk0 appos drug0 nmod slc0a0 conj 0fs nmod nod0 conj g0r appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 494 : { 1 : "NN nmod NNS nmod NN nsubj VBD dobj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod subjects nmod comparison nsubj *showed* dobj association nmod drug0 conj drug0" } 4 : { 1 : "Comparison between subjects with drug3 and the combined drug4 showed a significant association with drug1 ( OR 1.47 , CI 1.04-2 .08 ; p = 0.03 ) but not with drug2 ( OR 1.16 , CI 0.81-1 .64 ; p = 0.4 ) . " } } 495 : { 1 : "NN appos NN conj NN nmod NN appos NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj slc0a0 nmod drug0 appos *lrrk0* conj park0 compound drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 496 : { 1 : "NN appos NNS conj NN nmod NN appos NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 appos 0fs conj slc0a0 nmod drug0 appos *lrrk0* conj park0 compound drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 497 : { 1 : "NN appos NN conj NN nmod NNS conj NN nmod NN appos NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj nod0 nmod 0fs conj slc0a0 nmod drug0 appos *lrrk0* conj park0 compound drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 498 : { 1 : "NN compound NN appos NN nmod NNP appos NN nmod NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound *disease* appos e0k nmod snca appos drug0 nmod lrrk0 conj park0 compound drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 499 : { 1 : "NN compound NNS nmod JJR nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound subjects nmod *higher* nsubj frequency nmod allele nmod drug0" } 4 : { 1 : "The frequency of the T allele of both drug1 and drug2 polymorphisms was significantly higher in drug3 subjects ( 23 % and 33 % ) compared to that in normal glucose-tolerant subjects ( 19 % and 28 % ; P = .001 and P = .0001 , respectively ) . " } } 500 : { 1 : "NN appos NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 appos *lrrk0* conj park0 compound drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 501 : { 1 : "NN compound NNS nmod JJR nsubj NN nmod NN nmod NN conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound subjects nmod *higher* nsubj frequency nmod allele nmod drug0 conj polymorphisms compound drug0" } 4 : { 1 : "The frequency of the T allele of both drug1 and drug2 polymorphisms was significantly higher in drug3 subjects ( 23 % and 33 % ) compared to that in normal glucose-tolerant subjects ( 19 % and 28 % ; P = .001 and P = .0001 , respectively ) . " } } 502 : { 1 : "NN appos NN conj NN nmod NNS conj NN nmod NN appos NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj nod0 nmod 0fs conj slc0a0 nmod drug0 appos lrrk0 nmod *drug0*" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 503 : { 1 : "NN compound NN appos NN nmod NNP appos NN" 2 : 1 3 : { 1 : "drug0 compound *disease* appos e0k nmod snca appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 504 : { 1 : "NN compound NN appos NN nmod NNP appos NN nmod NN appos NN nmod NN conj NNS appos NN" 2 : 1 3 : { 1 : "drug0 compound *disease* appos e0k nmod snca appos drug0 nmod lrrk0 appos drug0 nmod slc0a0 conj 0fs appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 505 : { 1 : "NN nmod VBN parataxis VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* parataxis associated nsubjpass drug0" } 4 : { 1 : "However , several variants were associated with drug2 ; in particular , drug1 was associated in both general and within-family analyses ( both P = 0.0007 ) . " } } 506 : { 1 : "NN appos NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj slc0a0 nmod *drug0*" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 507 : { 1 : "NN appos NN conj NN nmod NNS conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj nod0 nmod 0fs conj *slc0a0* conj g0r appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 508 : { 1 : "NN nmod VBN acl:relcl NN nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl *drug0* nmod replication nmod families compound drug0" } 4 : { 1 : "When testing drug1 and drug2 for replication in Finnish drug3 families , these single nucleotide polymorphisms were associated with drug4 ( p = 0.01 and p = 0.007 ) . " } } 509 : { 1 : "NN compound NN appos NN nmod NNP appos NN nmod NN appos NN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *disease* appos e0k nmod snca appos drug0 nmod lrrk0 appos drug0 nmod slc0a0 conj g0r appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 510 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 compound families nmod drug0 nmod *associated* nsubjpass drug0 conj drug0" } 4 : { 1 : "These data show that drug1 and drug2 are significantly associated with high drug3 in drug4 families from two different populations . " } } 511 : { 1 : "NN appos NNS conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos 0fs conj *slc0a0* conj g0r appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 512 : { 1 : "NN appos NN conj NN nmod NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos g0r conj nod0 nmod 0fs conj slc0a0 nmod *drug0*" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 513 : { 1 : "NN compound NN appos NN nmod NNP appos NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *disease* appos e0k nmod snca appos drug0 nmod lrrk0 appos drug0" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 514 : { 1 : "NN appos NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 appos 0fs conj slc0a0 nmod *drug0*" } 4 : { 1 : "To best of our knowledge , we first screened these variants known to be associated with drug10 disease , E46K ( drug1 ) in SNCA , drug2 in LRRK2 , drug3 n PARK2 , drug4 in SLC41A1 , drug5 , drug6 , G908R ( drug7 ) , 1007fs ( drug8 ) in NOD2 and G2385R ( drug9 ) in LRRK2 from southern China population . " } } 515 : { 1 : "NN nmod VBN ccomp VBN nmod NN nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod observed ccomp *observed* nmod tg nmod alleles nmod drug0 conj drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 516 : { 1 : "NN compound NNS nmod NNS conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod polymorphisms conj *association* nmod drug0" } 4 : { 1 : "In association analysis , we found statistically significant association of drug1 ( p = 0.001 , OR = 3.011 , CI95 % = 1.494-6 .071 ) and drug2 ( p = 2.62 * 10 ^ { -4 } , OR = 14.117 , CI95 % = 1.884-105 .799 ) polymorphisms with drug3 patients . " } } 517 : { 1 : "NN conj NN nsubjpass VBN advcl VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 conj genotype nsubjpass associated advcl *associated* nsubjpass genotype compound drug0" } 4 : { 1 : "Whereas the NOD2 genotype and drug2 are positively associated with drug3 , the drug1 genotype is positively associated with drug4 ( L2 ) disease . " } } 518 : { 1 : "NN nmod NN nmod NN nmod NNS conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *association* nmod polymorphisms conj g/a appos drug0" } 4 : { 1 : "BACKGROUND : Evidence has suggested that tumour necrosis factor ( TNF ) - a may be involved in the aetiology of psoriasis , but the underlying association of the TNF-a polymorphisms -238 G/A ( drug1 ) and -308 G/A ( drug2 ) with the risk of drug3 is still unconfirmed . " } } 519 : { 1 : "NN conj NN nmod NN conj NN root , punct NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod abstinence conj ratio root , punct *drug0*" } 4 : { 1 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " } } 520 : { 1 : "NN nmod VBN acl NNS nsubjpass VBN nmod NN punct -LRB- root NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl alleles nsubjpass *associated* nmod abstinence punct [ root drug0" } 4 : { 1 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " } } 521 : { 1 : "NN nmod NN conj NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod abstinence conj *ratio* conj 0mo nmod drug0" } 4 : { 1 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " } } 522 : { 1 : "NN nmod NN nmod NN nmod NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *association* nmod polymorphisms dep g/a appos drug0" } 4 : { 1 : "BACKGROUND : Evidence has suggested that tumour necrosis factor ( TNF ) - a may be involved in the aetiology of psoriasis , but the underlying association of the TNF-a polymorphisms -238 G/A ( drug1 ) and -308 G/A ( drug2 ) with the risk of drug3 is still unconfirmed . " } } 523 : { 1 : "NN compound NNS nmod VBN nsubjpass NNS conj NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *detected* nsubjpass frequencies conj drug0 dep haplotype compound drug0" } 4 : { 1 : "In addition , higher frequencies of the MMP1 drug1 2G allele ( p = 0.017 , OR 1.49 , 95 % CI 1.06-2 .08 ) and the MMP1/MMP3 drug2 / drug3 2G/G haplotype ( OR 1.45 , 95 % CI 1.01-2 .10 ) were detected in drug4 patients than in controls ( n = 295 ) . " } } 524 : { 1 : "NN nmod NN conj VBN nsubjpass NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod risk conj *associated* nsubjpass presence nmod c.-0a appos drug0" } 4 : { 1 : "The presence of the variant allele TNFA c.-238A ( drug1 ) was associated with lower serum levels of TNF-a , and with significantly decreased risk of drug2 in both cohorts . " } } 525 : { 1 : "NN compound NN dep NN" 2 : 1 3 : { 1 : "drug0 compound haplotype dep *drug0*" } 4 : { 1 : "In addition , higher frequencies of the MMP1 drug1 2G allele ( p = 0.017 , OR 1.49 , 95 % CI 1.06-2 .08 ) and the MMP1/MMP3 drug2 / drug3 2G/G haplotype ( OR 1.45 , 95 % CI 1.01-2 .10 ) were detected in drug4 patients than in controls ( n = 295 ) . " } } 526 : { 1 : "NN compound NNS nmod VBN nsubjpass NNS conj NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *detected* nsubjpass frequencies conj drug0" } 4 : { 1 : "In addition , higher frequencies of the MMP1 drug1 2G allele ( p = 0.017 , OR 1.49 , 95 % CI 1.06-2 .08 ) and the MMP1/MMP3 drug2 / drug3 2G/G haplotype ( OR 1.45 , 95 % CI 1.01-2 .10 ) were detected in drug4 patients than in controls ( n = 295 ) . " } } 527 : { 1 : "NN compound NNS nmod VBN nsubjpass NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *detected* nsubjpass frequencies nmod allele compound drug0" } 4 : { 1 : "In addition , higher frequencies of the MMP1 drug1 2G allele ( p = 0.017 , OR 1.49 , 95 % CI 1.06-2 .08 ) and the MMP1/MMP3 drug2 / drug3 2G/G haplotype ( OR 1.45 , 95 % CI 1.01-2 .10 ) were detected in drug4 patients than in controls ( n = 295 ) . " } } 528 : { 1 : "NN appos NN nmod VBN ccomp VBN nmod NN nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod observed ccomp *observed* nmod tg nmod alleles nmod drug0 conj drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 529 : { 1 : "NN nmod VBN acl NNS nsubjpass VBN nmod NN punct -LRB- root NN punct , root NN conj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl alleles nsubjpass *associated* nmod abstinence punct [ root drug0 punct , root ratio conj abstinence nmod drug0 conj drug0" } 4 : { 1 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " } } 530 : { 1 : "NN compound NNS nmod NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod *c0t* conj g-0a dep drug0" } 4 : { 1 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 531 : { 1 : "NN appos NN conj NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos g-0c conj *c0t* conj g-0a dep drug0 appos drug0" } 4 : { 1 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 532 : { 1 : "NN compound NNS nmod NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod *c0t* conj g-0a dep drug0 appos drug0" } 4 : { 1 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 533 : { 1 : "NN conj NN nmod NN conj NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod abstinence conj *ratio* conj 0mo nmod drug0" } 4 : { 1 : "RESULTS : Risk alleles previously associated with drug5 were significantly ( P < 0.05 ) associated with reduced abstinence in the PLA pharmacotherapy group ( PG ) at 6MO [ for drug1 , odds ratio ( 95 % confidence interval ) 0.41 ( 0.17-0 .99 ) ] , and at end of treatment and at 6MO [ for drug2 , 0.42 ( 0.19-0 .93 ) and 0.31 ( 0.12-0 .80 ) ] , and with increased abstinence in the NRT PG at 6MO [ for drug3 , 2.07 ( 1.11-3 .87 ) and for drug4 , 2.54 ( 1.29-4 .99 ) ] " } } 534 : { 1 : "NN conj NN nmod VBN ccomp VBN nmod NN nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod observed ccomp *observed* nmod tg nmod alleles nmod drug0 conj drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 535 : { 1 : "NN dep NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 dep g-0a conj *c0t* appos drug0" } 4 : { 1 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 536 : { 1 : "NN compound NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod *c0t* appos drug0" } 4 : { 1 : "We genotyped and analyzed 4 SNPs in 3 genes : PTPN22 C1858T ( drug1 ) , TNFA G-308A , G-238A ( drug2 , drug3 ) and MIF G-173C ( drug4 ) in 647 drug5 cases and 751 healthy controls . " } } 537 : { 1 : "NN nmod NN dobj VBG advcl VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod susceptibility dobj conferring advcl *play* nsubj drug0" } 4 : { 1 : "CONCLUSIONS : This meta-analysis suggests that the drug1 and -308 promoter polymorphisms may play different roles in conferring susceptibility to drug2 . " } } 538 : { 1 : "NN compound NNS nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *polymorphisms* compound drug0" } 4 : { 1 : "In association analysis , we found statistically significant association of drug1 ( p = 0.001 , OR = 3.011 , CI95 % = 1.494-6 .071 ) and drug2 ( p = 2.62 * 10 ^ { -4 } , OR = 14.117 , CI95 % = 1.884-105 .799 ) polymorphisms with drug3 patients . " } } 539 : { 1 : "NN compound NN dep NN conj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound haplotype dep drug0 conj *frequencies* nmod allele compound drug0" } 4 : { 1 : "In addition , higher frequencies of the MMP1 drug1 2G allele ( p = 0.017 , OR 1.49 , 95 % CI 1.06-2 .08 ) and the MMP1/MMP3 drug2 / drug3 2G/G haplotype ( OR 1.45 , 95 % CI 1.01-2 .10 ) were detected in drug4 patients than in controls ( n = 295 ) . " } } 540 : { 1 : " NN acl VBG dobj NN appos NN" 2 : 1 3 : { 1 : " *drug0* acl carrying dobj mdm0 appos drug0" } 4 : { 1 : "However , in a multivariate analysis , patients with drug2 carrying the heterozygous MDM2 ( drug1 ) T/G genotype had significantly improved DFS compared with patients carrying the wild-type genotype ( adjusted hazard ratio ( AHR ) , 0.63 ; 95 % confidence interval ( CI ) [ 0.45-0 .88 ] ) . " } } 541 : { 1 : "NN nmod NN nmod VB ccomp VBD nsubj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod contribute ccomp *revealed* nsubj analysis nmod type compound drug0" } 4 : { 1 : "Stratified analysis by drug2 type revealed that the STK drug1 polymorphism may contribute to the risk of drug3 ( AA vs. TT : OR = 1.21 , 95 % CI = 1.01-1 .44 , Pheterogeneity = 0.002 ) , drug4 ( AA vs. UNASSIGNED : OR = 1.24 , 95 % CI = 1.05-1 .47 , Pheterogeneity = 0.124 ) , and drug5 ( AA vs. UNASSIGNED : OR = 1.19 , 95 % CI = 1.02-1 .39 , Pheterogeneity = 0.148 ) " } } 542 : { 1 : "CD dep JJ dep VBN dep NN dep NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 dep = dep associated dep or dep *data* nmod model appos drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 543 : { 1 : "NN dep NN conj JJ dep VBN dep NN dep NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 dep snp conj = dep associated dep or dep *data* nmod model appos drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 544 : { 1 : "NN compound NN nmod VBN dep NN dep NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod associated dep or dep *data* nmod model appos drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 545 : { 1 : "NN compound NN nmod NN nsubj VBD ccomp VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound type nmod analysis nsubj *revealed* ccomp contribute nsubj polymorphism compound drug0" } 4 : { 1 : "Stratified analysis by drug2 type revealed that the STK drug1 polymorphism may contribute to the risk of drug3 ( AA vs. TT : OR = 1.21 , 95 % CI = 1.01-1 .44 , Pheterogeneity = 0.002 ) , drug4 ( AA vs. UNASSIGNED : OR = 1.24 , 95 % CI = 1.05-1 .47 , Pheterogeneity = 0.124 ) , and drug5 ( AA vs. UNASSIGNED : OR = 1.19 , 95 % CI = 1.02-1 .39 , Pheterogeneity = 0.148 ) " } } 546 : { 1 : "NN nmod VBN advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* advcl associated nmod drug0" } 4 : { 1 : "Whereas the NOD2 genotype and drug2 are positively associated with drug3 , the drug1 genotype is positively associated with drug4 ( L2 ) disease . " } } 547 : { 1 : "NN compound NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility conj *kinase* dep polymorphism appos drug0" } 4 : { 1 : "The association between the Serine/threonine kinase 15 ( STK15 ) F31I polymorphism ( drug1 ) and drug2 susceptibility remains controversial . " } } 548 : { 1 : "NN nmod VBN advcl VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated advcl *associated* nsubjpass genotype compound drug0" } 4 : { 1 : "Whereas the NOD2 genotype and drug2 are positively associated with drug3 , the drug1 genotype is positively associated with drug4 ( L2 ) disease . " } } 549 : { 1 : "NN nmod VBN advcl VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* advcl associated nsubjpass genotype conj drug0" } 4 : { 1 : "Whereas the NOD2 genotype and drug2 are positively associated with drug3 , the drug1 genotype is positively associated with drug4 ( L2 ) disease . " } } 550 : { 1 : "NN conj NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj *frequencies* nmod allele compound drug0" } 4 : { 1 : "In addition , higher frequencies of the MMP1 drug1 2G allele ( p = 0.017 , OR 1.49 , 95 % CI 1.06-2 .08 ) and the MMP1/MMP3 drug2 / drug3 2G/G haplotype ( OR 1.45 , 95 % CI 1.01-2 .10 ) were detected in drug4 patients than in controls ( n = 295 ) . " } } 551 : { 1 : "CD dep JJ dep NN dep JJ dep CD" 2 : 1 3 : { 1 : "drug0 dep = dep *or* dep = dep drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 552 : { 1 : "NN nmod VBN acl:relcl NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl *drug0*" } 4 : { 1 : "When testing drug1 and drug2 for replication in Finnish drug3 families , these single nucleotide polymorphisms were associated with drug4 ( p = 0.01 and p = 0.007 ) . " } } 553 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NNS nmod NNS compound NNP appos NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod cohort nmod *genotyped* nsubjpass polymorphisms nmod genes compound aurka appos drug0" } 4 : { 1 : "METHODS : Six single nucleotide polymorphisms ( SNPs ) in the AURKA ( drug1 ) , ERBB2 ( drug2 ) , MDM2 ( drug3 ) , CDH1 ( drug4 ) , CDKN2A ( drug5 ) , and TP73 ( drug6 ) genes were genotyped in a consecutive cohort of 346 drug7 patients , who had underwent surgical resection with curative intent . " } } 554 : { 1 : "NN conj NN nmod VBN ccomp VBN nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod observed ccomp *observed* nmod tg nmod families compound drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 555 : { 1 : "NN nmod VBN ccomp VBN nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod observed ccomp *observed* nmod tg nmod families compound drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 556 : { 1 : "NN compound NNS nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 compound families nmod replication nmod *drug0* conj drug0" } 4 : { 1 : "When testing drug1 and drug2 for replication in Finnish drug3 families , these single nucleotide polymorphisms were associated with drug4 ( p = 0.01 and p = 0.007 ) . " } } 557 : { 1 : "NN compound NN nmod VBN dep JJ conj NN dep NN" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod *associated* dep = conj snp dep drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 558 : { 1 : "NN dep NN conj JJ dep CD" 2 : 1 3 : { 1 : "drug0 dep snp conj *=* dep drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 559 : { 1 : "NN compound NN nmod VBN dep JJ dep CD" 2 : 1 3 : { 1 : "drug0 compound susceptibility nmod *associated* dep = dep drug0" } 4 : { 1 : "The results showed that four SNPs in AURKA ( data in recessive model , drug1 : OR = 2.19 , 95 % CI = 1.03-4 .66 , p = 0.0422 ; drug2 : OR = 0.38 , 95 % CI = 0.18-0 .82 , p = 0.0141 ; drug3 : OR = 1.54 , 95 % CI = 1.18-2 .00 , p = 0.0014 ; drug4 : OR = 0.68 , 95 % CI = 0.47-0 .98 , p = 0.0380 ) and one SNP in BRCA1 ( drug5 , dominant model OR = 1.35 , 95 % CI = 1.11-1 .64 , p = 0.0030 ) were associated with drug6 susceptibility . " } } 560 : { 1 : "NN appos NN nmod VBN ccomp VBN nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 nmod observed ccomp *observed* nmod tg nmod families compound drug0" } 4 : { 1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . " } } 561 : { 1 : "NN conj NN nmod NNS nmod NN nsubj VBD dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod subjects nmod comparison nsubj *showed* dobj association nmod drug0" } 4 : { 1 : "Comparison between subjects with drug3 and the combined drug4 showed a significant association with drug1 ( OR 1.47 , CI 1.04-2 .08 ; p = 0.03 ) but not with drug2 ( OR 1.16 , CI 0.81-1 .64 ; p = 0.4 ) . " } } 562 : { 1 : "NN nmod:npmod JJ amod NN amod JJ nmod:npmod NN" 2 : 1 3 : { 1 : "drug0 nmod:npmod = amod *tf* amod = nmod:npmod drug0" } 4 : { 1 : "The minor alleles of drug1 T = TF ( TCF7L2 ) , drug2 T = TF ( TCF7L2 ) , drug3 ( -30 G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . " } } 563 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep *drug0* appos drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 564 : { 1 : "NN nmod NN nsubjpass VBN advcl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod effect nsubjpass *known* advcl associated nmod drug0" } 4 : { 1 : "Though drug1 / C3/A4/A5 genetic polymorphisms are associated with drug2 , their effect on central drug3 is less known " } } 565 : { 1 : "NN nmod NN nsubjpass VBN advcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod effect nsubjpass *known* advcl associated nsubjpass polymorphisms compound drug0" } 4 : { 1 : "Though drug1 / C3/A4/A5 genetic polymorphisms are associated with drug2 , their effect on central drug3 is less known " } } 566 : { 1 : "NN nmod NN dobj VB dep NN" 2 : 1 3 : { 1 : "drug0 nmod risk dobj constitute dep *drug0*" } 4 : { 1 : "The present study demonstrated that carrying rare alleles of drug1 , -1131 T > C and G185C alone do not constitute a risk for ischemic drug2 in the studied Turkish subjects . " } } 567 : { 1 : "NN compound NN conj NN nmod NN nmod NNS nmod NN nsubj VBD ccomp VBN nsubj NN" 2 : 1 3 : { 1 : "drug0 compound mellitus conj age nmod adjustment nmod genotypes nmod analysis nsubj *revealed* ccomp affected nsubj drug0" } 4 : { 1 : "Multivariable logistic regression analysis of combined genotypes with adjustment for age , gender and drug3 mellitus revealed that drug1 and drug2 significantly and synergistically affected drug4 . " } } 568 : { 1 : "NN dobj VBN nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj *affected* nsubj drug0" } 4 : { 1 : "Multivariable logistic regression analysis of combined genotypes with adjustment for age , gender and drug3 mellitus revealed that drug1 and drug2 significantly and synergistically affected drug4 . " } } 569 : { 1 : "NN nmod NN conj VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod risk conj *associated* nsubjpass drug0" } 4 : { 1 : "In conclusion , the drug1 may be associated with elevated levels of fasting TG , TC , LDL-C and decreased HDL-C , and increased risk of drug2 , especially in East Asians . " } } 570 : { 1 : "NN nmod NN nmod NNS nsubjpass VBN nmod NN dep NN conj NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod effects nsubjpass *associated* nmod m0t dep genotype conj carriers nmod c-0t appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 571 : { 1 : "NN conj NN nmod NN nmod NNS nsubjpass VBN nmod NN dep NN conj NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 conj totalcholesterol nmod association nmod effects nsubjpass *associated* nmod m0t dep genotype conj carriers nmod c-0t appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 572 : { 1 : "NN nmod NN nmod NNS nsubjpass VBN nmod NN dep NN conj NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod effects nsubjpass *associated* nmod m0t dep genotype conj genotype compound g-0a appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 573 : { 1 : "NN conj NN nmod NN nmod NNS nsubjpass VBN nmod NN dep NN conj NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 conj totalcholesterol nmod association nmod effects nsubjpass *associated* nmod m0t dep genotype conj genotype compound g-0a appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 574 : { 1 : "NN appos NN nmod NNS conj NN conj NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 appos c-0t nmod carriers conj *genotype* conj genotype compound g-0a appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 575 : { 1 : "NN compound NN conj NN nmod NN nmod NNS nmod NN nsubj VBD ccomp VBN nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 compound mellitus conj age nmod adjustment nmod genotypes nmod analysis nsubj *revealed* ccomp affected nsubj drug0 conj drug0" } 4 : { 1 : "Multivariable logistic regression analysis of combined genotypes with adjustment for age , gender and drug3 mellitus revealed that drug1 and drug2 significantly and synergistically affected drug4 . " } } 576 : { 1 : "NN dobj VBN ccomp VBD nsubj NN nmod NNS nmod NN nmod NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj affected ccomp *revealed* nsubj analysis nmod genotypes nmod adjustment nmod age conj mellitus compound drug0" } 4 : { 1 : "Multivariable logistic regression analysis of combined genotypes with adjustment for age , gender and drug3 mellitus revealed that drug1 and drug2 significantly and synergistically affected drug4 . " } } 577 : { 1 : "NN conj NN compound NNS nmod NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj lipid compound disorders nmod *roles* nmod polymorphisms nmod drug0" } 4 : { 1 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " } } 578 : { 1 : "NN nmod NN nmod NN dobj VBD conj VBD dobj NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod prevention nmod importance dobj suggested conj *confirmed* dobj roles nmod polymorphisms nmod drug0" } 4 : { 1 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " } } 579 : { 1 : "NN nmod NN nmod NN dobj VBD conj VBD dobj NNS nmod NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod prevention nmod importance dobj suggested conj *confirmed* dobj roles nmod disorders compound lipid conj drug0" } 4 : { 1 : "Our cross-sectional study confirmed the essential roles of the polymorphisms of the drug1 , drug2 and drug3 in the lipid or drug4 disorders , and suggested the importance of fat intake control in the individualized prevention of drug5 . " } } 580 : { 1 : "NN dobj VBN nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj *affected* nsubj drug0 conj drug0" } 4 : { 1 : "Multivariable logistic regression analysis of combined genotypes with adjustment for age , gender and drug3 mellitus revealed that drug1 and drug2 significantly and synergistically affected drug4 . " } } 581 : { 1 : "NN conj NNS nmod VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj populations nmod *affect* dobj prevalence nmod drug0" } 4 : { 1 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . " } } 582 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod prevalence dobj *affect* nsubj variants nmod drug0 conj drug0" } 4 : { 1 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . " } } 583 : { 1 : "NN conj NNS nmod VB nsubj NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj populations nmod *affect* nsubj variants nmod drug0 conj drug0" } 4 : { 1 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . " } } 584 : { 1 : "NN nmod NN dobj VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod prevalence dobj *affect* nsubj variants nmod drug0" } 4 : { 1 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . " } } 585 : { 1 : "NN conj NNS nmod VB nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 conj populations nmod *affect* nsubj variants nmod drug0" } 4 : { 1 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . " } } 586 : { 1 : "NN dep NN appos NN appos NN" 2 : 1 3 : { 1 : "drug0 dep g0t appos *t-0c* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 587 : { 1 : "NN conj NN nmod NN nmod NNS nsubjpass VBN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 conj totalcholesterol nmod association nmod effects nsubjpass *associated* nmod m0t appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 588 : { 1 : "NN appos NN nmod NNS conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos c-0t nmod carriers conj genotype dep *m0t* appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 589 : { 1 : "NN nmod NNS nsubjpass VBN nmod NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod patients nsubjpass *genotyped* nmod variants dep drug0 conj drug0" } 4 : { 1 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " } } 590 : { 1 : "NN nmod NNS nsubjpass VBN nmod NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod patients nsubjpass *genotyped* nmod variants dep drug0 appos drug0" } 4 : { 1 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " } } 591 : { 1 : "NN appos NN nmod NN dobj VB conj VBZ nmod NN nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 appos cpt0b/chkb nmod association dobj confirm conj *extends* nmod observation nmod association nmod drug0 conj drug0" } 4 : { 1 : "CONCLUSIONS : The study extends on the observation of a strong multiethnic association of polymorphisms in the drug1 and drug2 with drug4 , but does not confirm the association of CPT1B/CHKB ( drug3 ) in the Chinese population . " } } 592 : { 1 : "NN dobj VB xcomp VBN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj influence xcomp shown conj *associated* nsubjpass variation nmod drug0" } 4 : { 1 : "Common variation at drug1 is robustly associated with smoking quantity and was recently shown to influence drug2 during pregnancy , but its influence on birth weight is not clear . " } } 593 : { 1 : "NN compound NNS nmod JJR conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod higher conj *associated* nsubjpass allele nmod drug0" } 4 : { 1 : "Stepwise multiple regression analysis revealed that the risk allele ( C ) for SNP drug1 was significantly associated with decreased CPT1B mRNA expression ( P = 1.0 * 10 ( -9 ) ) , and the CPT1B expression was higher in the drug2 patients than in the controls ( P = 0.005 ) . " } } 594 : { 1 : "NN nmod NNS nsubjpass VBN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod patients nsubjpass *genotyped* nmod variants dep drug0" } 4 : { 1 : "METHODS : Overall , 150 patients with drug6 and ascites were genotyped for TLR2 gene variants drug1 ( drug2 ) , drug3 ( drug4 ) , Pro631His ( drug5 ) and the TLR2GT microsatellite polymorphism in intron 2 . " } } 595 : { 1 : "NN compound NN dep VBZ nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound virus dep *is* nsubj relationship nmod presence nmod drug0" } 4 : { 1 : "CONCLUSIONS : There is a close relationship between the presence of TLR3 drug1 / CT and an increased risk of pneumonia in children infected by the pandemic A / drug2 / 2009 drug3 virus . " } } 596 : { 1 : "NN compound NN dep VBZ nsubj NN nmod NN nmod NNS acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 compound virus dep *is* nsubj relationship nmod presence nmod children acl infected nmod drug0" } 4 : { 1 : "CONCLUSIONS : There is a close relationship between the presence of TLR3 drug1 / CT and an increased risk of pneumonia in children infected by the pandemic A / drug2 / 2009 drug3 virus . " } } 597 : { 1 : "NN compound NN nmod NN dobj VBD nsubj NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound severity nmod association dobj *demonstrated* nsubj alleles nmod polymorphisms nmod drug0" } 4 : { 1 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 severity ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) " } } 598 : { 1 : "NN nmod VBN acl NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod infected acl children nmod *presence* nmod drug0" } 4 : { 1 : "CONCLUSIONS : There is a close relationship between the presence of TLR3 drug1 / CT and an increased risk of pneumonia in children infected by the pandemic A / drug2 / 2009 drug3 virus . " } } 599 : { 1 : "NN nmod NN nmod NNS nsubjpass VBN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod effects nsubjpass *associated* nmod m0t appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 600 : { 1 : "NN nmod NN nmod NNS dobj VBD conj VBD dobj NN conj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod respect nmod differences dobj revealed conj *revealed* dobj prevalence conj allele nmod snp compound drug0" } 4 : { 1 : "Case-control comparisons revealed higher prevalence of short CAG alleles as well as of the A allele of the drug1 SNP in female drug3 cases than in controls , but revealed no significant differences with respect to the drug2 . " } } 601 : { 1 : "NN compound NNS nmod NN conj NN dobj VBD conj VBD dobj NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod allele conj prevalence dobj *revealed* conj revealed dobj differences nmod respect nmod drug0" } 4 : { 1 : "Case-control comparisons revealed higher prevalence of short CAG alleles as well as of the A allele of the drug1 SNP in female drug3 cases than in controls , but revealed no significant differences with respect to the drug2 . " } } 602 : { 1 : "NN nmod VB xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod associate xcomp *identified* nsubjpass variants nmod drug0" } 4 : { 1 : "Recently , TCF7L2 variants , including the microsatellite marker drug1 and the nearly perfectly linked SNP drug2 , were identified to associate with drug3 " } } 603 : { 1 : "NN nmod VB xcomp VBN nsubjpass NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associate xcomp *identified* nsubjpass variants nmod drug0 conj drug0" } 4 : { 1 : "Recently , TCF7L2 variants , including the microsatellite marker drug1 and the nearly perfectly linked SNP drug2 , were identified to associate with drug3 " } } 604 : { 1 : "NN appos NN compound NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos g-0a compound genotype conj genotype dep *m0t* appos drug0" } 4 : { 1 : "Further , effects of a stronger beneficial association between n-3 drug4 in RBCs and plasma lipid parameters - including lower totalcholesterol ( TC ) , drug5 ( LDL-C ) or higher high-density lipoprotein cholesterol ( HDL-C ) concentrations - were associated with AGT M235T ( drug1 ) TT genotype , CETP G-971A ( drug2 ) AG genotype , T allele carriers of CETP C-4502T ( drug3 ) , and T allele carriers ofCETP Ile405Val ( rs5882 ) . " } } 605 : { 1 : "NN compound NNS nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod *allele* nmod snp compound drug0" } 4 : { 1 : "Case-control comparisons revealed higher prevalence of short CAG alleles as well as of the A allele of the drug1 SNP in female drug3 cases than in controls , but revealed no significant differences with respect to the drug2 . " } } 606 : { 1 : "NN compound NNS nmod VBD dobj NN conj NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod *genotyped* dobj microsatellite conj polymorphisms dep drug0 appos drug0" } 4 : { 1 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " } } 607 : { 1 : "NN nmod VBN advcl VBD parataxis VBD ccomp VBD nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod associated advcl *identified* parataxis found ccomp showed nsubj drug0" } 4 : { 1 : "We identified drug1 as strongly associated with drug3 , In particular , we found that drug2 located 8 kb from the EDA2R gene showed the best result ( P = 7.77 e ( -7 ) ) . " } } 608 : { 1 : "NN compound NNS nmod VBD dobj NN conj NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound cases nmod *genotyped* dobj microsatellite conj polymorphisms dep drug0" } 4 : { 1 : "We genotyped the CAG microsatellite and six haplotype-tagging single nucleotide polymorphisms ( drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ) of the androgen receptor gene in 987 drug7 cases and 1,034 controls from a study conducted in New Hampshire and eastern Massachusetts between May 1992 and July 2003 . " } } 609 : { 1 : "NN nsubj VBD ccomp VBD parataxis VBD dobj NN" 2 : 1 3 : { 1 : "drug0 nsubj showed ccomp found parataxis *identified* dobj drug0" } 4 : { 1 : "We identified drug1 as strongly associated with drug3 , In particular , we found that drug2 located 8 kb from the EDA2R gene showed the best result ( P = 7.77 e ( -7 ) ) . " } } 610 : { 1 : "NN nmod VBN advcl VBD dobj NN" 2 : 1 3 : { 1 : "drug0 nmod associated advcl *identified* dobj drug0" } 4 : { 1 : "We identified drug1 as strongly associated with drug3 , In particular , we found that drug2 located 8 kb from the EDA2R gene showed the best result ( P = 7.77 e ( -7 ) ) . " } } 611 : { 1 : "NN nmod NN dobj VBD nsubj NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod association dobj *demonstrated* nsubj alleles nmod polymorphisms nmod drug0" } 4 : { 1 : "Variant alleles of polymorphisms of TLR2 drug1 , drug2 , and drug3 demonstrated a consistent association with drug4 ( p = 0.008 , p = 0.006 and p = 0.029 respectively ) . " } } 612 : { 1 : "NN appos NN dep NN appos NN appos NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep g0t appos *t-0c* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 613 : { 1 : "NN appos NN dep NN conj NN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos leu0pro dep t0c conj intron0 nmod a/g conj *t-0c* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 614 : { 1 : "NN nmod VBN acl NNS nmod NNS nmod NNS dep VBN nsubjpass NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl subjects nmod sizes nmod *differences* dep associated nsubjpass apoa0 appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 615 : { 1 : "NN nmod VBN dep NNS nmod NNS nmod NNS acl VBN nsubjpass NNS nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *differences* nmod sizes nmod subjects acl associated nsubjpass variants nmod apoa0 conj apoe appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 616 : { 1 : "NN compound NNS nmod NN nmod VBN acl NNS nmod NNS nmod NNS dep VBN nsubjpass NN appos NN" 2 : 1 3 : { 1 : "drug0 compound subjects nmod drug0 nmod associated acl subjects nmod sizes nmod *differences* dep associated nsubjpass apoa0 appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 617 : { 1 : "NN nmod VBN dep NNS nmod NNS nmod NNS acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *differences* nmod sizes nmod subjects acl associated nmod drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 618 : { 1 : "NN nmod VBN dep NNS nmod NNS nmod NNS acl VBN nmod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *differences* nmod sizes nmod subjects acl associated nmod drug0 nmod subjects compound drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 619 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NNS nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound subjects nmod drug0 nmod *associated* nsubjpass variants nmod apoa0 conj apoe appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 620 : { 1 : "NN nmod VBN dep NNS nmod NNS nmod NNS acl VBN nsubjpass NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod associated dep *differences* nmod sizes nmod subjects acl associated nsubjpass variants nmod apoa0 appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 621 : { 1 : "NN appos NN nsubjpass VBN dep NNS nmod NNS nmod NNS acl VBN nsubjpass NNS nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos apoa0 nsubjpass associated dep *differences* nmod sizes nmod subjects acl associated nsubjpass variants nmod apoa0 conj apoe appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 622 : { 1 : "NN appos NN nsubjpass VBN dep NNS nmod NNS nmod NNS acl VBN nsubjpass NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 appos apoa0 nsubjpass associated dep *differences* nmod sizes nmod subjects acl associated nsubjpass variants nmod apoa0 appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 623 : { 1 : "NN compound NNS nmod NN nmod VBN nsubjpass NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 compound subjects nmod drug0 nmod *associated* nsubjpass variants nmod apoa0 appos drug0" } 4 : { 1 : "significant differences in the association effect sizes between subjects with and without MetS ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with drug4 in drug5 subjects , while APOA4 ( drug3 ) was associated with drug6 in non-MetS subjects . " } } 624 : { 1 : "NN dobj VBG acl NN acl:relcl NNS compound NN" 2 : 1 3 : { 1 : "drug0 dobj developing acl risk acl:relcl *patients* compound drug0" } 4 : { 1 : "drug1 and drug2 polymorphisms may serve as biomarkers in the South Indian population to identify drug3 patients who are at risk of developing drug4 . " } } 625 : { 1 : "NN appos NN compound NN nsubjpass VBN parataxis NN acl:relcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 appos t-0c compound variant nsubjpass reported parataxis *a0* acl:relcl shown nsubjpass variants compound drug0" } 4 : { 1 : "OBJECTIVE : Apolipoprotein A5 ( drug1 ) gene variants have been shown to be associated with elevated TG levels ; the T-1131C ( drug2 ) variant has been reported to confer risk for the drug3 in adult populations . " } } 626 : { 1 : "NN nmod VB xcomp VBN nsubjpass NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod confer xcomp *reported* nsubjpass variant compound t-0c appos drug0" } 4 : { 1 : "OBJECTIVE : Apolipoprotein A5 ( drug1 ) gene variants have been shown to be associated with elevated TG levels ; the T-1131C ( drug2 ) variant has been reported to confer risk for the drug3 in adult populations . " } } 627 : { 1 : "NN nmod NNS nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod measures nmod *associated* nsubjpass genotype compound drug0" } 4 : { 1 : "whereas drug1 genotype was not associated with measures of drug2 . " } } 628 : { 1 : "NN nmod NN nmod VBN advcl DT nmod NN" 2 : 1 3 : { 1 : "drug0 nmod prevalence nmod associated advcl *le* nmod drug0" } 4 : { 1 : "le of drug1 as also associated with increased prevalence of drug2 . " } } 629 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass genotypes nmod drug0" } 4 : { 1 : "Genotypes at drug1 were not associated with any drug2 . " } } 630 : { 1 : "NN nmod VB xcomp VBN parataxis NN acl:relcl VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod confer xcomp reported parataxis *a0* acl:relcl shown nsubjpass variants compound drug0" } 4 : { 1 : "OBJECTIVE : Apolipoprotein A5 ( drug1 ) gene variants have been shown to be associated with elevated TG levels ; the T-1131C ( drug2 ) variant has been reported to confer risk for the drug3 in adult populations . " } } 631 : { 1 : "NN nmod NN nmod VBN conj VBD nsubj NNP nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod reduction nmod associated conj *occurred* nsubj homozygosity nmod allele nmod drug0" } 4 : { 1 : "Homozygosity for the minor allele ( TT ) of SNP drug1 occurred in 9 % of individuals and was associated with a 31 % reduction in drug2 in a recessive model . " } } 632 : { 1 : "NN compound NN nmod NN nsubj NN" 2 : 1 3 : { 1 : "drug0 compound disease nmod *factor* nsubj drug0" } 4 : { 1 : "BACKGROUND : drug4 ( HTG ) is a well-established independent risk factor for drug5 disease and the influence of several geneti c variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " } } 633 : { 1 : "NN conj NN nmod VBN nsubjpass NNS nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj concentration nmod *associated* nsubjpass snps nmod polymorphisms compound drug0" } 4 : { 1 : "These results suggest that different SNPs in drug1 polymorphisms may be associated with triglyceride concentration and drug2 in each of these ethnic origins . " } } 634 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass polymorphisms nmod gene compound a0 appos drug0" } 4 : { 1 : "Single nucleotide polymorphisms ( SNPs ) in the apolipoprotein A5 ( drug1 ) gene have been associated with drug2 . " } } 635 : { 1 : "NN nsubj NN conj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nsubj *factor* conj described nmod drug0" } 4 : { 1 : "BACKGROUND : drug4 ( HTG ) is a well-established independent risk factor for drug5 disease and the influence of several geneti c variants in genes related with triglyceride ( TG ) metabolism has been described , including drug1 , drug2 and drug3 . " } } 636 : { 1 : "NN appos NN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos intron0 nmod a/g conj *t-0c* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 637 : { 1 : "NN dobj VBG acl NN acl:relcl NNS dobj VB xcomp VB nsubj NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj developing acl risk acl:relcl patients dobj identify xcomp *serve* nsubj polymorphisms compound drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 polymorphisms may serve as biomarkers in the South Indian population to identify drug3 patients who are at risk of developing drug4 . " } } 638 : { 1 : "NN dobj VBG acl NN acl:relcl NNS dobj VB xcomp VB nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 dobj developing acl risk acl:relcl patients dobj identify xcomp *serve* nsubj polymorphisms compound drug0" } 4 : { 1 : "drug1 and drug2 polymorphisms may serve as biomarkers in the South Indian population to identify drug3 patients who are at risk of developing drug4 . " } } 639 : { 1 : "NN nmod NN nmod NN conj NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod intron0 nmod a/g conj *t-0c* appos g0t dep drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 640 : { 1 : "NN conj NN nmod NN nmod NN conj NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod intron0 nmod a/g conj *t-0c* appos g0t dep drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 641 : { 1 : "NN appos NN conj NN appos NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos g-0a conj *t-0c* appos g0t dep drug0 appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 642 : { 1 : "NN appos NN nmod NN conj NN appos NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos intron0 nmod a/g conj *t-0c* appos g0t dep drug0 appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 643 : { 1 : "NN appos NN dep NN conj NN nmod NN conj NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 appos leu0pro dep t0c conj intron0 nmod a/g conj *t-0c* appos g0t dep drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 644 : { 1 : "NN appos NN conj NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 appos g-0a conj *t-0c* appos g0t dep drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 645 : { 1 : "NN appos NN nmod NN conj NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 appos intron0 nmod a/g conj *t-0c* appos g0t dep drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 646 : { 1 : "NN nmod NN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod intron0 nmod a/g conj *t-0c* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 647 : { 1 : "NN conj NN nmod NN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod intron0 nmod a/g conj *t-0c* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 648 : { 1 : "NN compound NNS dobj VB xcomp VB nsubj NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 compound patients dobj identify xcomp *serve* nsubj polymorphisms compound drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 polymorphisms may serve as biomarkers in the South Indian population to identify drug3 patients who are at risk of developing drug4 . " } } 649 : { 1 : "NN appos NN dep NN conj NN nmod NN conj NN appos NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 appos leu0pro dep t0c conj intron0 nmod a/g conj *t-0c* appos g0t dep drug0 appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 650 : { 1 : "NN conj NN nmod NN nmod NN conj NN appos NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod intron0 nmod a/g conj *t-0c* appos g0t dep drug0 appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 651 : { 1 : "NN nmod NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *intron0* conj t0c dep leu0pro appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 652 : { 1 : "NN conj NN nmod NN conj NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *intron0* conj t0c dep leu0pro appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 653 : { 1 : "NN compound NNS dobj VB xcomp VB nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound patients dobj identify xcomp *serve* nsubj polymorphisms compound drug0" } 4 : { 1 : "drug1 and drug2 polymorphisms may serve as biomarkers in the South Indian population to identify drug3 patients who are at risk of developing drug4 . " } } 654 : { 1 : "NN nmod NN nmod NN conj NN appos NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod intron0 nmod a/g conj *t-0c* appos g0t dep drug0 appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 655 : { 1 : "NN conj NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *intron0* appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 656 : { 1 : "NN nmod NN nmod NN conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod intron0 nmod a/g conj *t-0c* conj g-0a appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 657 : { 1 : "NN conj NN nmod NN nmod NN conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod intron0 nmod a/g conj *t-0c* conj g-0a appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 658 : { 1 : "NN appos NN nmod NN conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos intron0 nmod a/g conj *t-0c* conj g-0a appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 659 : { 1 : "NN appos NN dep NN conj NN nmod NN conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos leu0pro dep t0c conj intron0 nmod a/g conj *t-0c* conj g-0a appos drug0" } 4 : { 1 : "This study examined the associations of the APOA5 T-1131C ( drug1 ) , G553T ( drug2 , drug3 ) , GCK G-30A ( drug4 ) , GCKR A/G at intron16 ( drug5 ) and T1403C ( Leu446Pro , drug6 ) polymorphisms with drug7 and drug8 in Japanese , considering lifestyle factors " } } 660 : { 1 : "NN conj NNP nsubjpass VBN acl CD dep NN appos NN compound NN" 2 : 1 3 : { 1 : "drug0 conj apoe nsubjpass associated acl -0 dep apoa0 appos *s0w* compound drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 661 : { 1 : "NN conj NN nmod NN nmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod risk nmod *associated* nmod drug0" } 4 : { 1 : "The nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of drug3 as well as drug4 . " } } 662 : { 1 : "NN conj NN nmod NN nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod risk nmod *associated* nsubjpass drug0" } 4 : { 1 : "The nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of drug3 as well as drug4 . " } } 663 : { 1 : "NN nmod NN nmod VBN advcl NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod associated advcl *variant* compound drug0" } 4 : { 1 : "As expected , the most strongly associated SNP was the APOE e4 drug1 variant ( HR = 2.47 [ 1.58 , 3.87 ] , p = 7.52 * 10 ( -5 ) ) , although variants within the more recently implicated SORL1 and RUNX1 genes were also strongly associated with drug2 in drug3 ( HR = 0.54 [ 0.37 , 0.80 ] , p = 0.002 and HR = 1.61 [ 1.15 , 2.26 ] , p = 0.006 respectively ) . " } } 664 : { 1 : "NN nmod VBN advcl NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated advcl *variant* compound drug0" } 4 : { 1 : "As expected , the most strongly associated SNP was the APOE e4 drug1 variant ( HR = 2.47 [ 1.58 , 3.87 ] , p = 7.52 * 10 ( -5 ) ) , although variants within the more recently implicated SORL1 and RUNX1 genes were also strongly associated with drug2 in drug3 ( HR = 0.54 [ 0.37 , 0.80 ] , p = 0.002 and HR = 1.61 [ 1.15 , 2.26 ] , p = 0.006 respectively ) . " } } 665 : { 1 : "NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *drug0*" } 4 : { 1 : "As expected , the most strongly associated SNP was the APOE e4 drug1 variant ( HR = 2.47 [ 1.58 , 3.87 ] , p = 7.52 * 10 ( -5 ) ) , although variants within the more recently implicated SORL1 and RUNX1 genes were also strongly associated with drug2 in drug3 ( HR = 0.54 [ 0.37 , 0.80 ] , p = 0.002 and HR = 1.61 [ 1.15 , 2.26 ] , p = 0.006 respectively ) . " } } 666 : { 1 : "NN nmod NN dobj VBZ nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk dobj *has* nsubj cgtc nmod order nmod drug0" } 4 : { 1 : "Disease association analysis revealed a susceptibility haplotype CGTC ( in order of drug1 , drug2 , drug3 , drug4 ) and the carriers of this haplotype has higher risk of drug5 ( OR 3.53 , 95 % CI 1.21-11 .0 , P = 0.017 ) and osteoporosis ( OR 3.61 , 95 % CI 1.53-9 .48 , P = 0.002 ) after adjusting the confounding effect of age , BMI and years since menopause . " } } 667 : { 1 : "NN compound NN nmod VBN xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod associated xcomp *found* nsubjpass markers nmod drug0" } 4 : { 1 : "Several markers in strong LD ( r ( 2 ) > 0.7 ) with drug1 were found to be significantly associated with drug2 risk in recent genome-wide association studies with similar effect sizes , providing independent support of the current findings . " } } 668 : { 1 : "NN nmod:poss NN conj NNS nmod VBN nsubjpass NN appos NN dep NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod:poss disease conj levels nmod *associated* nsubjpass genotype appos e0/e0/e0 dep allele dep allele compound drug0" } 4 : { 1 : "BACKGROUND : Apolipoprotein E ( APOE ) genotype ( e2/e3/e4 : drug1 e4 allele ; drug2 e2 allele ) is strongly associated with both lipid levels and A drug3 's disease . " } } 669 : { 1 : "NN compound NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 compound allele dep *allele* compound drug0" } 4 : { 1 : "BACKGROUND : Apolipoprotein E ( APOE ) genotype ( e2/e3/e4 : drug1 e4 allele ; drug2 e2 allele ) is strongly associated with both lipid levels and A drug3 's disease . " } } 670 : { 1 : "NN nmod:poss NN conj NNS nmod VBN nsubjpass NN appos NN dep NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod:poss disease conj levels nmod *associated* nsubjpass genotype appos e0/e0/e0 dep allele compound drug0" } 4 : { 1 : "BACKGROUND : Apolipoprotein E ( APOE ) genotype ( e2/e3/e4 : drug1 e4 allele ; drug2 e2 allele ) is strongly associated with both lipid levels and A drug3 's disease . " } } 671 : { 1 : " NN dep SYM" 2 : 1 3 : { 1 : " *drug0* dep drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 672 : { 1 : "NN compound NNS nmod VBN nsubjpass NNS dep NN conj NN dep SYM" 2 : 1 3 : { 1 : "drug0 compound patients nmod *studied* nsubjpass polymorphisms dep drug0 conj drug0 dep drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 673 : { 1 : "SYM dep NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj *drug0* conj drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 674 : { 1 : "NN nmod NNS nmod JJ nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod *different* nsubj frequency nmod genotype nmod drug0" } 4 : { 1 : "The frequency of the G genotype in COMT drug1 was statistically different between patients with drug2 and controls ( P = .04 ) , and between patients with drug3 and controls ( P = .02 ) . " } } 675 : { 1 : "NN nmod NNS conj JJ nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod patients conj *different* nmod patients nmod drug0" } 4 : { 1 : "The frequency of the G genotype in COMT drug1 was statistically different between patients with drug2 and controls ( P = .04 ) , and between patients with drug3 and controls ( P = .02 ) . " } } 676 : { 1 : "NN conj NNS nmod NN nsubj VBD dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj subjects nmod comparison nsubj *showed* dobj association nmod drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 677 : { 1 : "NN conj NNS nmod NN nsubj VBD dobj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj subjects nmod comparison nsubj *showed* dobj association nmod drug0 conj drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 678 : { 1 : "NN conj NNS nmod NN nsubj VBD dobj NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj subjects nmod comparison nsubj *showed* dobj association conj association nmod drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 679 : { 1 : "NN nmod NNS conj JJ nsubj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod patients conj *different* nsubj frequency nmod genotype nmod drug0" } 4 : { 1 : "The frequency of the G genotype in COMT drug1 was statistically different between patients with drug2 and controls ( P = .04 ) , and between patients with drug3 and controls ( P = .02 ) . " } } 680 : { 1 : "NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj *affect* nsubj drug0" } 4 : { 1 : "drug1 did n't affect drug2 , suggesting its potential modality-specific effects on human pain . " } } 681 : { 1 : "NN nmod NN nsubjpass VBN ccomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod association nsubjpass examined ccomp *associated* nsubjpass drug0" } 4 : { 1 : "OBJECTIVE : drug1 has been associated with drug2 and athero-thrombosis however the association with drug3 ( AAA ) has not been previously examined . " } } 682 : { 1 : "NN nmod NN nsubjpass VBN ccomp VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod association nsubjpass examined ccomp *associated* nmod drug0" } 4 : { 1 : "OBJECTIVE : drug1 has been associated with drug2 and athero-thrombosis however the association with drug3 ( AAA ) has not been previously examined . " } } 683 : { 1 : "NN nmod VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *occurred* nsubj frequency nmod drug0" } 4 : { 1 : "The frequency of the A genotype in PLCH1 drug1 occurred more frequently in drug2 than in controls ( P = .02 ) . " } } 684 : { 1 : "NN appos NN nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 appos risk nmod *associated* nsubjpass snp compound drug0" } 4 : { 1 : "In this study , we found that the COMT drug1 SNP was significantly associated with a reduced risk of drug2 , especially drug3 , which suggests that this SNP may have a protective effect . " } } 685 : { 1 : "NN conj NNS nmod NN nsubj VBD dobj NN conj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj subjects nmod comparison nsubj *showed* dobj association conj association nmod drug0 conj drug0" } 4 : { 1 : "comparison between NGT control subjects and the combined drug5 / IGT case group showed strong association with drug1 and drug2 ( P = 0.008-0 .01 ; OR 1.53-1 .57 ) and marginal association with drug3 and drug4 ( P = 0.07 and P = 0.04 , respectively ) . " } } 686 : { 1 : "NN compound NNS nmod VBN nsubjpass NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *studied* nsubjpass polymorphisms dep drug0 appos drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 687 : { 1 : "NN compound NNS nmod VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *studied* nsubjpass polymorphisms dep drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 688 : { 1 : "NN nmod NN nsubj VBD ccomp VBD conj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod duration nsubj had ccomp revealed conj *were* nsubj effects nmod drug0" } 4 : { 1 : "There were also no significant effects of drug1 or E4 carriers on the development of drug2 , but multivariate logistic regression testing revealed that the duration of drug3 and triglyceride and hemoglobin A1c concentrations had independent effects on the development of drug4 . " } } 689 : { 1 : "NN nmod NN nmod VBD ccomp VBD conj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod had ccomp revealed conj *were* nsubj effects nmod drug0" } 4 : { 1 : "There were also no significant effects of drug1 or E4 carriers on the development of drug2 , but multivariate logistic regression testing revealed that the duration of drug3 and triglyceride and hemoglobin A1c concentrations had independent effects on the development of drug4 . " } } 690 : { 1 : "NN nmod NN nsubj VBD ccomp VBD conj VBD nsubj NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod duration nsubj had ccomp revealed conj *were* nsubj effects nmod development nmod drug0" } 4 : { 1 : "There were also no significant effects of drug1 or E4 carriers on the development of drug2 , but multivariate logistic regression testing revealed that the duration of drug3 and triglyceride and hemoglobin A1c concentrations had independent effects on the development of drug4 . " } } 691 : { 1 : "NN nmod NN nmod VBD ccomp VBD conj VBD nsubj NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod had ccomp revealed conj *were* nsubj effects nmod development nmod drug0" } 4 : { 1 : "There were also no significant effects of drug1 or E4 carriers on the development of drug2 , but multivariate logistic regression testing revealed that the duration of drug3 and triglyceride and hemoglobin A1c concentrations had independent effects on the development of drug4 . " } } 692 : { 1 : "NN compound NNS nmod VBN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 compound events nmod *associated* dep 0p0 dep drug0" } 4 : { 1 : "Nine loci were statistically associated with incident drug10 events in white participants : 9p21 ( drug1 ; P = 4.7 * 10 ( -41 ) ) , 16q23 .1 ( drug2 ; P = 0.0004 ) , 6p24 .1 ( drug3 ; P = 0.0002 ) , 2q36 .3 ( drug4 ; P = 6.7 * 10 ( -6 ) ) , MTHFD1L ( drug5 , P = 5.1 * 10 ( -10 ) ) , APOE ( drug6 ; P = 2.7 * 10 ( -18 ) ) , ZNF627 ( drug7 ; P = 5.0 * 10 ( -8 ) ) , CXCL12 ( drug8 ; P = 1.4 * 10 ( -6 ) ) and LPL ( drug9 ; P = 2.7 * 10 ( -17 ) ) " } } 693 : { 1 : "NN conj NN nmod VBN nsubjpass NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *observed* nsubjpass ld nmod drug0 conj drug0" } 4 : { 1 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . " } } 694 : { 1 : "NN nmod NNS nmod VB nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod *differ* nsubj frequency nmod drug0" } 4 : { 1 : "CONCLUSIONS : The frequency of drug1 did not differ between patients with drug2 and controls . " } } 695 : { 1 : "NN conj NN nmod NNS nsubj VBD nmod NN" 2 : 1 3 : { 1 : "drug0 conj diet nmod effects nsubj *depended* nmod drug0" } 4 : { 1 : "Analysis of gene-diet and gene-obesity interactions did not confirm that the effects of diet and drug2 on TC and LDL-C level significantly depended on drug1 . " } } 696 : { 1 : "NN nmod VBN nsubjpass NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *observed* nsubjpass ld nmod drug0 conj drug0" } 4 : { 1 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . " } } 697 : { 1 : "SYM dep NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj *drug0* appos drug0" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 698 : { 1 : "NN nmod NN nmod VBD nsubj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod *had* nsubj duration nmod drug0" } 4 : { 1 : "There were also no significant effects of drug1 or E4 carriers on the development of drug2 , but multivariate logistic regression testing revealed that the duration of drug3 and triglyceride and hemoglobin A1c concentrations had independent effects on the development of drug4 . " } } 699 : { 1 : "NN conj NN nmod VBN nsubjpass NN appos NN" 2 : 1 3 : { 1 : "drug0 conj risk nmod *associated* nsubjpass polymorphism appos drug0" } 4 : { 1 : "The nicotinic acetylcholine receptor polymorphism ( drug1 ) on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of COPD as well as drug3 . " } } 700 : { 1 : "NN nmod VBN acl NNS nmod NNS nmod NNS nmod NN conj VBG advcl VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl subjects nmod sizes nmod differences nmod accounting conj *correcting* advcl associated nsubjpass drug0" } 4 : { 1 : "RESULTS : After correcting for multiple testing ( p < 0.05 ) and accounting for significant differences in the association effect sizes between subjects with and without drug4 ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with HDL-C and LDL-C responses in MetS subjects , while APOA4 drug3 was associated with TG response in non-MetS subjects . " } } 701 : { 1 : "NN nmod NN dobj VBG acl NN dobj VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod susceptibility dobj predicting acl locus dobj *represents* nsubj gene compound drug0" } 4 : { 1 : "Our findings confirm that the drug1 gene represents an important locus for predicting inherited susceptibility to drug2 . " } } 702 : { 1 : "SYM dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 conj *drug0*" } 4 : { 1 : "Five polymorphisms ( -491 drug1 , -427 drug2 , -219 drug3 , and e drug4 - drug5 ) were studied in 1308 drug6 patients and 1082 control individuals from the Central-Northern Italy . " } } 703 : { 1 : "NN nmod NNS nsubjpass VBN nmod NNS acl VBP" 2 : 1 3 : { 1 : "drug0 nmod associations nsubjpass *observed* nmod genotypes acl drug0" } 4 : { 1 : "RESULTS : Significant associations with drug4 were observed for genotypes drug1 A/T ( odds ratio [ OR ] , 2.1 ; 95 % confidence interval [ CI ] , 1.0-4 .5 ) , drug2 T/C ( OR , 4.4 ; 95 % CI , 1.9-10 .2 ) , and drug3 ( OR , 4.1 ; 95 % CI , 1.6-10 .9 ) " } } 704 : { 1 : "NN nsubjpass VBN advcl VBG conj NN nmod NNS nmod NNS nmod NNS acl VBN nsubjpass NNS nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nsubjpass associated advcl *correcting* conj accounting nmod differences nmod sizes nmod subjects acl associated nsubjpass variants nmod apoa0 conj apoe appos drug0" } 4 : { 1 : "RESULTS : After correcting for multiple testing ( p < 0.05 ) and accounting for significant differences in the association effect sizes between subjects with and without drug4 ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with HDL-C and LDL-C responses in MetS subjects , while APOA4 drug3 was associated with TG response in non-MetS subjects . " } } 705 : { 1 : "NN dobj VBG acl NN nsubjpass VBN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj determining acl locus nsubjpass *marked* nmod drug0" } 4 : { 1 : "In conclusion , the major locus determining familial drug2 up to high age as detected by GWAS was marked by drug1 , which tags the deleterious effects of the ApoE e4 allele . " } } 706 : { 1 : "NN nsubjpass VBN advcl VBG conj NN nmod NNS nmod NNS nmod NNS acl VBN nsubjpass NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nsubjpass associated advcl *correcting* conj accounting nmod differences nmod sizes nmod subjects acl associated nsubjpass variants nmod apoa0 appos drug0" } 4 : { 1 : "RESULTS : After correcting for multiple testing ( p < 0.05 ) and accounting for significant differences in the association effect sizes between subjects with and without drug4 ( p < 0.05 ) , variants of APOA5 ( drug1 ) and APOE ( drug2 ) were associated with HDL-C and LDL-C responses in MetS subjects , while APOA4 drug3 was associated with TG response in non-MetS subjects . " } } 707 : { 1 : "NN conj NN nmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 conj risk nmod *associated* nmod drug0" } 4 : { 1 : "The nicotinic acetylcholine receptor polymorphism ( drug1 ) on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of COPD as well as drug3 . " } } 708 : { 1 : "NN dobj VBG acl NN conj NN" 2 : 1 3 : { 1 : "drug0 dobj defining acl e0 conj *drug0*" } 4 : { 1 : "Although there was only moderate linkage disequilibrium between drug1 and the ApoE e4 defining SNP drug2 , we could not find an APOE-independent effect of drug3 on drug4 , either in cross-sectional or in longitudinal analyses . " } } 709 : { 1 : "NN nmod NN nmod VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *associated* nmod drug0" } 4 : { 1 : "The nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of drug3 as well as drug4 . " } } 710 : { 1 : "NN nmod VBZ conj VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod acts conj *associated* nsubjpass polymorphism compound drug0" } 4 : { 1 : "Thus , the drug1 polymorphism is not associated with drug2 in the Caucasian population but acts as a modifier of the AAO in drug3 with a sexual dimorphism : the Val allele is associated with a younger AAO in men with idiopathic PD . " } } 711 : { 1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 nmod risk dobj show xcomp *seen* nsubjpass drug0" } 4 : { 1 : "CONCLUSIONS : drug1 was seen to show a decreased risk for drug2 in Asian population " } } 712 : { 1 : "NN conj NN nmod NN conj NNS nmod VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod prognosis conj risks nmod *contributed* nsubj polymorphism compound drug0" } 4 : { 1 : "The data show a statistical association and suggest biological plausibility that the drug1 T > C polymorphism contributed to increased risks and poor prognosis of both drug2 and drug3 . " } } 713 : { 1 : "NN nmod NN conj NNS nmod VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod prognosis conj risks nmod *contributed* nsubj polymorphism compound drug0" } 4 : { 1 : "The data show a statistical association and suggest biological plausibility that the drug1 T > C polymorphism contributed to increased risks and poor prognosis of both drug2 and drug3 . " } } 714 : { 1 : "NN compound NN nmod NNS nsubjpass VBN dep NN" 2 : 1 3 : { 1 : "drug0 compound group nmod volumes nsubjpass *associated* dep drug0" } 4 : { 1 : "The increased volumes in the genu , splenium and total CC in the drug3 group were associated with polymorphisms within the candidate genes : drug1 , drug2 and UFD1L ( drug4 ) . " } } 715 : { 1 : "NN compound NN nmod NNS nsubjpass VBN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound group nmod volumes nsubjpass *associated* dep drug0 conj drug0" } 4 : { 1 : "The increased volumes in the genu , splenium and total CC in the drug3 group were associated with polymorphisms within the candidate genes : drug1 , drug2 and UFD1L ( drug4 ) . " } } 716 : { 1 : "NN appos NN conj NN dep VBN nsubjpass NNS nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 appos ufd0l conj drug0 dep *associated* nsubjpass volumes nmod group compound drug0" } 4 : { 1 : "The increased volumes in the genu , splenium and total CC in the drug3 group were associated with polymorphisms within the candidate genes : drug1 , drug2 and UFD1L ( drug4 ) . " } } 717 : { 1 : "NN nmod VBZ dobj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *confers* dobj risk nmod drug0 conj drug0" } 4 : { 1 : "The drug1 allele of the COMT gene confers a significantly increased risk for drug2 and drug3 in drug4 . " } } 718 : { 1 : "NN conj NN nmod NN dobj VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod risk dobj *confers* nsubj allele compound drug0" } 4 : { 1 : "The drug1 allele of the COMT gene confers a significantly increased risk for drug2 and drug3 in drug4 . " } } 719 : { 1 : "NN nmod VBZ dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *confers* dobj risk nmod drug0" } 4 : { 1 : "The drug1 allele of the COMT gene confers a significantly increased risk for drug2 and drug3 in drug4 . " } } 720 : { 1 : "NN dobj VB ccomp VBD conj VBN xcomp VB dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj determine ccomp helped conj *found* xcomp affect dobj risk compound drug0" } 4 : { 1 : "However , drug1 polymorphisms were found to significantly affect drug3 risk , and the drug2 polymorphism helped determine drug4 . " } } 721 : { 1 : "NN conj NN compound NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 compound combination nmod *association* nmod drug0" } 4 : { 1 : "The association of drug1 with the drug2 and drug3 combination could help to explain the contradictory results of previous studies . " } } 722 : { 1 : "NN dobj VB ccomp VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 dobj determine ccomp *helped* nsubj polymorphism compound drug0" } 4 : { 1 : "However , drug1 polymorphisms were found to significantly affect drug3 risk , and the drug2 polymorphism helped determine drug4 . " } } 723 : { 1 : "NN compound NNS nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 compound ratings nmod *associated* nsubjpass genotype compound drug0" } 4 : { 1 : "The OPRM1 drug1 genotype was associated with patients ' drug2 ratings at 15 min in the postanesthesia care unit ( PACU ) ( p = .01 ) and patients ' drug3 at 15 min in the PACU ( p = .02 ) . " } } 724 : { 1 : "NN nmod VBN acl NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl *drug0*" } 4 : { 1 : "Our haplotype trend analysis identified a drug1 significantly associated with drug2 ( p = .0013 ) , drug3 ( p = .0024 ) , and drug4 ( p = .017 ) . " } } 725 : { 1 : "NN nmod NN nmod JJ nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod measure nmod log-transformed nmod *associated* nsubjpass allele nmod drug0" } 4 : { 1 : "Moreover , the T allele at drug1 was inversely associated with log-transformed , HOMA - % B ( beta = -0.07 , p = 0.005 ) as a measure of drug2 , and drug3 ( beta = -0.06 , p = 0.02 ) . " } } 726 : { 1 : "NN conj VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj *associated* nsubjpass allele nmod drug0" } 4 : { 1 : "Moreover , the T allele at drug1 was inversely associated with log-transformed , HOMA - % B ( beta = -0.07 , p = 0.005 ) as a measure of drug2 , and drug3 ( beta = -0.06 , p = 0.02 ) . " } } 727 : { 1 : "NN conj VBN nmod JJ nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj *associated* nmod log-transformed nmod measure nmod drug0" } 4 : { 1 : "Moreover , the T allele at drug1 was inversely associated with log-transformed , HOMA - % B ( beta = -0.07 , p = 0.005 ) as a measure of drug2 , and drug3 ( beta = -0.06 , p = 0.02 ) . " } } 728 : { 1 : "NN conj NNS nmod VBN nsubjpass NN compound NN" 2 : 1 3 : { 1 : "drug0 conj ratings nmod *associated* nsubjpass genotype compound drug0" } 4 : { 1 : "The OPRM1 drug1 genotype was associated with patients ' drug2 ratings at 15 min in the postanesthesia care unit ( PACU ) ( p = .01 ) and patients ' drug3 at 15 min in the PACU ( p = .02 ) . " } } 729 : { 1 : "NN nmod NNS nmod VB dobj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod episodes nmod *represent* dobj predictors nmod drug0" } 4 : { 1 : "Allele G fromCOMT SNPs drug1 and drug2 may represent reliable state-dependent predictors of global drug3 during manic and mixed episodes in drug4 . " } } 730 : { 1 : "NN nmod NNS dobj VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod predictors dobj *represent* nsubj drug0 conj drug0" } 4 : { 1 : "Allele G fromCOMT SNPs drug1 and drug2 may represent reliable state-dependent predictors of global drug3 during manic and mixed episodes in drug4 . " } } 731 : { 1 : "NN nmod NNS nmod VB nsubj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod episodes nmod *represent* nsubj drug0 conj drug0" } 4 : { 1 : "Allele G fromCOMT SNPs drug1 and drug2 may represent reliable state-dependent predictors of global drug3 during manic and mixed episodes in drug4 . " } } 732 : { 1 : "NN nmod NNS dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod predictors dobj *represent* nsubj drug0" } 4 : { 1 : "Allele G fromCOMT SNPs drug1 and drug2 may represent reliable state-dependent predictors of global drug3 during manic and mixed episodes in drug4 . " } } 733 : { 1 : "NN nmod NNS nmod VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod episodes nmod *represent* nsubj drug0" } 4 : { 1 : "Allele G fromCOMT SNPs drug1 and drug2 may represent reliable state-dependent predictors of global drug3 during manic and mixed episodes in drug4 . " } } 734 : { 1 : "NN nmod VBZ conj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod acts conj *associated* nmod drug0" } 4 : { 1 : "Thus , the drug1 polymorphism is not associated with drug2 in the Caucasian population but acts as a modifier of the AAO in drug3 with a sexual dimorphism : the Val allele is associated with a younger AAO in men with idiopathic PD . " } } 735 : { 1 : "NN compound NN dobj VB xcomp VBN conj VBD nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 compound risk dobj affect xcomp *found* conj helped nsubj polymorphism compound drug0" } 4 : { 1 : "However , drug1 polymorphisms were found to significantly affect drug3 risk , and the drug2 polymorphism helped determine drug4 . " } } 736 : { 1 : "NN compound NN dobj VB xcomp VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound risk dobj affect xcomp *found* nsubjpass polymorphisms compound drug0" } 4 : { 1 : "However , drug1 polymorphisms were found to significantly affect drug3 risk , and the drug2 polymorphism helped determine drug4 . " } } 737 : { 1 : "NN compound NN conj NN nmod NN nsubjpass VBN advcl JJ nmod NN" 2 : 1 3 : { 1 : "drug0 compound behavior conj drug0 nmod association nsubjpass *observed* advcl relevant nmod drug0" } 4 : { 1 : "CONCLUSIONS : Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 behavior was observed " } } 738 : { 1 : "NN nmod NN nmod VBP nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *contribute* nsubj gene compound drug0" } 4 : { 1 : "Our data strongly confirm that drug1 gene contribute to the risk of drug2 . " } } 739 : { 1 : "NN nmod NN nmod VBZ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod development nmod *has* nsubj drug0" } 4 : { 1 : "In conclusion , our findings provide evidence that in addition to other genes , drug1 also has a significant role in the development of drug2 , and demonstrate that analysing the complex phenotype associations of genes by haplotype tagging is a powerful method . " } } 740 : { 1 : "NN conj NN nmod NN nsubjpass VBN advcl JJ conj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod association nsubjpass *observed* advcl relevant conj control nmod genotype compound drug0" } 4 : { 1 : "Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 was observed . " } } 741 : { 1 : "NN compound NN conj NN nmod NN nsubjpass VBN advcl JJ conj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound behavior conj drug0 nmod association nsubjpass *observed* advcl relevant conj control nmod genotype compound drug0" } 4 : { 1 : "CONCLUSIONS : Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 behavior was observed " } } 742 : { 1 : "NN nmod NN nmod NN dobj VBP conj VBD dobj NN nmod NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod degree nmod association dobj find conj *found* dobj association nmod status conj genotype compound drug0" } 4 : { 1 : "RESULTS : We found no association between drug2 status and SNP drug1 genotype nor did we find a significant association to the degree of drug3 " } } 743 : { 1 : "NN nmod NN nmod NN dobj VBP conj VBD dobj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod degree nmod association dobj find conj *found* dobj association nmod status compound drug0" } 4 : { 1 : "RESULTS : We found no association between drug2 status and SNP drug1 genotype nor did we find a significant association to the degree of drug3 " } } 744 : { 1 : "NN nmod NN dobj VBD nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod risk dobj *demonstrated* nsubj polymorphisms compound drug0" } 4 : { 1 : "drug1 and drug2 polymorphisms demonstrated an increased and decreased risk for drug3 , respectively . " } } 745 : { 1 : "NN nmod NN dobj VBD nsubj NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod risk dobj *demonstrated* nsubj polymorphisms compound drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 polymorphisms demonstrated an increased and decreased risk for drug3 , respectively . " } } 746 : { 1 : "NN dobj VB ccomp VBD conj VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 dobj determine ccomp helped conj *found* nsubjpass polymorphisms compound drug0" } 4 : { 1 : "However , drug1 polymorphisms were found to significantly affect drug3 risk , and the drug2 polymorphism helped determine drug4 . " } } 747 : { 1 : "NN conj NN nmod NN nsubjpass VBN advcl JJ nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod association nsubjpass *observed* advcl relevant nmod drug0" } 4 : { 1 : "Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 was observed . " } } 748 : { 1 : "NN compound NN conj NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound assessment conj drug0 nmod *associated* nsubjpass genotype nmod drug0" } 4 : { 1 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " } } 749 : { 1 : "NN nmod NN conj NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod risk conj *genotype* conj status compound drug0" } 4 : { 1 : "However , we found an association between drug1 genotype ( Val/Val ) and A drug2 carrier status and the risk of drug3 and drug4 . " } } 750 : { 1 : "NN conj NN nmod NN conj NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod risk conj *genotype* conj status compound drug0" } 4 : { 1 : "However , we found an association between drug1 genotype ( Val/Val ) and A drug2 carrier status and the risk of drug3 and drug4 . " } } 751 : { 1 : "NN compound NN nsubj VBD conj VBN nsubjpass NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound polymorphism nsubj helped conj *found* nsubjpass polymorphisms compound drug0" } 4 : { 1 : "However , drug1 polymorphisms were found to significantly affect drug3 risk , and the drug2 polymorphism helped determine drug4 . " } } 752 : { 1 : "NN nmod NN nmod NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod risk nmod *polymorphisms* compound drug0 conj drug0" } 4 : { 1 : "A significant association was observed between , drug1 ( OR = 1.95 , C.I. 1.13-3 .36 ) and drug2 ( OR = 2.39 , C.I. 1.24-4 .24 ) polymorphisms with the risk of drug3 . " } } 753 : { 1 : "NN conj NN nmod NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod risk conj *genotype* compound drug0" } 4 : { 1 : "However , we found an association between drug1 genotype ( Val/Val ) and A drug2 carrier status and the risk of drug3 and drug4 . " } } 754 : { 1 : "NN nmod NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod assessment conj *drug0* conj drug0" } 4 : { 1 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " } } 755 : { 1 : "NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod *assessment* compound drug0" } 4 : { 1 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " } } 756 : { 1 : "NN nmod NN conj NN nmod VBN nsubjpass NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod assessment conj drug0 nmod *associated* nsubjpass genotype nmod drug0" } 4 : { 1 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " } } 757 : { 1 : "NN compound NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 compound assessment conj *drug0* conj drug0" } 4 : { 1 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . " } } 758 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN dep NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep *drug0* appos drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 759 : { 1 : "NN nmod VBN acl CD dep NN appos NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl -0 dep apoa0 appos *s0w* compound drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 760 : { 1 : "NN conj NN nmod NN conj RB dep JJ parataxis NNS nmod DT nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod absence conj irrespective dep significant parataxis *genotypes* nmod those nmod s0w compound drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 761 : { 1 : "NN nmod NN dobj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod prevalence dobj *influence* nsubj drug0" } 4 : { 1 : "Our results support the hypothesis that drug1 influence the prevalence of drug2 and possibly overweight in drug3 patients . " } } 762 : { 1 : "NN nmod VBN conj VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod replicated conj *associated* nmod reduction nmod drug0" } 4 : { 1 : "Two polymorphisms ( drug1 , drug2 ) that define the epsilon2 , epsilon3 , and epsilon4 isoforms of apolipoprotein E were significantly associated with percent reduction in drug3 ( epsilon2 carriers 53.8 % , epsilon3/epsilon3 48.1 % , and epsilon4 carriers 46.4 % , respectively , P = 0.00039 ) and replicated in the drug4 ( epsilon2 carriers 22.1 % , epsilon3/epsilon3 21.8 % , and epsilon4 carriers 16.6 % , respectively , P = 0.00038 ) . " } } 763 : { 1 : "NN compound NNS nmod JJ conj VBP nsubj NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod overweight conj *influence* nsubj drug0" } 4 : { 1 : "Our results support the hypothesis that drug1 influence the prevalence of drug2 and possibly overweight in drug3 patients . " } } 764 : { 1 : "NN compound NNS nmod JJ conj VBP dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod overweight conj *influence* dobj prevalence nmod drug0" } 4 : { 1 : "Our results support the hypothesis that drug1 influence the prevalence of drug2 and possibly overweight in drug3 patients . " } } 765 : { 1 : "NN dobj VB acl NN nmod NN" 2 : 1 3 : { 1 : "drug0 dobj induce acl *interaction* nmod drug0" } 4 : { 1 : "These associations warrant prospective study to assess interaction between drug1 and the propensity of antipsychotics to induce drug2 . " } } 766 : { 1 : "NN nmod VBN conj VBN nsubjpass NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod replicated conj *associated* nsubjpass polymorphisms dep drug0 appos drug0" } 4 : { 1 : "Two polymorphisms ( drug1 , drug2 ) that define the epsilon2 , epsilon3 , and epsilon4 isoforms of apolipoprotein E were significantly associated with percent reduction in drug3 ( epsilon2 carriers 53.8 % , epsilon3/epsilon3 48.1 % , and epsilon4 carriers 46.4 % , respectively , P = 0.00039 ) and replicated in the drug4 ( epsilon2 carriers 22.1 % , epsilon3/epsilon3 21.8 % , and epsilon4 carriers 16.6 % , respectively , P = 0.00038 ) . " } } 767 : { 1 : "NN nmod VBN conj VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod replicated conj *associated* nsubjpass polymorphisms dep drug0" } 4 : { 1 : "Two polymorphisms ( drug1 , drug2 ) that define the epsilon2 , epsilon3 , and epsilon4 isoforms of apolipoprotein E were significantly associated with percent reduction in drug3 ( epsilon2 carriers 53.8 % , epsilon3/epsilon3 48.1 % , and epsilon4 carriers 46.4 % , respectively , P = 0.00039 ) and replicated in the drug4 ( epsilon2 carriers 22.1 % , epsilon3/epsilon3 21.8 % , and epsilon4 carriers 16.6 % , respectively , P = 0.00038 ) . " } } 768 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS dep NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod reduction nmod *associated* nsubjpass polymorphisms dep drug0 appos drug0" } 4 : { 1 : "Two polymorphisms ( drug1 , drug2 ) that define the epsilon2 , epsilon3 , and epsilon4 isoforms of apolipoprotein E were significantly associated with percent reduction in drug3 ( epsilon2 carriers 53.8 % , epsilon3/epsilon3 48.1 % , and epsilon4 carriers 46.4 % , respectively , P = 0.00039 ) and replicated in the drug4 ( epsilon2 carriers 22.1 % , epsilon3/epsilon3 21.8 % , and epsilon4 carriers 16.6 % , respectively , P = 0.00038 ) . " } } 769 : { 1 : "NN dobj VB xcomp VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 dobj influence xcomp *found* nsubjpass snps nmod drug0" } 4 : { 1 : "Among SNPs tested with an allele frequency of at least 5 % , only SNPs in drug1 are found to influence drug2 significantly . " } } 770 : { 1 : "NN compound NN conj NN nmod VBN nmod NNS acl VBN nmod NNP appos NN" 2 : 1 3 : { 1 : "drug0 compound risk conj ratio nmod *associated* nmod snps acl associated nmod mi appos drug0" } 4 : { 1 : "Of the 3 SNPs most significantly associated with MI , drug1 , which defines the Apo E2 isoform , was associated with both a lower Apo B/A1 ratio ( P = 1.0 x10 ( -7 ) ) and lower drug2 risk ( P = 0.0004 ) . " } } 771 : { 1 : "NN nmod NN conj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk conj density nmod *association* nmod drug0" } 4 : { 1 : "BACKGROUND : The association of drug1 ( APOE ) genotypes with bone mineral density ( BMD ) and risk of drug2 have remained unclear . " } } 772 : { 1 : "NN nmod NN nmod NNS dobj VBP nsubj DT nmod NNS acl VBN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod synthesis nmod alterations dobj *suggest* nsubj those nmod diets acl associated nmod allele compound drug0" } 4 : { 1 : "Lower lipid profile values among patients , even those on lipid-rich diets associated with the drug1 allele , suggest alterations in the lipid synthesis and metabolism pathways in drug2 . " } } 773 : { 1 : " NN conj NN acl VBG dobj NN acl:relcl JJ nsubj NN compound NN" 2 : 1 3 : { 1 : " *drug0* conj region acl containing dobj e acl:relcl inconsistent nsubj gene compound drug0" } 4 : { 1 : "OBJECTIVE : Although several studies have reported an association between drug2 ( OSA ) and the chromosomal region containing the Apolipoprotein E ( drug1 ) gene , findings about the exact location in the ApoE gene have been inconsistent . " } } 774 : { 1 : "NN compound NN nmod VBD nsubj NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod *had* nsubj variants compound drug0 conj drug0" } 4 : { 1 : "drug1 and drug2 variants had additive effects on drug3 risk , and after adjusting for pigmentation characteristics , the risk was persistent , even though both genes had a strong impact on pigmentation " } } 775 : { 1 : "NN compound NNS nmod VBN acl NN nmod NN nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound populations nmod associated acl drug0 nmod inheritance nmod *role* nmod locus compound drug0" } 4 : { 1 : "We conducted additional genotyping to clarify the role of the drug1 locus in the inheritance of drug2 and other pigmentary traits associated with drug3 risk inwhite populations " } } 776 : { 1 : "NN compound NNS nmod VBN acl NN" 2 : 1 3 : { 1 : "drug0 compound populations nmod associated acl *drug0*" } 4 : { 1 : "We conducted additional genotyping to clarify the role of the drug1 locus in the inheritance of drug2 and other pigmentary traits associated with drug3 risk inwhite populations " } } 777 : { 1 : "NN nmod NN dobj VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod risk dobj *modify* nsubj marker compound drug0" } 4 : { 1 : "GAB2 drug1 marker does not modify the risk of drug2 in Spanish APOE epsilon 4 carriers . " } } 778 : { 1 : "NN compound NN nmod VBD nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod *had* nsubj variants compound drug0" } 4 : { 1 : "drug1 and drug2 variants had additive effects on drug3 risk , and after adjusting for pigmentation characteristics , the risk was persistent , even though both genes had a strong impact on pigmentation " } } 779 : { 1 : "NN nmod NN nmod NN nmod VB xcomp JJ xcomp JJ conj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod thediagnosis nmod screening nmod serve xcomp enough xcomp robust conj *offer* nsubj drug0" } 4 : { 1 : "In a clinical setting , drug1 could offer additional biological evidence of whether a subject may develop drug2 , but it is not robust enough to serve as an independent screening or predictive test in thediagnosis of drug3 " } } 780 : { 1 : "NN nmod NN nmod NN nmod VB xcomp JJ xcomp JJ conj VB dobj NN acl VB dobj NN" 2 : 1 3 : { 1 : "drug0 nmod thediagnosis nmod screening nmod serve xcomp enough xcomp robust conj *offer* dobj evidence acl develop dobj drug0" } 4 : { 1 : "In a clinical setting , drug1 could offer additional biological evidence of whether a subject may develop drug2 , but it is not robust enough to serve as an independent screening or predictive test in thediagnosis of drug3 " } } 781 : { 1 : "NN compound NN nmod VBN acl:relcl NNS nmod VBN nsubjpass NN" 2 : 1 3 : { 1 : "drug0 compound status nmod associated acl:relcl haplotypes nmod *included* nsubjpass drug0" } 4 : { 1 : "The sliding window haplotype trend regression test revealed that SNP drug1 was included in all haplotypes that are significantly associated with drug2 status . " } } 782 : { 1 : "NN dobj VB acl NN dobj VB nsubj NN" 2 : 1 3 : { 1 : "drug0 dobj develop acl evidence dobj *offer* nsubj drug0" } 4 : { 1 : "In a clinical setting , drug1 could offer additional biological evidence of whether a subject may develop drug2 , but it is not robust enough to serve as an independent screening or predictive test in thediagnosis of drug3 " } } 783 : { 1 : "NN conj NNS nmod NN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 conj blocks nmod *association* nmod snps dep drug0" } 4 : { 1 : "We observed nominal association between four SNPs ( drug1 , drug2 , drug3 , and drug4 ) in three haplotype blocks and drug5 , age at diagnosis , and 2-h glucose levels ( P = 0.001-0 .055 ) . " } } 784 : { 1 : "NN conj NN nmod NN nmod VBN xcomp VBN acl:relcl NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod associated xcomp found acl:relcl *gene* compound drug0" } 4 : { 1 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " } } 785 : { 1 : "NN nmod VBN xcomp VBN acl:relcl NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp found acl:relcl *gene* compound drug0" } 4 : { 1 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " } } 786 : { 1 : "NN conj VBN nmod NN nmod VBN nsubjpass NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 conj predicted nmod drug0 nmod *associated* nsubjpass snps dep drug0 conj drug0" } 4 : { 1 : "Two SNPs ( drug1 and drug2 ) were associated with the drug3 of predicted and drug4 ; SNP-by-gender interactions were observed . " } } 787 : { 1 : "NN conj VBN nmod NN" 2 : 1 3 : { 1 : "drug0 conj predicted nmod *drug0*" } 4 : { 1 : "Two SNPs ( drug1 and drug2 ) were associated with the drug3 of predicted and drug4 ; SNP-by-gender interactions were observed . " } } 788 : { 1 : "NN nmod NN dobj VBD xcomp VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod relationship dobj *investigated* xcomp using dobj nucleotidepolymorphism compound drug0" } 4 : { 1 : "We investigated thecausal relationship between drug2 and symptoms of drug3 and drug4 in the Norwegian HUNT study using the drug1 single nucleotidepolymorphism ( SNP ) variant located in the nicotine acetylcholine receptor gene cluster on chromosome 15 as an instrumental variable for smokingphenotypes " } } 789 : { 1 : "NN nmod NN nmod NN dobj VBD xcomp VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod relationship dobj *investigated* xcomp using dobj nucleotidepolymorphism compound drug0" } 4 : { 1 : "We investigated thecausal relationship between drug2 and symptoms of drug3 and drug4 in the Norwegian HUNT study using the drug1 single nucleotidepolymorphism ( SNP ) variant located in the nicotine acetylcholine receptor gene cluster on chromosome 15 as an instrumental variable for smokingphenotypes " } } 790 : { 1 : "NN conj VBN nmod NN nmod VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 conj predicted nmod drug0 nmod *associated* nsubjpass snps dep drug0" } 4 : { 1 : "Two SNPs ( drug1 and drug2 ) were associated with the drug3 of predicted and drug4 ; SNP-by-gender interactions were observed . " } } 791 : { 1 : "NN nmod VBN acl:relcl NN conj NN conj NNS compound NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl *r0l* conj r0c conj polymorphisms compound r0c appos drug0" } 4 : { 1 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " } } 792 : { 1 : "NN nmod NN nmod CD appos NN nmod NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod factor nmod one appos e0 nmod effects nmod relationship appos *drug0*" } 4 : { 1 : "This paper addresses a tenet of the literature on drug1 , i.e. , the relationship between the effects of the e4 , one of the established genetic risk factor for drug2 , and its expression levels as determined by APOE promoter polymorphisms . " } } 793 : { 1 : "NN appos NN compound NNS conj NN conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos r0c compound polymorphisms conj r0c conj *r0l* conj d0h appos drug0" } 4 : { 1 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " } } 794 : { 1 : "NN appos NN compound NNS conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos r0c compound polymorphisms conj *r0c* appos drug0" } 4 : { 1 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " } } 795 : { 1 : "NN nmod NN nmod VBN xcomp VBN acl:relcl NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod associated xcomp found acl:relcl *gene* compound drug0" } 4 : { 1 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " } } 796 : { 1 : "NN conj NN nmod NN nmod NN dobj VBD xcomp VBG dobj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod relationship dobj *investigated* xcomp using dobj nucleotidepolymorphism compound drug0" } 4 : { 1 : "We investigated thecausal relationship between drug2 and symptoms of drug3 and drug4 in the Norwegian HUNT study using the drug1 single nucleotidepolymorphism ( SNP ) variant located in the nicotine acetylcholine receptor gene cluster on chromosome 15 as an instrumental variable for smokingphenotypes " } } 797 : { 1 : "NN conj NN nsubj VBD parataxis VBN dep NN conj NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nsubj showed parataxis associated dep age conj *aa* conj haplotype compound drug0" } 4 : { 1 : "VKORC1 3673 AA or GA genotype ( P < 0.0001 ) , one or two variant alleles of CYP2C9 gene ( P = 0.0004 ) , drug1 e2 haplotype ( P = 0.01 ) , and increasing age ( P < 0.0001 ) were all associated with lower warfarin dose , whereas drug2 ( P = 0.025 ) and drug3 ( P = 0.0059 ) showed association with higher warfarin doses . " } } 798 : { 1 : "NN nmod VBN xcomp VBN acl:relcl NN nmod VBD dobj NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp found acl:relcl gene nmod *exposed* dobj drug0" } 4 : { 1 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " } } 799 : { 1 : "NN nmod NN nmod VBN xcomp VBN acl:relcl NN nmod VBD dobj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod associated xcomp found acl:relcl gene nmod *exposed* dobj drug0" } 4 : { 1 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " } } 800 : { 1 : "NN conj NN nmod NN nmod VBN xcomp VBN acl:relcl NN nmod VBD dobj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod drug0 nmod associated xcomp found acl:relcl gene nmod *exposed* dobj drug0" } 4 : { 1 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " } } 801 : { 1 : "NN nsubj VBD parataxis VBN dep NN conj NN conj NN compound NN" 2 : 1 3 : { 1 : "drug0 nsubj showed parataxis associated dep age conj *aa* conj haplotype compound drug0" } 4 : { 1 : "VKORC1 3673 AA or GA genotype ( P < 0.0001 ) , one or two variant alleles of CYP2C9 gene ( P = 0.0004 ) , drug1 e2 haplotype ( P = 0.01 ) , and increasing age ( P < 0.0001 ) were all associated with lower warfarin dose , whereas drug2 ( P = 0.025 ) and drug3 ( P = 0.0059 ) showed association with higher warfarin doses . " } } 802 : { 1 : "NN compound NN nmod VBD dobj NN" 2 : 1 3 : { 1 : "drug0 compound gene nmod *exposed* dobj drug0" } 4 : { 1 : "CONCLUSIONS : The present study exposed a susceptibility haplotype drug1 , within drug2 gene , which was found to be associated with drug3 and risk of drug4 and drug5 in postmenopausal females of India . " } } 803 : { 1 : "NN nmod NNS xcomp VB advcl VB nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod effects xcomp *seem* advcl have nsubj genotype compound drug0" } 4 : { 1 : "CONCLUSIONS : Although drug1 genotype does have strong associations with lipid levels in childhood , there does not seem to be meaningful effects on drug2 , suggesting that any detrimental effects of the e4 allele on cognitive function are not important until later life . " } } 804 : { 1 : "NN nmod NN nmod JJ nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod *responsible* nsubj drug0" } 4 : { 1 : "drug1 alone is responsible for the association of APOE with drug2 ; " } } 805 : { 1 : "NN compound NNS nmod NNS nsubj NN" 2 : 1 3 : { 1 : "drug0 compound requirements nmod *determinants* nsubj drug0" } 4 : { 1 : "CONCLUSIONS : The study shows that drug1 , drug2 polymorphisms , APOE e2 variant , and several clinical/demographic variables are important determinants of drug3 dose requirements in Egyptian patients . " } } 806 : { 1 : "NN compound NNS nmod NNS nsubj NN conj NNS compound NN" 2 : 1 3 : { 1 : "drug0 compound requirements nmod *determinants* nsubj drug0 conj polymorphisms compound drug0" } 4 : { 1 : "CONCLUSIONS : The study shows that drug1 , drug2 polymorphisms , APOE e2 variant , and several clinical/demographic variables are important determinants of drug3 dose requirements in Egyptian patients . " } } 807 : { 1 : "NN nmod VBN acl:relcl NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod associated acl:relcl *r0l* appos drug0" } 4 : { 1 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " } } 808 : { 1 : "NN nmod NN nmod NNS nmod NN dobj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod allele nmod ors nmod association dobj *showed* nsubj variants nmod drug0" } 4 : { 1 : "Among them , genetic variants in drug1 showed the strongest association with drug4 risk , with ORs ( 95 % CIs ) of 1.44 ( 1.29-1 .60 , P < 0.001 ) per T allele of drug2 and 1.46 ( 1.15-1 .84 , P = 0.002 ) per T allele of drug3 " } } 809 : { 1 : "NN compound NN nmod NN dobj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod association dobj *showed* nsubj variants nmod drug0" } 4 : { 1 : "Among them , genetic variants in drug1 showed the strongest association with drug4 risk , with ORs ( 95 % CIs ) of 1.44 ( 1.29-1 .60 , P < 0.001 ) per T allele of drug2 and 1.46 ( 1.15-1 .84 , P = 0.002 ) per T allele of drug3 " } } 810 : { 1 : "NN nmod VBN nsubjpass NN nmod NN conj NNS nmod NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass heterozygosity nmod deletion conj alleles nmod polymorphism nmod gene appos drug0" } 4 : { 1 : "OBJECTIVE : Heterozygosity for a 32 base pair deletion in the CCR5 gene ( CCR5wt/d32 ) and the minor alleles of a single-nucleotide polymorphism in the HCP5 gene ( drug1 ) and in the HLA-C gene region ( -35 HLA-C ; drug2 ) has been associated with a drug3 " } } 811 : { 1 : "NN dep NN dep NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 dep hla-c dep region conj *gene* appos drug0" } 4 : { 1 : "OBJECTIVE : Heterozygosity for a 32 base pair deletion in the CCR5 gene ( CCR5wt/d32 ) and the minor alleles of a single-nucleotide polymorphism in the HCP5 gene ( drug1 ) and in the HLA-C gene region ( -35 HLA-C ; drug2 ) has been associated with a drug3 " } } 812 : { 1 : "NN nmod VBN nsubjpass NN nmod NN conj NNS nmod NN nmod NN conj NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass heterozygosity nmod deletion conj alleles nmod polymorphism nmod gene conj region dep hla-c dep drug0" } 4 : { 1 : "OBJECTIVE : Heterozygosity for a 32 base pair deletion in the CCR5 gene ( CCR5wt/d32 ) and the minor alleles of a single-nucleotide polymorphism in the HCP5 gene ( drug1 ) and in the HLA-C gene region ( -35 HLA-C ; drug2 ) has been associated with a drug3 " } } 813 : { 1 : "NN nmod NN nmod VBZ nsubj NN amod RB nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod control nmod *associates* nsubj polymorphism amod upstream nmod hla-c dep drug0" } 4 : { 1 : "A single nucleotide polymorphism ( SNP ) 35 kb upstream of HLA-C ( drug1 ; termed -35 ) associates with control of drug2 , and with levels of HLA-C messenger RNA transcripts and cell-surface expression , but the mechanism underlying its varied expression is unknown . " } } 814 : { 1 : "NN nmod VBN nsubjpass NNS nmod NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *replicated* nsubjpass associations nmod variants nmod drug0" } 4 : { 1 : "RESULTS : Significant associations between the minor allele variants of SNPs HLA-C drug1 and HCP5 drug2 and a lower viral load at set point could be replicated in the drug3 . " } } 815 : { 1 : "NN compound NN nmod NN dobj VB xcomp VBN conj VBN nsubjpass NNS acl VBG dobj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound infection nmod progression dobj influence xcomp shown conj *identified* nsubjpass polymorphisms acl affecting dobj expression dep drug0 conj drug0" } 4 : { 1 : "Two polymorphisms affecting HLA-Csurface expression ( drug1 and drug2 ) have recently been identified , and shown to influence progression of drug3 infection . " } } 816 : { 1 : "NN compound NN conj NN nmod NN xcomp VBG advcl NN xcomp NN dobj VBD nsubj NN appos NN" 2 : 1 3 : { 1 : "drug0 compound progression conj expression nmod marker xcomp making advcl disequilibrium xcomp dobj *reported* nsubj indel appos drug0" } 4 : { 1 : "This 263 indel ( drug1 ) is reported to be in strong linkage disequilibrium ( LD ) with a single nucleotide polymorphism ( SNP ) 35 kilobases upstream of HLA-C ( -35 T/C ; rs9264942 ) in Caucasian individuals , making this SNP a potential marker for both HLA-C expression and drug2 disease progression " } } 817 : { 1 : "NN compound NN nmod NN dobj VB xcomp VBN conj VBN nsubjpass NNS acl VBG dobj NN dep NN" 2 : 1 3 : { 1 : "drug0 compound infection nmod progression dobj influence xcomp shown conj *identified* nsubjpass polymorphisms acl affecting dobj expression dep drug0" } 4 : { 1 : "Two polymorphisms affecting HLA-Csurface expression ( drug1 and drug2 ) have recently been identified , and shown to influence progression of drug3 infection . " } } 818 : { 1 : "NN nmod NN nmod NN nmod NNS nmod NNS amod JJ dep NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod *replication* nmod snps nmod samples amod family-based dep drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 819 : { 1 : "NN nmod NN nmod NN nmod NNS nmod NNS amod JJ dep NN dep JJ dobj CD conj NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod *replication* nmod snps nmod samples amod family-based dep drug0 dep = dobj 0.0 conj drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 820 : { 1 : "NN conj CD dobj JJ dep NN" 2 : 1 3 : { 1 : "drug0 conj 0.0 dobj = dep *drug0*" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 821 : { 1 : "NN nmod VBN nsubjpass NNS nmod NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *replicated* nsubjpass associations nmod variants nmod drug0 conj drug0" } 4 : { 1 : "RESULTS : Significant associations between the minor allele variants of SNPs HLA-C drug1 and HCP5 drug2 and a lower viral load at set point could be replicated in the drug3 . " } } 822 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 823 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 824 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 825 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep *drug0*" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 826 : { 1 : "NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 dep tcf0l0 dep *fto* dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 827 : { 1 : "NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep *drug0*" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 828 : { 1 : "NN appos NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 appos drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 829 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 830 : { 1 : "CD nmod JJ xcomp VBP dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod important xcomp appear dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 831 : { 1 : "NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 dep runx0 dep drug0 dep celf0 dep drug0 dep l0mbtl0 dep drug0 dep tcf0l0 dep *fto* dep drug0 dep tspan0 dep drug0" } 4 : { 1 : "Through an exhaustive search of pair-wise interactions and a selected search of three - to five-way interactions conditioned on significant pair-wise results , we identified 24 core SNPs in six genes ( FTO : drug1 , drug2 , drug3 , drug4 , drug5 , drug6 ; TSPAN8 : drug7 ; TCF7L2 : drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , drug14 , drug15 ; L3MBTL3 : drug16 , drug17 ; CELF4 : drug18 , drug19 ; RUNX1 : drug20 , drug21 , drug22 , drug23 , drug24 ) that appear to be important for drug25 . " } } 832 : { 1 : "NN nmod NN nmod NN nmod NN nmod NNS nmod NN dobj VBD nsubj NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod allele nmod drug0 nmod allele nmod ors nmod association dobj *showed* nsubj variants nmod drug0" } 4 : { 1 : "Among them , genetic variants in drug1 showed the strongest association with drug4 risk , with ORs ( 95 % CIs ) of 1.44 ( 1.29-1 .60 , P < 0.001 ) per T allele of drug2 and 1.46 ( 1.15-1 .84 , P = 0.002 ) per T allele of drug3 " } } 833 : { 1 : "NN nmod NN nmod NN nmod NNS amod JJ dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod *replication* nmod snps amod case-control dep drug0 conj drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 834 : { 1 : "NN dep JJ amod NNS nmod NNS amod JJ dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep family-based amod samples nmod *snps* amod case-control dep drug0 conj drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 835 : { 1 : "NN nmod NN conj VBN nsubjpass NNS appos NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod risk conj *associated* nsubjpass polymorphisms appos drug0 conj drug0" } 4 : { 1 : "BACKGROUND : Two single-nucleotide polymorphisms , drug1 and drug2 , located within the nicotinic acetylcholine receptor gene cluster on chromosome 15q25 locus , are associated with heaviness of drug3 , risk for drug4 , and other smoking-related health outcomes . " } } 836 : { 1 : "NN nmod NN conj VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod risk conj *associated* nmod heaviness nmod drug0" } 4 : { 1 : "BACKGROUND : Two single-nucleotide polymorphisms , drug1 and drug2 , located within the nicotinic acetylcholine receptor gene cluster on chromosome 15q25 locus , are associated with heaviness of drug3 , risk for drug4 , and other smoking-related health outcomes . " } } 837 : { 1 : "NN conj CD dep JJ amod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 conj 0 dep 0-like amod factor nmod *polymorphisms* compound drug0" } 4 : { 1 : "OBJECTIVE : We aimed to replicate the association of the drug1 ( IVS3C/T ) and drug2 ( IVS3C/T ) polymorphisms of transcription factor 7-like 2 ( TCF7L2 ) and drug3 ( drug4 ) in Han Chinese people in Henan province , China . " } } 838 : { 1 : "NN appos NN conj CD dep JJ amod NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj 0 dep 0-like amod factor nmod *polymorphisms* compound drug0" } 4 : { 1 : "OBJECTIVE : We aimed to replicate the association of the drug1 ( IVS3C/T ) and drug2 ( IVS3C/T ) polymorphisms of transcription factor 7-like 2 ( TCF7L2 ) and drug3 ( drug4 ) in Han Chinese people in Henan province , China . " } } 839 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS appos NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod heaviness nmod *associated* nsubjpass polymorphisms appos drug0 conj drug0" } 4 : { 1 : "BACKGROUND : Two single-nucleotide polymorphisms , drug1 and drug2 , located within the nicotinic acetylcholine receptor gene cluster on chromosome 15q25 locus , are associated with heaviness of drug3 , risk for drug4 , and other smoking-related health outcomes . " } } 840 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS appos NN" 2 : 1 3 : { 1 : "drug0 nmod heaviness nmod *associated* nsubjpass polymorphisms appos drug0" } 4 : { 1 : "BACKGROUND : Two single-nucleotide polymorphisms , drug1 and drug2 , located within the nicotinic acetylcholine receptor gene cluster on chromosome 15q25 locus , are associated with heaviness of drug3 , risk for drug4 , and other smoking-related health outcomes . " } } 841 : { 1 : "NN nmod NN conj VBN nsubjpass NNS appos NN" 2 : 1 3 : { 1 : "drug0 nmod risk conj *associated* nsubjpass polymorphisms appos drug0" } 4 : { 1 : "BACKGROUND : Two single-nucleotide polymorphisms , drug1 and drug2 , located within the nicotinic acetylcholine receptor gene cluster on chromosome 15q25 locus , are associated with heaviness of drug3 , risk for drug4 , and other smoking-related health outcomes . " } } 842 : { 1 : "NN compound NN nmod NN nmod NNS nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod *association* nmod ors nmod allele nmod drug0" } 4 : { 1 : "Among them , genetic variants in drug1 showed the strongest association with drug4 risk , with ORs ( 95 % CIs ) of 1.44 ( 1.29-1 .60 , P < 0.001 ) per T allele of drug2 and 1.46 ( 1.15-1 .84 , P = 0.002 ) per T allele of drug3 " } } 843 : { 1 : "NN compound NN nmod NN nmod NNS nmod NN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod *association* nmod ors nmod allele nmod drug0 nmod allele nmod drug0" } 4 : { 1 : "Among them , genetic variants in drug1 showed the strongest association with drug4 risk , with ORs ( 95 % CIs ) of 1.44 ( 1.29-1 .60 , P < 0.001 ) per T allele of drug2 and 1.46 ( 1.15-1 .84 , P = 0.002 ) per T allele of drug3 " } } 844 : { 1 : "NN conj CD dobj JJ dep NN dep JJ amod NNS nmod NNS amod JJ dep NN conj NN" 2 : 1 3 : { 1 : "drug0 conj 0.0 dobj = dep drug0 dep family-based amod samples nmod *snps* amod case-control dep drug0 conj drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 845 : { 1 : "NN conj CD dep JJ amod NN nmod NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 conj 0 dep 0-like amod factor nmod *polymorphisms* compound drug0 conj drug0" } 4 : { 1 : "OBJECTIVE : We aimed to replicate the association of the drug1 ( IVS3C/T ) and drug2 ( IVS3C/T ) polymorphisms of transcription factor 7-like 2 ( TCF7L2 ) and drug3 ( drug4 ) in Han Chinese people in Henan province , China . " } } 846 : { 1 : "NN nmod VBN nsubjpass NN conj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass genotype conj model nmod drug0" } 4 : { 1 : "CONCLUSIONS : The CC genotype and the recessive model of the variant drug1 ( IVS3C/T ) and CC haplotype of drug2 ( IVS3C/T ) and drug3 ( IVS3C/T ) in TCF7L2may be associated with drug4 in Han Chinese people in Henan province , China . . " } } 847 : { 1 : "NN dep JJ amod NNS nmod NNS amod JJ dep NN dep NN" 2 : 1 3 : { 1 : "drug0 dep family-based amod samples nmod *snps* amod case-control dep drug0 dep drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 848 : { 1 : "NN conj CD dobj JJ dep NN dep JJ amod NNS nmod NNS amod JJ dep NN dep NN" 2 : 1 3 : { 1 : "drug0 conj 0.0 dobj = dep drug0 dep family-based amod samples nmod *snps* amod case-control dep drug0 dep drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 849 : { 1 : "NN nmod NN nmod NN nmod NNS amod JJ dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod *replication* nmod snps amod case-control dep drug0 dep drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 850 : { 1 : "NN appos NN conj CD dep JJ amod NN nmod NNS compound NN conj NN" 2 : 1 3 : { 1 : "drug0 appos drug0 conj 0 dep 0-like amod factor nmod *polymorphisms* compound drug0 conj drug0" } 4 : { 1 : "OBJECTIVE : We aimed to replicate the association of the drug1 ( IVS3C/T ) and drug2 ( IVS3C/T ) polymorphisms of transcription factor 7-like 2 ( TCF7L2 ) and drug3 ( drug4 ) in Han Chinese people in Henan province , China . " } } 851 : { 1 : "NN nmod NN nmod NN nmod NNS amod JJ dep NN" 2 : 1 3 : { 1 : "drug0 nmod association nmod *replication* nmod snps amod case-control dep drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 852 : { 1 : "NN dep JJ amod NNS nmod NNS amod JJ dep NN" 2 : 1 3 : { 1 : "drug0 dep family-based amod samples nmod *snps* amod case-control dep drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 853 : { 1 : "NN conj CD dobj JJ dep NN dep JJ amod NNS nmod NNS amod JJ dep NN" 2 : 1 3 : { 1 : "drug0 conj 0.0 dobj = dep drug0 dep family-based amod samples nmod *snps* amod case-control dep drug0" } 4 : { 1 : "Here , we report replication of association between drug6 and three SNPs in the case-control ( drug1 , P = 0.003 ; drug2 , P = 0.00002 ; and . drug3 , P = 0.000004 ) and two SNPs in the family-based ( drug4 , P = 0.01 and drug5 , P = 0.04 ) samples from northern Sweden . " } } 854 : { 1 : "NN nmod VBN nsubjpass NN conj NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass genotype conj model nmod drug0 nmod drug0" } 4 : { 1 : "CONCLUSIONS : The CC genotype and the recessive model of the variant drug1 ( IVS3C/T ) and CC haplotype of drug2 ( IVS3C/T ) and drug3 ( IVS3C/T ) in TCF7L2may be associated with drug4 in Han Chinese people in Henan province , China . . " } } 855 : { 1 : "NN nmod VBN nsubjpass NN conj NN nmod NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass genotype conj model nmod drug0 nmod drug0 conj drug0" } 4 : { 1 : "CONCLUSIONS : The CC genotype and the recessive model of the variant drug1 ( IVS3C/T ) and CC haplotype of drug2 ( IVS3C/T ) and drug3 ( IVS3C/T ) in TCF7L2may be associated with drug4 in Han Chinese people in Henan province , China . . " } } 856 : { 1 : "NN nmod NN conj RB dep JJ parataxis NNS nmod DT nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod absence conj irrespective dep significant parataxis *genotypes* nmod those nmod s0w compound drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 857 : { 1 : "NN appos NN compound NNS conj NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 appos r0c compound polymorphisms conj r0c conj *r0l* appos drug0" } 4 : { 1 : "Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C ( drug4 ) polymorphisms , all of which are associated with lifelong drug5 . " } } 858 : { 1 : "NN nmod NNS nmod NN dobj VBP advcl VBZ nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod genetics nmod involvement dobj *suggest* advcl needs nsubj role nmod drug0 conj drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 859 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 860 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 861 : { 1 : "NN nmod NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 862 : { 1 : "NN dep VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 863 : { 1 : "NN dep NN conj NN conj NN dep VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 864 : { 1 : "NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 865 : { 1 : "NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 866 : { 1 : "NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 867 : { 1 : "NN conj NN nmod VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 868 : { 1 : "NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 869 : { 1 : "NN nmod NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 870 : { 1 : "NN dep NN dep NN conj NN conj NN dep VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 871 : { 1 : "NN nmod NN dep NN conj NN conj NN dep VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 872 : { 1 : "NN dep NN conj NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 dep b conj drug0 conj *drug0* conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 873 : { 1 : "NN dep NN dep NN conj NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep b conj drug0 conj *drug0* conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 874 : { 1 : "NN dep NN appos NN dep NN dep NN conj NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0* conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 875 : { 1 : "NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 876 : { 1 : "NN nmod NN dep NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj drug0 conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 877 : { 1 : "NN nmod VBN dep NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 878 : { 1 : "NN nmod NN nmod VBN dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod *associated* dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 879 : { 1 : "NN dep NN dep NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep b conj drug0 conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 880 : { 1 : "NN dep NN appos NN dep NN dep NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 881 : { 1 : "NN nmod NN dep NN conj NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj drug0 conj *drug0* conj drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 882 : { 1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 883 : { 1 : "NN dep NN appos NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 dep gamma appos drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 884 : { 1 : "NN nmod NN nmod VBN acl NN nsubj NN" 2 : 1 3 : { 1 : "drug0 nmod regulation nmod involved acl *polymorphism* nsubj drug0" } 4 : { 1 : "CONCLUSIONS : drug1 is a functional polymorphism involved in the regulation of the drug2 . " } } 885 : { 1 : "NN compound NN nmod NN nmod VBN nsubjpass NNS dep NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod association nmod *tested* nsubjpass polymorphisms dep drug0" } 4 : { 1 : "BACKGROUND : Single nucleotide polymorphisms ( SNPs ) drug1 ( e4 ) and drug2 ( e2 ) , both invoking changes in the amino-acid sequence of the apolipoprotein E ( APOE ) gene , have previously been tested for association with drug3 risk . " } } 886 : { 1 : "NN compound NN nmod NN nmod VBN nsubjpass NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound risk nmod association nmod *tested* nsubjpass polymorphisms dep drug0 conj drug0" } 4 : { 1 : "BACKGROUND : Single nucleotide polymorphisms ( SNPs ) drug1 ( e4 ) and drug2 ( e2 ) , both invoking changes in the amino-acid sequence of the apolipoprotein E ( APOE ) gene , have previously been tested for association with drug3 risk . " } } 887 : { 1 : "NN nmod NN nsubj NN appos NNS nmod VBN nsubjpass NNS nmod NN" 2 : 1 3 : { 1 : "drug0 nmod ratio nsubj interval appos meta-analyses nmod *included* nsubjpass studies nmod drug0" } 4 : { 1 : "Furthermore , studies of APOE drug1 , drug2 , ( defining e2/e3/e4 alleles ; 12 studies ) and APOB drug3 ( eight studies ) were included in meta-analyses , the observational hazard ratio ( HR ) for symptomatic drug4 for the fifth versus first quintile of LDL-C was 0.94 ( 95 % confidence interval : 0.76-1 .17 ) , despite a corresponding 134 % increase in LDL-C . " } } 888 : { 1 : "NN conj NN nmod NN conj RB dep JJ parataxis NNS nmod DT nmod NN appos NN dep CD acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod absence conj irrespective dep significant parataxis *genotypes* nmod those nmod s0w appos apoa0 dep -0 acl associated nmod drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 889 : { 1 : "NN conj NN nmod NN conj RB dep JJ parataxis NNS nmod DT nmod NN appos NN dep CD acl VBN nsubjpass NNP conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod absence conj irrespective dep significant parataxis *genotypes* nmod those nmod s0w appos apoa0 dep -0 acl associated nsubjpass apoe conj drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 890 : { 1 : "NN nmod NN conj RB dep JJ parataxis NNS nmod DT nmod NN appos NN dep CD acl VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod absence conj irrespective dep significant parataxis *genotypes* nmod those nmod s0w appos apoa0 dep -0 acl associated nmod drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 891 : { 1 : "NN nmod VBN nsubjpass NNP conj NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass apoe conj drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 892 : { 1 : "NN nmod NN conj RB dep JJ parataxis NNS nmod DT nmod NN appos NN dep CD acl VBN nsubjpass NNP conj NN" 2 : 1 3 : { 1 : "drug0 nmod absence conj irrespective dep significant parataxis *genotypes* nmod those nmod s0w appos apoa0 dep -0 acl associated nsubjpass apoe conj drug0" } 4 : { 1 : "We found that : ( i ) genotypes , including those of drug1 S19W , APOA5 -1131 T > C , APOE , GCKR , drug2 and TBL2/MLXIPL , were significantly associated with severe drug3 ; ( ii ) odds ratios for these genetic variables were significant in both univariate and multivariate regressionanalyses , irrespective of the presence or absence of drug4 or drug5 ; ( iii ) a significant fraction-about one-quarter-of the explained variation in disease status was associated with these genotypes . " } } 893 : { 1 : "NN nmod VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 894 : { 1 : "NN nmod NN nsubj NN appos NNS nmod VBN nsubjpass NNS nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod ratio nsubj interval appos meta-analyses nmod *included* nsubjpass studies nmod drug0 appos drug0" } 4 : { 1 : "Furthermore , studies of APOE drug1 , drug2 , ( defining e2/e3/e4 alleles ; 12 studies ) and APOB drug3 ( eight studies ) were included in meta-analyses , the observational hazard ratio ( HR ) for symptomatic drug4 for the fifth versus first quintile of LDL-C was 0.94 ( 95 % confidence interval : 0.76-1 .17 ) , despite a corresponding 134 % increase in LDL-C . " } } 895 : { 1 : "NN compound NNS nmod VBN nsubjpass NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 compound patients nmod *associated* nsubjpass heterogeneity nmod region compound drug0" } 4 : { 1 : "In drug2 patients , genetic heterogeneity in the drug1 genomic region is significantly associated with variation in serum ApoE and ApoB levels , and also with fibrosis suggesting a pleiotropic attribute of this genomic region . " } } 896 : { 1 : "NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 897 : { 1 : "NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 898 : { 1 : "NN dep NN dep NN conj NN conj NN dep VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 dep drug0 dep b conj drug0 conj drug0 dep *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 899 : { 1 : "NN nmod NN nsubj NN appos NNS nmod VBN nsubjpass NNS nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod ratio nsubj interval appos meta-analyses nmod *included* nsubjpass studies nmod drug0 conj drug0" } 4 : { 1 : "Furthermore , studies of APOE drug1 , drug2 , ( defining e2/e3/e4 alleles ; 12 studies ) and APOB drug3 ( eight studies ) were included in meta-analyses , the observational hazard ratio ( HR ) for symptomatic drug4 for the fifth versus first quintile of LDL-C was 0.94 ( 95 % confidence interval : 0.76-1 .17 ) , despite a corresponding 134 % increase in LDL-C . " } } 900 : { 1 : "NN conj NN nmod VBN nsubjpass NNS nmod NN dep NNS dep NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *associated* nsubjpass alleles nmod protein dep snps dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 901 : { 1 : "NN conj NN nmod NN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *association* nmod effect nmod drug0" } 4 : { 1 : "Multivariate analysis showed association between drug1 and drug3 , independently from the effect of drug2 . " } } 902 : { 1 : "NN compound NN appos NN" 2 : 1 3 : { 1 : "drug0 compound *variant* appos drug0" } 4 : { 1 : "Pooled DNA GWAS enabled the identification of a novel drug2 candidate risk variant , drug1 ( 9q21 .33 ) , tagging a possible genomic enhancer affecting proximal transcribed elements including DAPK1 gene . " } } 903 : { 1 : "NN nmod NN root , punct VBD xcomp VB dobj NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod intake root , punct *was* xcomp assess dobj effect nmod drug0" } 4 : { 1 : "The aim of this study was to assess the effect of drug1 , the intake of drug2 , and drug3 in Lithuanian adult population . " } } 904 : { 1 : "NN nmod VBN xcomp VBN nsubjpass NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod associated xcomp *found* nsubjpass drug0 conj drug0" } 4 : { 1 : "drug1 , SFA intake , and drug2 were found to be associated with drug3 in Lithuanian adult population . " } } 905 : { 1 : "NN conj NN nmod NNS nmod NN dobj VBP advcl VBZ nsubj NN nmod NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod genetics nmod involvement dobj *suggest* advcl needs nsubj role nmod drug0 conj drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 906 : { 1 : "NN dep NN appos NN dep NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep gamma appos drug0 dep drug0 dep b conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 907 : { 1 : "NN dep NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 dep gamma appos drug0 dep *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 908 : { 1 : "NN appos NN dep VBD dep NN dep NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 appos apoa0 dep *identified* dep tc dep apob dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 909 : { 1 : "NN appos NNP conj NN dep VBD dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 appos iii conj apoa0 dep *identified* dep tc dep apob dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 910 : { 1 : "NN compound NNS nsubj VBD dep NN dep NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound associations nsubj *identified* dep tc dep apob dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 911 : { 1 : "NN appos NNP conj NN dep VBD dep NN dep NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 appos iii conj apoa0 dep *identified* dep tc dep apob dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 912 : { 1 : "NN compound NNS nsubj VBD dep NN appos NN" 2 : 1 3 : { 1 : "drug0 compound associations nsubj *identified* dep apoa0 appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 913 : { 1 : "NN compound NNS nsubj VBD dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 compound associations nsubj *identified* dep tc dep apob dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 914 : { 1 : "NN conj NN dep NN dep NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep apob dep *tc* dep hl/lipc appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 915 : { 1 : "NN appos NN dep VBD dep NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 appos apoa0 dep *identified* dep tc dep apob dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 916 : { 1 : "NN appos NNP conj NN dep VBD dep VBZ dep NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 appos iii conj apoa0 dep *identified* dep designs dep .0 conj .0 dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 917 : { 1 : "NN dep NN dep NN dep NN appos NN" 2 : 1 3 : { 1 : "drug0 dep apob dep *tc* dep hl/lipc appos drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 918 : { 1 : "NN compound NNS nsubj VBD dep VBZ dep NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 compound associations nsubj *identified* dep designs dep .0 conj .0 dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 919 : { 1 : "NN appos NNP conj NN dep VBD nsubj NNS compound NN" 2 : 1 3 : { 1 : "drug0 appos iii conj apoa0 dep *identified* nsubj associations compound drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 920 : { 1 : "NN nmod:poss NN nmod NNS nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod:poss disease nmod diseases nmod interaction dep *drug0*" } 4 : { 1 : "Collectively , these results also suggest and claim for further investigations on drug1 / HP interaction in other age-related diseases such as drug2 's disease , drug3 and drug4 's disease . " } } 921 : { 1 : "NN conj NN nmod NN nsubj VBZ advcl VBP dobj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod role nsubj needs advcl *suggest* dobj involvement nmod locus compound drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 922 : { 1 : "NN nmod NNS nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod genetics nmod *involvement* nmod locus compound drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 923 : { 1 : "NN conj NN nmod NNS nmod NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod genetics nmod *involvement* nmod locus compound drug0" } 4 : { 1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . " } } 924 : { 1 : "NN nmod NNS nmod VB nsubj NN nmod NNS compound NN" 2 : 1 3 : { 1 : "drug0 nmod patients nmod *differ* nsubj frequency nmod polymorphisms compound drug0" } 4 : { 1 : "CONCLUSIONS : The frequency of drug1 polymorphisms did not differ between patients with drug2 and controls . " } } 925 : { 1 : "NN nmod:poss NN conj NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod:poss disease conj *disease* conj drug0" } 4 : { 1 : "Collectively , these results also suggest and claim for further investigations on drug1 / HP interaction in other age-related diseases such as drug2 's disease , drug3 and drug4 's disease . " } } 926 : { 1 : "NN conj NN nmod:poss NN" 2 : 1 3 : { 1 : "drug0 conj *disease* nmod:poss drug0" } 4 : { 1 : "Collectively , these results also suggest and claim for further investigations on drug1 / HP interaction in other age-related diseases such as drug2 's disease , drug3 and drug4 's disease . " } } 927 : { 1 : "NN nmod:poss NN conj NN nmod:poss NN" 2 : 1 3 : { 1 : "drug0 nmod:poss disease conj *disease* nmod:poss drug0" } 4 : { 1 : "Collectively , these results also suggest and claim for further investigations on drug1 / HP interaction in other age-related diseases such as drug2 's disease , drug3 and drug4 's disease . " } } 928 : { 1 : "NN conj NN nmod NNS nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 conj disease nmod diseases nmod interaction dep *drug0*" } 4 : { 1 : "Collectively , these results also suggest and claim for further investigations on drug1 / HP interaction in other age-related diseases such as drug2 's disease , drug3 and drug4 's disease . " } } 929 : { 1 : "NN nmod:poss NN conj NN nmod NNS nmod NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod:poss disease conj disease nmod diseases nmod interaction dep *drug0*" } 4 : { 1 : "Collectively , these results also suggest and claim for further investigations on drug1 / HP interaction in other age-related diseases such as drug2 's disease , drug3 and drug4 's disease . " } } 930 : { 1 : "NN nmod NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj *drug0*" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 931 : { 1 : "NN appos NN dep VBD dep VBZ dep NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 appos apoa0 dep *identified* dep designs dep .0 conj .0 dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 932 : { 1 : "NN dep NN dep NN dep VBD dep VBZ dep NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 dep apob dep tc dep *identified* dep designs dep .0 conj .0 dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 933 : { 1 : "NN nmod NN nmod VBN dep NN conj NN conj NN dep NN dep NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0 appos gamma dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 934 : { 1 : "NN nmod NN dep NN conj NN conj NN dep VBN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 935 : { 1 : "NN nmod NN dep NN conj NN conj NN dep VBN nmod NN nmod NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 dep b conj drug0 conj drug0 dep *associated* nmod drug0 nmod drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 936 : { 1 : "NN nmod NN nmod NNS dep NN" 2 : 1 3 : { 1 : "drug0 nmod *association* nmod polymorphisms dep drug0" } 4 : { 1 : "For example , the association of polymorphisms drug1 and drug2 with drug3 was heterogeneous between Caucasians ( OR = 1.32 and 1.22 ; 95 % CI : 1.25-1 .44 and 1.05-1 .42 ; P < 0.0005 and 0.008 , respectively ) and East Asians ( OR = 1.51 and 1.03 ; 95 % CI : 0.76-3 and 0.47-2 .27 ; P = 0.237 and 0.934 , respectively ) under theallelic model , and this association was relatively strengthened under the dominant model . " } } 937 : { 1 : "NN nmod VBN dep NN conj NN conj NN dep NN dep NN appos NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0 appos gamma dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 938 : { 1 : "NN nmod VBN dep NN conj NN conj NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 939 : { 1 : "NN nmod NN nmod VBN dep NN conj NN conj NN dep NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0 dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 940 : { 1 : "NN nmod VBN dep NN conj NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 941 : { 1 : "NN nmod NN nmod VBN dep NN conj NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 nmod drug0 nmod *associated* dep drug0 conj drug0 conj b dep drug0" } 4 : { 1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4 / C2 cluster SNP drug11 with lower serum TG . " } } 942 : { 1 : "NN conj NN dep NN dep NN dep VBD dep VBZ dep NN conj NN dep NN conj NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep apob dep tc dep *identified* dep designs dep .0 conj .0 dep drug0 conj drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 943 : { 1 : "NN nmod NN nmod NNS dep NN conj NN" 2 : 1 3 : { 1 : "drug0 nmod *association* nmod polymorphisms dep drug0 conj drug0" } 4 : { 1 : "For example , the association of polymorphisms drug1 and drug2 with drug3 was heterogeneous between Caucasians ( OR = 1.32 and 1.22 ; 95 % CI : 1.25-1 .44 and 1.05-1 .42 ; P < 0.0005 and 0.008 , respectively ) and East Asians ( OR = 1.51 and 1.03 ; 95 % CI : 0.76-3 and 0.47-2 .27 ; P = 0.237 and 0.934 , respectively ) under theallelic model , and this association was relatively strengthened under the dominant model . " } } 944 : { 1 : "NN conj NN nmod VBN nsubjpass NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *observed* nsubjpass ld nmod tomm0 appos drug0" } 4 : { 1 : "Inside this region of 26.9 kb , LD ( r2 > 0.50 ) between TOMM40 ( drug1 ) and APOE ( drug2 ) was observed in drug3 and in controls , but not in drug4 " } } 945 : { 1 : "NN appos NN dep VBD dep VBZ dep NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 appos apoa0 dep *identified* dep designs dep .0 conj .0 dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 946 : { 1 : "NN compound NNS nsubj VBD dep VBZ dep NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 compound associations nsubj *identified* dep designs dep .0 conj .0 dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 947 : { 1 : "NN appos NNP conj NN dep VBD dep VBZ dep NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 appos iii conj apoa0 dep *identified* dep designs dep .0 conj .0 dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 948 : { 1 : "NN nmod VBN nsubjpass NN nmod NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *observed* nsubjpass ld nmod tomm0 appos drug0" } 4 : { 1 : "Inside this region of 26.9 kb , LD ( r2 > 0.50 ) between TOMM40 ( drug1 ) and APOE ( drug2 ) was observed in drug3 and in controls , but not in drug4 " } } 949 : { 1 : "NN conj NN dep NN dep NN dep VBD dep VBZ dep NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 conj drug0 dep apob dep tc dep *identified* dep designs dep .0 conj .0 dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 950 : { 1 : "NN nmod NN nmod VBZ nsubj NN compound NN" 2 : 1 3 : { 1 : "drug0 nmod factor nmod *deserves* nsubj allele compound drug0" } 4 : { 1 : "The SIRT2 drug1 T allele deserves further investigation as a novel minor genetic risk factor for drug2 in the APOE e4-negative Caucasian population . " } } 951 : { 1 : "NN dep NN dep NN dep VBD dep VBZ dep NN conj NN dep NN" 2 : 1 3 : { 1 : "drug0 dep apob dep tc dep *identified* dep designs dep .0 conj .0 dep drug0" } 4 : { 1 : "There was moderate consistency between the cross-sectional and longitudinal findings , with eight SNP : drug8 associations consistently identified across both study designs : [ APOE .2 and APOE .4 ( drug1 and drug2 ) ] : TC ; HL/LIPC ( drug3 ) : HDL ; [ APOB ( drug4 ) , APOE .2 and APOE .4 ( drug5 and drug6 ) ] : LDL ; [ APOA5 ( drug7 ) and APOC III ( drug9 ) ] : TG . " } } 952 : { 1 : "NN nmod VBN nsubjpass NN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 nmod *observed* nsubjpass ld nmod tomm0 conj apoe appos drug0" } 4 : { 1 : "Inside this region of 26.9 kb , LD ( r2 > 0.50 ) between TOMM40 ( drug1 ) and APOE ( drug2 ) was observed in drug3 and in controls , but not in drug4 " } } 953 : { 1 : "NN conj NN nmod VBN nsubjpass NN nmod NN conj NN appos NN" 2 : 1 3 : { 1 : "drug0 conj drug0 nmod *observed* nsubjpass ld nmod tomm0 conj apoe appos drug0" } 4 : { 1 : "Inside this region of 26.9 kb , LD ( r2 > 0.50 ) between TOMM40 ( drug1 ) and APOE ( drug2 ) was observed in drug3 and in controls , but not in drug4 " } } 954 : { 1 : "NN conj NN nmod NN compound NN" 2 : 1 3 : { 1 : "drug0 conj brain nmod *variant* compound drug0" } 4 : { 1 : "Gene expression analysis indicated an association between genotypes of the drug1 variant and CHRNA5 expression in brain and peripheral drug2 , and with the rs16969968 and rs17477223 variants in brain . " } } } }